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Abstract. 
By asymmetric transfer hydrogenation, substituted quinolines, which are generally 
regarded as challenging substrates for reduction, were successfully converted into 
tetrahydroquinolines using “tethered” Ru(II) and “tethered” Rh(III) complexes in formic 
acid/triethylamine. 
An ether-linked “tethered” catalyst was successfully synthesized through a sequence 
that avoids the use of a Birch reduction for the formation of a 1,4-cyclohexadiene 
moiety. The ether link is incorporated between the basic amine of the ligand and the η6-
arene ring, giving results comparable to the alkyl-“tethered” complexes. 
N-alkylated complexes containing a straight-chain substituent attached to a hydroxyl, 
ether or ester function can act as effective catalysts for the reduction of ketones, and 
also contains the required functionality for attachment of the catalyst to a heterogeneous 
support.
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1.     Introduction. 
1.1     Chirality. 
 The term chirality is derived from the Greek word for hand (cheir), 
which is a mathematical approach to the concept of “handedness”-the existence of 
left/right opposition, and was coined by Lord Kelvin in his Baltimore lectures on 
molecular dynamics and the wave theory of light in which he stated “I call any 
geometrical figure, or group of points, chiral, and say it has chirality, if its image in a 
plane mirror, ideally realized, cannot be brought to coincide with itself”. Human hands 
are perhaps the most universally recognized example of chirality: The left hand is non-
superimposable mirror image of the right hand and no matter how the two hands are 
oriented, it is impossible for all the major feature of both hands to coincide (Figure 2).
1
 
 
Figure 2. Human hands, an example of chirality. 
In the context of chemistry, two structures that are not identical, but are mirror images 
of each other are called enantiomers (Scheme 1). Enantiomers are a type of isomer 
called stereoisomers, as the isomers differ not in the connectivity of the atoms, but only 
Figure 1.  Lord Kelvin (William Thomson), Professor of Natural 
Philosophy in the University of Glasgow from 1846-1899. 
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in the overall shape of the molecule. Structures that are not superimposable on their 
mirror image, and therefore can exist as two enantiomers, are called chiral. 
 
Scheme 1.  Enantiomers of cyanohydrin from the reaction between an aldehyde and 
cyanide.  
Structures that are superimposable on their mirror images are called achiral (Scheme 2). 
The essential difference between the two examples shown is symmetry. Acetone 
cyanohydrin has a plane of symmetry running through the molecule, whereas the 
aldehyde cyanohydrin has no plane of symmetry, and it cannot have a plane of 
symmetry, because it contains a tetrahedral carbon atom carrying four different groups: 
OH, CN, RCH2 and H. Such a carbon atom is known as a stereogenic centre or chiral 
centre.
1
  
 
Scheme 2. Achiral structures of acetone cyanohydrin. 
Structures that have more than one stereogenic centre can give rise to stereoisomers that 
that are not mirror images of one another called diasteroisomers. Two diastereoisomers 
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are different compounds meaning their physical and chemical properties are different, 
and have different relative stereochemistry. Diastereoisomers maybe achiral (Figure 3) 
or chiral (Figure 3).
1
  
 
Figure 3. Achiral and chiral diastereoisomers. 
Enantiomers have identical NMR spectra, IR spectra, physical and chemical properties 
in the absence of an external chiral influence meaning the same melting point, boiling 
point, solubility properties and chromatographic retention times. The single exception is 
the ability of the enantiomers to rotate plane-polarized light. We call the enantiomer that 
rotates plane-polarized light to the right (gives a positive rotation) the (+)-enantiomer 
(or the d: dextrorotatory enantiomer) and the enantiomer that rotates plane-polarized 
light to the left (gives a negative rotation) the (-)-enantiomer (or the l : laevorotatory 
enantiomer).  
The direction in which light is rotated is not dependent on whether a stereogenic centre 
is R or S. An (R) compound is equally as likely to be (+) as (-), if it is (+) then its (S) 
enantiomer must be (-). Observation of the rotation of plane-polarized light is known as 
polarimetry and it is calculated by using the following equation: [α] = α (angle through 
which the light is rotated by) / l (path length in dm) x c (in g/100 cm
3
) and the light 
usually used is from a sodium lamp (symbol D is used to represent this) with a 
wavelength of 589 nm.  If the angle is very small then mercury lamp with a wavelength 
of 546 nm can be used for this purpose. The specific rotation [α] value obtained can be 
used as a guide to the enantiomeric purity of a sample, in other words to how much of 
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each enantiomer it contains, specific rotation values are usually used for comparison 
with known literature values in order to confirm the configuration of the enantiomers 
obtained. Chiral derivatizing  agent
2
 (CDA) for e.g. Mosher‟s acid can be used to 
determine enantiomeric excess and configuration of simple chiral amines and alcohols 
as it can convert a mixture of enantiomers into diastereoisomers, which means it can 
then be possible to distinguish them using NMR. X-Ray crystallography is most 
commonly used to determine the configuration of novel chiral compounds. The way in 
which R/S is assigned to each stereocentre or E (trans)/Z (cis) is assigned to each double 
bond is by the Cahn-Ingold-Prelog priority rules. For the assignment of R/S, each of the 
four substituents around the chiral centre is given a priority number. Atoms with higher 
atomic numbers get higher priority. If two (or more) of the atoms attached to the chiral 
centre are identical, then the priority number is assigned by assessing the atoms attached 
to those atoms. The molecules are then arranged so that the lowest priority substituent is 
pointing away from you. If you move in a clockwise manner from highest to the second 
lowest assigned substituent, then the chiral centre is given the label R (for rectus, Latin 
for right), and if you are moving in an anticlockwise manner then the chiral centre is 
given the label S (for sinister, Latin for left). The procedure is very similar when 
assigning E/Z, but in this case if two higher groups are cis, the alkene is Z (from the 
German zusammen, means together), and if they are trans the alkene is E (from the 
German entgegen, means opposite).
1
 
1.2     Biological significance of chirality. 
All proteins, enzymes, amino acids, carbohydrates, nucleosides and a number of 
alkaloids and hormones are chiral compounds. In contrast to chiral artificial products, 
almost all (some are racemic or made in both forms) natural compounds are under 
single enantiomeric form, for example, all natural amino acids are L-isomer and all 
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natural sugars (carbohydrates) are D-isomers. The D/L notation (a very old convention), 
not to be confused with d: dextrorotatory and l: laevorotatory, is derived from the signs 
of optical rotation of R and S glyceraldehyde respectively (Figure 4), with D-glucose 
being the natural enantiomer, and L-glucose the unnatural enantiomer. 
 
Figure 4. Illustration of glyceraldehyde with D-(natural)/L-(unnatural) and R/S 
notations. 
Amino acids are classified in to L-(natural) and D-(unnatural), with most L-amino acids 
being of S-configuration (Figure 5).  
 
Figure 5. Amino acids classified in to L-(natural) and D-(unnatural). 
Although the chemical and physical properties for enantiomers in the absence of an 
external chiral influence are the same, most enantiomers of drugs exhibit marked 
differences in biological activities such as pharmacology, toxicology, pharmacokinetics 
and metabolism when exposed to a chiral surrounding. For example thalidomide 1, 
which was marketed as the racemate led to a tragedy in the 1960s in Europe. The 
sedative-hypnotic drug thalidomide exhibited irreversible neurotoxicity and 
teratological (mutagenic) effects in which babies were born deformed. The drug was 
prescribed to pregnant women to counter morning sickness. Studies showed that these 
effects were caused by the (S)-enantiomer and that the (R)-enantiomer contained the 
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desired therapeutic activity. More recently studies were concluded that both 
enantiomers of thalidomide are unstable and spontaneously epimerize to form the 
racemate in-vivo in humans (Figure 6).
3a
 
Albuterol (salbutamol) 2 is sold as a racemate, and is the leading bronchodilator, which 
is a β2-adrenergic receptor agonist that can increase bronchial airway diameter without 
increasing heart rate. The bronchodilator activity resides in (R)-albuterol also known as 
levosalbutamol which is sold as the trade name xopenex. The (S)-albuterol enantiomer 
is not inert as it indirectly antagonizes the benefits of (R)-albuterol and may have 
proinflammatory effects. These are pharmacokinetic differences between the 
enantiomers with (S)-albuterol being cleared more slowly. The (S)-enantiomer tends to 
accumulate in preference to the therapeutically effective (R)-enantiomer. 
Levosalbutamol sold as the single (R) enantiomer has the same bronchodilator activity 
as racemic albuterol, but has a superior side-effect profile (Figure 6).
3a,3b
 
Parkinson‟s disease sufferers are treated with the non-proteinogenic amino acid DOPA 
3. DOPA is chiral, and only (S)-DOPA (known as L-DOPA) is effective in storing nerve 
function. The active form of the drug is an achiral compound dopamine which is formed 
by decarboxylation of 3 and is used to increase dopamine concentrations and dopamine-
responsive dystonia, but it cannot cross the blood-brain barrier to reach the site of 
action. (S)-DOPA can and is then decarboxylated by the enzyme dopamine 
decarboxylase to dopamine. This enzyme however is not able to metabolize (R)-DOPA 
(known as D-DOPA), and so to prevent the build-up of (R)-DOPA which could prove to 
be fatal, it is essential that DOPA is administered pure as the (S)-enantiomer (Figure 
6).
3b
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Bupivacaine 4, currently the most widely used long acting local anaesthetic agent in 
both surgery and obstetrics has a good safety record, but its use has resulted in fatal 
cardiotoxicity, usually after accidental intravascular injection. The single (S)-enantiomer 
version of bupivacaine called levobupivacaine was introduced, which has clinically 
equivalent anaesthetic potency to bupivacaine, but with reduced CNS and 
cardiotoxicity. Due to the differences observed in biological activities for different 
enantiomers of drugs, all chiral forms of a drug are tested rigorously for possible side 
effects and for chiral stability in vivo before approval (Figure 6).
3a,3c
 
 
Figure 6. Examples of chiral drug molecules, with the tick representing the active 
enantiomer, and cross representing the toxic enantiomer. 
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1.3     Asymmetric catalysis. 
In order to understand the concept of asymmetric reactions you have to focus on the two 
transition states for the formation of R and S enantiomers. In a racemic reaction, where 
an achiral reagent is reacted with an achiral molecule, the transition states of both R and 
S enantiomers are of equal energy (∆Gi = ∆Gii), therefore both R and S enantiomers are 
produced in equal amounts to yield a racemic product. In an enantioselective reaction 
the catalyst used (or reagent) facilitates one of the transition states to be at lower energy 
than the other as shown in Figure 7 (a reminiscent of an enzyme-catalysed biological 
reaction). The catalyst interacts with an achiral substrate (the type of substrate used is 
also important) in the transition state which has lowered in energy by ∆∆G# from ∆Gi 
and in this case it favours the formation of the (R)-enantiomer, whereas transition state 
for the formation of the (S)-enantiomer may remain unaffected or may increase or 
decrease (not decrease too much) in energy. The value of ∆∆G# plays a crucial role in 
determining the selectivity of the reaction. 
 
Figure 7. Reaction coordinates for the asymmetric synthesis of chiral substrate. 
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The use of catalysts proves to be very economical as very low quantities of catalyst (less 
than 1 mol%) is usually required in an asymmetric catalysis reaction and the catalyst 
can also be isolated after a reaction and reused. Some established asymmetric catalytic 
reactions will now be reviewed. 
1.3.1     Sharpless epoxidation. 
The Sharpless epoxidation reaction is an enantioselective chemical reaction to prepare 
2,3-epoxyalcohols from primary and secondary allylic alcohols. It was discovered in 
1980 by Barry K. Sharpless and Tsutomu Katsuki. The simplicity of this metal-
catalysed asymmetric epoxidation is what makes this method so attractive, as the 
necessary components (+) or (-)-diethyl tartrate, titanium tetraisopropoxide and tert-
butyl hydroperoxide are all commercially available at low to moderate cost (Scheme 3). 
 
Scheme 3. Asymmetric synthesis of 2,3-epoxyalcohols. 
This chiral epoxidation system possesses two key features; first of all it gives uniformly 
high asymmetric inductions throughout a range of substitution patterns in the allylic 
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alcohol substrate. Secondly depending on the tartrate enantiomer used, the system is 
able to deliver the epoxide oxygen from the same enantioface of the olefin regardless of 
the substitution pattern. As illustrated in Scheme 3 the use of (+)-diethyl tartrate leads to 
addition of the epoxide oxygen from the bottom face, and using (-)-diethyl tartrate as 
expected from the top face. Transition-metal-catalysed epoxidations work only on 
allylic alcohols, so there is one limitation to the method because the coordination of an 
alcohol to the titanium metal is crucial for the reaction to take place. An example of 
where Sharpless epoxidation has been employed is for the synthesis of propranolol, 
which is a sympatholytic non-selective beta blocker and is used to treat hypertension, 
anxiety and panic. Not many target molecules are themselves epoxides, but one of the 
great advantages of epoxides is its high versatility, meaning they can react with many 
types of nucleophiles to give 1, 2-disubstituted products.
4a
 
 
Scheme 4. Synthesis of (S)-propranolol 8 with the use of Sharpless epoxidation. 
The most obvious starting material for this synthesis, allyl alcohol itself gives an 
epoxide which is hard to handle. So Sharpless instead used the silicon-substituted allylic 
alcohol 5 for the asymmetric epoxidation step giving 6 in 60 % yield and 95 % ee. The 
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hydroxyl group was mesylated and displaced with 1-naphthoxide to give 7 and then 
after treatment with fluoride to remove the silicon, the epoxide was opened with 
isopropylamine to give (S)-propranolol 8 (Scheme 4).
4b
 
1.3.2     Hydroboration. 
In 1981, Itsuno reported the asymmetric reduction of aromatic ketones utilizing the 
borane complexes of chiral amino-alcohols (9-12, Figure 8) derived from α-amino-acids 
to give secondary alcohols with up to 60% ee.
5a
 Application of such complexes for 
asymmetric reduction was first reported by Fiaud and Kagan
5b
 who used borane-chiral 
amine complexes derived from ephedrine in the reduction of ketones but obtained very 
low ee (3.6 – 5.0%). Attempts were also made to use the borane complexes with (R)-
(+)-, (S)-(-)-α-methylbenzylamine, or α-amino-esters in the presence of BF3.Et2O in 
asymmetric reductions of ketones but limited success was achieved (ee of up to 20%).  
 
Figure 8. Chiral amino-alcohols used for the formation of chiral alkoxy-amine-borane 
complexes. 
In 1983 after 2 years, Itsuno reported very high selectivities for the reduction of 
aromatic ketones (94 – 100 %) by using the new chiral borane complex 14 prepared 
from (S)-(-)-2-amino-3-methyl-1, 1-diphenylbutan-1-ol 13 and borane (Scheme 5).
5c-5e
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Scheme 5. Itsuno‟s chiral amine-borane system for asymmetric reduction of ketones. 
Soon after, Corey extended the idea and developed the 1,3,2-oxazaborolidines 16 
(Scheme 4) as a new generation of homochiral reduction catalysts, which rapidly 
reduces ketones with up to 97 % ee in the reduction of acetophenone. 
 
Scheme 6. Proposed mechanism for the catalytic enantioselective reduction of ketones 
by oxazaborolidines 16. 
Corey and co-workers had proposed the reaction mechanism shown in Scheme 6, to 
explain the selectivity obtained in the catalytic reduction. The first step involves the 
coordination of the reducing agent BH3 with the Lewis basic nitrogen atom of 16, this 
causes the activation of the BH3 as a hydride donor and also enhances the Lewis acidity 
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of the catalyst‟s endocyclic boron. Subsequently, the endocylic boron of the catalyst 
coordinates to the ketone at the sterically more accessible electron lone pair (i.e. the 
lone pair closer to the smaller substituent). This preferential binding in 18 acts to 
minimize the steric interactions between the ketone (the large substituent directed away) 
and the R group of the catalyst, and aligns the carbonyl and the coordinated borane for a 
favourable, face-selective hydride transfer through a six-membered transition state 18. 
Hydride transfer then yields chiral boron enolate 20, which upon acidic work-up yields 
the chiral alcohol. Dissociation of the reduction product from 19 may occur by two 
different pathways: 1) reaction of the alkoxide ligand attached to the endocylic boron 
atom with the adjacent boron atom of 19 to regenerate 16 and form the borinate 20 by 
cyclo-elimination; or 2) by the addition of BH3 to 19 to form a six-membered BH3-
bridged species 21, which decomposes to produce the catalyst-BH3 complex 17 and 
borinate 20.
5f
 
Oxazaborolidines are excellent homogeneous catalysts for the enantioselective 
reductions of prochiral carbonyl compounds and have gained significant synthetic utility 
in the synthesis of a significant number of natural products, including lactones, 
terpenoids, alkaloids, steroids and biotins.
5f, 5g, 5h
 
1.3.3     Asymmetric Hydrogenations. 
1.3.3.1     Wilkinson’s Catalyst. 
Asymmetric hydrogenation plays an important role in today‟s synthesis world. In 1966 
Sir Geoffrey Wilkinson who received the Nobel Prize in 1973 for his work on 
organometallic compounds introduced the first example of homogeneous catalysis. 
Chlorotris(triphenylphosphine)rhodium(I) known as the Wilkinson‟s catalyst 
[RhCl(PPh3)3] 22 (Scheme 7) is able to catalyse the hydrogenation of simple unhindered 
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alkenes in organic solvents rapidly under mild conditions.
6a
 The mechanism of 
Wilkinson‟s catalytic system is reasonably well-established, and it involves the initial 
dissociation of one or two triphenylphosphine ligands to give 14 e
-
 or 12 e
-
 complexes, 
respectively, followed by oxidative addition of H2 to the metal. Subsequent π-
complexation of alkene, intramolecular hydride transfer (olefin insertion), and reductive 
elimination results in extrusion of the alkane product as shown in Scheme 7. The 
reaction rates are dependent on the steric hindrance of the substrates.
6b, 6c
 
 
Scheme 7. Catalytic hydrogenation of propylene. 
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1.3.3.2     Schrock-Osborn catalyst. 
The Schrock-Osborn catalyst 23 (Figure 9), discovered in 1976 by 2005 Nobel Prize 
winner Richard R. Schrock and John Osborn, who carried out his doctoral study with 
Sir Geoffrey Wilkinson, is another example of a homogeneous catalyst for 
hydrogenation reactions and is more active than Wilkinson‟s catalyst due to the cationic 
metal centre being more electrophilic, favouring alkene coordination, which is often the 
rate determining step.
6d
 
 
Figure 9. Schrock-Osborn catalyst. 
1.3.3.3     Crabtree’s catalyst. 
In 1979 Professor Robert H. Crabtree developed an iridium based complex with 1,5-
cyclooctadiene, tris-cyclohexylphosphine and pyridine also known as Crabtree‟s 
catalyst 24 (Figure 10) while working on iridium analogues of the Wilkinson‟s 
rhodium-based catalyst.  
 
Figure 10. Crabtree‟s catalyst. 
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Crabtree‟s catalyst is another homogeneous catalyst for hydrogenation reactions and is 
more active than the Schrock-Osborn catalyst and at least 100 times more active than 
Wilkinson‟s catalyst. Crabtree‟s catalyst is also able to reduce tri- and tetra substituted 
alkenes, which the Wilkinson‟s catalyst and the Schrock-Osborn catalyst are 
unsuccessful in reducing (Table 1). It also gives superior directing effect for cyclic 
substrates.
6e 
 Turnover Frequency (TOF) 
Substrate =  
   
Wilkinson’s catalyst 
Benzene/EtOH, 25 °C 
650 700 13 - 
Schrock-Osborn 
Catalyst 
CH2Cl2, 25 °C 
4000 10 - - 
Crabtree’s catalyst 
CH2Cl2, 0 °C 
6400 4500 3800 4000 
Table 1. Rates (In mol of substrate reduced (mol of catalyst)
-1 
h
-1
) of hydrogenation of 
variously substituted olefins with active catalysts of different types. 
1.3.3.4     Asymmetric Hydrogenation using DIPAMP complexes. 
Since the discovery of Wilkinson‟s catalyst, it has inspired many research scientists to 
synthesise tertiary stereogenic carbon atoms by asymmetric hydrogenation of alkenes 
using optically active transition metal complexes. In 1977, William S. Knowles (Nobel 
Prize winner in 2001) and his collaborators Billy D. Vineyard and M. Jerry Sabacky 
discovered a bidentate C2 symmetric version 25 of the cationic Schrock-Osborn catalyst, 
giving very high enantioselectivities in the hydrogenation of achiral enamides.
7a
 This 
was the first demonstration that a chiral transition metal complex could effectively 
transfer chirality to a non-chiral substrate with selectivities that rival those observed in 
enzymes, and lead to the 1
st
 commercialized asymmetric process for the synthesis of L-
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DOPA 3 (Scheme 8),
7b
 a drug used for the treatment of Parkinson‟s disease as 
previously described. 
 
Scheme 8. Monsanto research group led by Knowles established a method for the 
industrial synthesis of L-DOPA 3. 
1.3.3.5     Asymmetric Hydrogenation using Ru(II)/Rh(III)-BINAP complexes. 
The discovery of BINAP-Ru complexes in the mid 1980‟s extensively broadened the 
scope of olefenic and ketonic substrates for asymmetric hydrogenation. In 1984 the 
axially disymmetric bis(triaryl)phosphine ligand discovered by Noyori and co-workers 
was first used for Rh(I)-catalysed asymmetric hydrogenations of α-(acylamino) acrylic 
acids and esters.
8a
 The use of BINAP when combined with Ru, proved to be a 
successful combination for the asymmetric hydrogenation of various unsaturated 
substrates (C=O and C=C bonds). The synthesis of the anti-inflammatory drug naproxen 
27’ was successfully carried with the use of this catalytic system, reducing the acrylic 
acid 27 using [(S)-BINAP-Ru(OAc)2] 26b, giving the product 27’ in 100% yield and 
97% ee (Scheme 9).
8b
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Scheme 9. The use of asymmetric hydrogenation for the synthesis of naproxen 27’. 
Asymmetric hydrogenation using various Ru-BINAP
8c,8d
, and Rh-BINAP
8e-8g
 derived 
complexes have been successfully applied to the reduction of β-keto esters,8h-8o and 
ketones
8p,8q
  
1.3.3.6     Asymmetric Hydrogenation using Ir(I) and Ru(II) complexes for the 
reduction of quinolines. 
Optically active tetrahydroquinoline derivatives are an important class of building 
blocks for asymmetric synthesis in pharmaceutical and agrochemical industries and for 
the total synthesis of natural products (Figure 11). The (S)-enantiomer of flumequine 28 
is an antibacterial agent of the quinolone family. Several other derivatives such as 
torcetrapib 29 and compound A 30, have attracted much attention as potent inhibitors of 
the cholesterol ester transfer protein, which is a target for the treatment of low high-
density lipoprotein cholesterol and atherosclerosis.
9a
 The conversion of quinolines to 
tetrahydroquinolines is a useful direct method for the synthesis of chiral, non-racemic 
N-containing heterocycles from readily available starting materials. A number of reports 
on the pressure hydrogenation of quinolines have been published.
9-11
 
Introduction 
 
19 
 
 
 Figure 11. Examples of important 1,2,3,4-tetrahydroquinoline derivatives. 
The first example reported by Zhou and co-workers in 2003 of asymmetric quinoline 
hydrogenation employed chiral biaryldiphosphine ligands 31 with an Ir(I) salt,
9b
 and 
gave products with ee‟s of up to 96% and conversion of up to 95% (Scheme 10). Iodine 
was found to be an essential additive.  
 
Scheme 10. Highly enantioselective iridium-catalyzed hydrogenation of heteroaromatic 
compounds, quinolines.
9b 
Reaction conditions: substrate (1 mmol), [Ir(COD)Cl]2 
(0.5%), (R)-MeO-Biphep 31 (1.1%), I2 (10%), toluene (5 cm
3
), H2 (600-700 psi), 25 °C. 
 
This method was applied for the asymmetric synthesis of three naturally occurring 
alkaloids angustureine 32, galipinine 33 and cuspareine 34 (Figure 12). 
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Figure 12. Bioactive compounds derived from chiral 1, 2, 3, 4-tetrahydroquinoline. 
A variety of iridium complexes have been reported using chiral phosphorous ligands, 
including diphosphines, diphosphites, monodentate phosphorous ligands, P, N ligands 
and other examples to catalyze the enantioselective hydrogenation of a wide range of 2-
alkyl-substituted quinoline derivatives, giving good to excellent enantioselectivities. 
Examples of some of these ligands have been shown (Scheme 11-16).  
 
The activation of quinolines with chloroformates has been reported to improve the rates 
of reactions, giving up to 90% ee and 95% conversion for quinolines and up to 83% ee 
and 87% conversion for isoquinolines
9c
 (Scheme 11). 
Scheme 11. AH of quinolines and isoquinolines activated by chloroformates.
9c
 Reaction 
conditions: substrate (1.0 mmol), [Ir(COD)Cl]2 (0.5%), (S)-SegPhos 35 (1.1%), THF (5 
cm
3
), Li2CO3 (1.2 mmol),ClCO2Bn (1.1 mmol). 
Asymmetric Ir-catalyzed hydrogenation of quinolines using BINOL-derived 
diphosphonites 36 gave enantioselectivity of up to 96% and conversion of up to 96%, 
with a chiral diphenyl backbone
9d
 (Scheme 12). 
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Scheme 12. AH of quinolines catalysed by iridium complexes of BINOL-derived 
diphosphonites 36.
9d 
Reaction conditions: substrate: [Ir(COD)Cl]2 : (S)-BINOL 36: 
I2=200: 1: 2: 2, H2 (600 psi), toluene, 23 °C, 20 hrs. 
Ir complexes with chiral ferrocenyloxazoline P, N ligands 37 are effective catalysts for 
the AH of heteroaromatic compounds such as quinolines, and up to 92% ee was 
obtained with conversions up to 95% (Scheme 13).
 9e
 
 
Scheme 13. AH of quinolines catalyzed by iridium with chiral ferrocenyloxazoline 
derived P, N ligands 37.
9e 
Reaction conditions: substrate (1 mmol) / [Ir(COD)Cl]2/chiral 
ligand 37/I2= 100/0.5/1.1/5, toluene (5 cm
3
), H2 (600 psi), rt. 
The use of nitrogen-donor ligands, such as diamines, in this application is less 
developed.  In 2006, Noyori and co-workers reported that chiral η6-arene-TsDPEN-
Ru(II) complex is not only excellent for ATH, but also for the AH reduction of aromatic 
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ketones.
9f
 Fan and co-workers later demonstrated that the AH of quinolines using chiral 
η6-arene-TsDPEN-Ru(II) complex 38 (Scheme 14) in an ionic liquid gave excellent 
results.
9g
 In this process, the ionic liquid was essential – reactions in methanol 
proceeded with much lower activity.  
 
Scheme 14. Hydrogenation of quinolines using a recyclable phosphine-free chiral 
cationic ruthenium catalyst.
9g 
Reaction conditions: substrate (0.20 mmol) in [BMIM]PF6 
(1.0 cm
3
), (S,S)-38 (1.0 mol%), H2 (50 atm), 25 °C, 15-24 hrs. 
Quinoline substrates were efficiently hydrogenated to give tetrahydroquinolines with up 
to 99% ee and up to 97% conversion, without the need for additives via this first 
phosphine free cationic Ru/TsDPEN catalyst.
9g
 The use of ionic liquid not only 
facilitates the recyclability, but also enhances the stability and selectivity of the catalyst.  
A new kind of highly effective phosphine-free Ir-catalysts for the asymmetric 
hydrogenation of quinolines was developed, giving products in up to 99% ee.
9h
 The 
reaction did not require inert gas protection throughout the entire operation, Scheme 15. 
The use of an acidic additive was demonstrated to be important for optimal activity. 
These results suggested that the reduction of quinolines was proceeding by an ionic 
catalytic pathway in which N-protonation was required to activate the hydride addition 
process,
9g, 9h
 which was different from the mechanism of the AH of ketones. 
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Scheme 15. Air-stable and phosphine-free iridium catalysts for highly enantioselective 
hydrogenation of quinoline derivatives.
9h
 Reaction conditions: substrate (0.75 mmol) in 
undegassed MeOH (1 cm
3
), (S, S)-40 (0.2 mol%), TFA (10 mol%), H2 (50 atm), 15 °C, 
24-28 hrs. 
Despite the significant progress made, the mechanism of quinoline reductions with these 
types of catalysts remained to be elucidated, in contrast to the better known asymmetric 
reduction of ketones. Fan and co-workers very recently reported the systematic study on 
the AH of a broad range of quinoline derivatives using Ru-diamine catalysts together 
with a detailed mechanistic study through experiments and DFT calculations. 
 
A wide range of quinoline derivatives, including 2-alkylquinolines, 2-arylquinolines, 2-
functionalized and 2,3-disubstituted quinolines were efficiently hydrogenated under 
mild conditions with up to >99% ee and up to 5000 TON, using η6-arene-N-
tosylethylenediamine-Ru(II) complexes 41 and 42 (Scheme 16).
9a
 
 
Introduction 
 
24 
 
Scheme 16. Asymmetric hydrogenation of 2-alkylquinolines, 2-arylquinolines, 2-
functionalized and 2, 3-disubstituted quinolines. Reaction conditions: 0.15-0.20 mmol 
substrate, 1 cm
3
 of MeOH/2 cm
3
 EtOH (2-arylquinolines), 0.2-1.0 mol% cat, 0-25 °C, 
H2 (50 atm), 12-48 hrs. 
The cascade hydrogenation of quinoline occurs through an ionic instead of a concerted 
catalytic pathway, involving 1,4-hydride transfer, isomerization, and 1,2-hydride 
transfer. As illustrated in Scheme 17, the ionized ruthenium complex Ru
+
 43 reversibly 
accommodates a dihydrogen to form dihydrogen complex H2-Ru
+
 44. Deprotonation of 
the dihydrogen ligand 44 by quinoline A generates both the active Ru-H 45 species and 
the activated substrate B. A subsequent 1,4-hydride transfer affords the enamine 
intermediate C and the regenerated Ru+ 43. Similarly, the enamine  C serves as a base 
to deprotonate the dihydrogen ligand 44, resulting in the Ru-H 45 and the iminium 
cation D. Then 1,2-hydride transfer gives the final product, 1,2,3,4-tetrahydroquinoline 
E, enantioselectively and regenerates Ru
+
 43. The dihydroquinoline intermediate C can 
be reversibly dehydrogenated by Ru-catalyst 43 to give the quinoline A, while the 1,2-
hydride transfer step is irreversible under the asymmetric hydrogenation conditions. The 
reaction between the activated iminium cation D and the Ru-H 45 takes place via a 
cyclic 10-membered transition structure TS-45, with the participation of TfO
-
 anion. 
Similarly to what has been shown by Noyori for ketone reductions, the 
enantioselectivity in this system originates from the CH/π interaction between the η6-
arene ligand in the Ru-complex and the fused phenyl ring of the dihydroquinoline.
9a
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1.4     Asymmetric transfer hydrogenation 
1.4.1     Traditional mechanisms 
 
Scheme 18. Reduction of multiple bonds via transfer hydrogenation. 
Transfer hydrogenation or hydrogen-transfer is the reduction of multiple bonds with the 
use of a hydrogen donor in the presence of a catalyst (Scheme 18). The process involves 
abstraction of hydrogen from the reagent (hydrogen donor) with the involvement of 
catalyst, followed by (or in concert with) hydride addition to the unsaturated functional 
group of the substrate (hydrogen acceptor). The benefits of transfer hydrogenation as 
opposed to pressure hydrogenation include procedural simplicity, avoidance of 
hazardous reagents such as molecular hydrogen and borane, as well as the need of 
pressure vessels (saving costs, as purchasing expensive equipment for handling these 
reagents is not required). In addition to this, the use of a specific hydrogen donor can 
favourably affect the rate and selectivity of a given reaction. However, the drawback 
with transfer hydrogenation is its unfavourable thermodynamics for the reduction of 
ketones, using alcohols, especially propan-2-ol, as hydrogen source. This means careful 
selection of hydrogen donor and reaction conditions are required if good conversion and 
ee are to be obtained.
13a-13c
 
From a mechanistic point of view, transfer hydrogenation of ketones can occur via two 
general reaction paths: (a) concerted process called, direct hydrogen transfer and (b) 
step-wise process called, the hydridic route.
13a 
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(a) Direct hydrogen transfer: 
This is a concerted process, and it involves the formation of a six-membered cyclic 
transition state in which both the hydrogen donor (
i
PrOH) and hydrogen acceptor 
(ketone) are held together in close proximity to the metal centre (TS-46, Scheme 19). 
This mechanism is similar to that proposed for the Meerwein-Ponndorf-Verley (MPV) 
reduction.
13d-13g
  
 
Scheme 19. Mechanism for the Meerwein-Ponndorf-Verley (MPV) reduction. 
(b) Hydridic route:  
Transfer hydrogenation via the hydridic route takes place in a step-wise manner, and it 
involves the intermediate formation of metal hydride 47 by interaction of catalyst with 
hydrogen donors such as IPA and formic acid 48, eliminating either acetone or carbon 
dioxide. The metal hydride 47 then undergoes hydride transfer with a coordinated 
ketone TS-47 (Scheme 20). 
Scheme 20. Hydridic mechanism for transfer hydrogenation of ketones. 
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The route taken in a particular system is dependent on the metal catalyst and hydrogen 
donor. Main group elements such as aluminium in the MPV reduction
13e,13f
 have been 
reported to take the hydrogen transfer route. As oppose to this, transition metal 
complexes, as stated by Noyori, “prefer the hydride mechanism”.13b An example of this 
is shown with [RhH(bipy)2], in the mechanism of [Rh(bipy)2Cl]-catalysed 
dehydrogenation of ethanol in the presence of a base.
13h
 Also, the involvement of a 
ruthenium dihydride species in a [RuCl2(PPh3)3] and NaOH catalyst system for the 
transfer hydrogenation of ketones was suggested by Bäckvall.
13i
 
In 1991, Bäckvall reported the enhanced activity of [RuCl2(PPh3)3] for the transfer 
hydrogenation of ketones by isopropanol with the use of catalytic amount of NaOH. No 
transfer hydrogenation took place without base.
13i
 This finding was important, as in 
previous ruthenium-catalysed transfer hydrogenation of ketones, the reaction took place 
at high temperatures.
13j,13k
 
1.4.2     Hydrogen sources. 
In transfer hydrogenation, one of the most common sources of hydrogen donors are 
secondary alcohols, in particular isopropanol. The use of isopropanol and other 
secondary alcohols however has the inherent problem of ketone/alcohol equilibrium, 
preventing high conversion being obtained. This is due to the similarity of the 
hydrogen source and the product; both being secondary alcohols. In effect, the reverse 
process may take place, where the chiral secondary alcohol (product) acts as the 
hydrogen donor, transferring its hydrogen and oxidising back to the starting ketone 
(starting material), and reducing the acetone back to isopropanol.
14a
 The reverse 
process which can be enhanced by elongated reaction times or high substrate 
concentration, has frequently caused deterioration in optical purity of the chiral 
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product. The oxidation potential of the substrate controls the position in which the 
equilibrium lies,
14b
 therefore 100% conversion is theoretically impossible and it is 
often required to use low substrate concentration to maximise the yield in the reaction. 
A base is normally used in transfer hydrogenation reactions, when isopropanol is 
utilized as the source of hydrogen (a), Scheme 21). 
In recent years, formic acid/triethylamine (5:2) mixture (triethylammonium formate), 
which is a highly activated form of formic acid,
14c
 has been used as the source of 
hydrogen in transfer hydrogenation reactions. The use of formic acid eradicates the 
problem of reversibility encountered with isopropanol, as the dehydrogenation of 
formic acid generates gaseous carbon dioxide which is usually released in to the 
atmosphere in an open system. This process is therefore irreversible, meaning 
complete reduction can now be theoretically achieved, and with enantioselectivity 
being under kinetic control. (b), Scheme 21) 
 
Scheme 21. Transfer hydrogenation reaction using a) isopropanol and b) formic acid 
as source of hydrogen.  
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1.4.3     Ligands for Asymmetric Transfer Hydrogenation. 
A general review on the more recently developed ligands used in asymmetric transfer 
hydrogenation will be presented. Acetophenone 49a is usually used, unless stated, as a 
model substrate for comparing the reactivity of the ligands. 
Throughout the years various phosphine 50-52,
15a-15d 
pyridine-based 53-55,
15e-15g
 
tetrahydrobi(oxazole) 56-58,
15h-15j
 diamine 59-62,
16a-16e
 diimine 63,
16f
 BINOL-derived 
diphosphonite 64,
16g
 tridentate 65-69
16h-16j, 17a-17b
 and tetradentate 70-71 ligands
17c
 have 
been used in conjunction with either Ru, Rh and Ir as ATH catalysts, giving poor to 
excellent enantioselectivity for the reduction of acetophenone  49a (Figure 13). 
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Figure 13. Types of ligands used over the years for the ATH of 49a. 
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These processes could still be further improved for practical use in organic synthesis, 
being limited by low catalytic activity, insufficient enantioselectivity, low 
substrate/catalyst molar ratio (S/C), or narrow scope. 
1.4.3.1     β-Amino alcohol ligands. 
In 1996, Noyori and co-workers discovered that the ATH reduction of aromatic ketones, 
using chiral β-amino alcohols 72-74 in propan-2-ol catalysed by arene-ruthenium(II) 
complex showed high-ligand acceleration effects, and high enantioselectivity (Scheme 
22).
17d
 
 
Scheme 22. ATH of 49a using Ru(II) complexes of 72, 73 and 74. 
Entry Ligand Time (hrs) % Yield % ee Configuration 
1 (1S,2S)-72 1 96 78 S 
2 (1S,2S)-73 1 94 92 S 
3 (1S,2R)-74 1 95 91 S 
Table 2. ATH of 49a using Ru(II) complexes of 72, 73 and 74. Reaction was carried out 
at 28 °C using a 0.1 moldm
-3
 solution (5 mmol) in IPA. Ketone:Ru:ligand:KOH = 
200:1:2:5. 
The highest chiral efficiency (Table 2) was shown by hexamethylbenzene-(1S, 2S)-2-
methylamino-1,2-diphenylethanol [(1S, 2S)-73], giving 49a’ in 92% ee and 94% yield 
after 1 hr at 28 °C. The reduction proceeded 5x faster than the reaction using 
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[{RuCl2(η
6
-C6H3Me3-1,3,5)}2]-(1S,2S)-N-(toluene-p-sulfonyl)-1,2-
diphenylethylenediamine system which was reported by Noyori in 1995.
17e
 
Intrigued by this, Wills (Scheme 23, 75-77)
17f
 and Anderson (Scheme 24, 78-80)
17g 
investigated the use of stereochemically rigid β-amino alcohol ligands with Ru(II) 
complexes, in the attempt to increase the activity of the catalyst, decrease the catalyst 
loading and to maximise enantioinduction for industrial applications. 
 
Scheme 23. ATH of 49a using Ru(II) complexes of 75, 76 and 77. 
Entry Ligand Time (hrs) % Yield % ee Configuration 
1 (1R,2S)-75 1.5 70 91 S 
2 (R)-76 2 95 23 S 
3 (1S,2R)-77 15 33 27 S 
Table 3. ATH of 49a using Ru(II) complexes of 75, 76 and 77. Reaction was carried out 
at 28 °C using 1 mol% of 75, 76 or 77, 0.25 mol% of [RuCl2(p-cymene)]2, 2.5 mol% of 
KOH, IPA. 
The stereochemically rigid amino alcohol 75 in conjunction with [RuCl2(p-cymene)]2 
proved to be an excellent catalyst for the reduction of 49a, giving 49a’ in 70% yield and 
91% ee (Table 3, Entry 1). The results obtained for the reduction of a series of aromatic 
ketones under identical conditions using 75 gave the corresponding alcohols in good to 
excellent yield‟s and ee‟s. In contrast to this, using a non-rigid amino alcohol 76 for the 
reduction of 49a did give a relatively high conversion of 95 % but quite a low ee of 23% 
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(Table 3, Entry 2). The importance of a primary amine group was clearly identified due 
to the low conv/ee (Table 3, Entry 3) obtained when 77 was employed for the ATH 
reduction.
17f
 
A new generation of 2-azanorbornyl stereochemically rigid amino alcohol ligands were 
highly active for the reduction of aromatic ketones and extremely active when a ketal 
function was introduced into the ligands 78-80.
17g
 
 
Scheme 24. ATH of 49a using Ru(II) complexes of 78, 79a-79d and 80. 
Entry Ligand Time (hrs) % conv % ee Product TOF 
(h
-1
) 
1 78 3 90 94 1050 
2 79a 1 92 96 3000 
3 79b 1 72 95 1900 
4 79c 1 90 96 2800 
5 79d 1 73 96 1500 
6 80 0.25 97 96 8500 
Table 4. ATH of 49a using Ru(II) complexes of 78, 79a-79d and 80. S/C = 1000 
The ATH reduction of 49a using [Ru(p-cymene)(79a)], showed an increase in 
conversion, ee and a threefold increase in rate when compared to [Ru(p-cymene)(78)]. 
The DFT studies showed that the possible explanation for this enhancement in rate is 
due to the presence of a dioxolane ring in 79a which lowers the energy in the transition 
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state caused by van der Waals attractions between the dipole in the dioxolane ring and 
the dipole in the substrate. Modifications made to the substituents on the ketal group 
(79b-79d) did not further enhance the activity of the catalyst. However when [Ru(p-
cymene)(80)] was used for the reduction of 49a, the activity of the catalyst was far 
greater than [Ru(p-cymene)(79a)], giving 97% conversion, 96% ee within 25 minutes 
with product TOF (h
-1
) of 8500 in comparison to 3000 for [Ru(p-cymene)(79a)]. 
Encouraged by this a study of different S/C ratios using [Ru(p-cymene)(80)] was carried 
out, and showed that even at an S/C ratio of 5000 the reaction proceeded to full 
conversion after 90 mins, but at an S/C ratio of 7000 the reaction stopped at 85% 
conversion (Table 5). The enantioselectivity was unaffected by lowering the quantity of 
catalyst and prolonged reaction times. The studies also showed that a wide range or 
aromatic ketones were reduced successfully, giving high rates/enantioselectivities with 
catalyst loading being as low as S/C = 1000.
17g
 
Entry S/C Time (mins) % conv % ee 
1 200 6 96 96 
2 1000 15 97 96 
3 3000 45 96 96 
4 4000 70 95 96 
5 5000 90 96 96 
6 7000 110 85 96 
Table 5. Catalyst-loading study for the ATH of 49a using [Ru(p-cymene)(80)] was 
carried out. 
The highest levels of acceleration to ATH reduction reactions was obtained by beta-
amino alcohols (some 70-fold over the background rate),
17h
 with mono-tosylated ligands 
coming second (ca. 30-fold over background rate), and the others giving slightly more 
than 7- to 8- fold acceleration. The major drawback with the use of beta-amino alcohol 
ligands is its incompatibility like most other ligands with the formic acid/triethylamine 
Introduction 
 
36 
 
system, solving the reversibility issue which occurs in the IPA/KOH system (Section 
1.4.2). Monotosylated ligands however work well with both systems. 
1.4.3.2     1,2-Monotosylated ligands. 
The development in the area of monotoyslated ligands out of all has been the most 
significant and important for ATH reactions. This area has been led by Noyori, who was 
the first to report the use of monoarylsulfonylated diamines, in particular 81, as ligands 
in Ru(II)-catalysed transfer hydrogenation, giving excellent conversions and 
enantioselectivities for aromatic ketones.
17e
 
 
Scheme 25. The first reported use of 1,2-monotyslated diamine ligand 81 in Ru(II)-
catalysed transfer hydrogenation using IPA/KOH and FA/TEA system. 
Entry Catalyst Time (hrs) % conv % ee Configuration 
1
a
 (S,S)-82 15 95 97 S 
2
b
 (S,S)-82 20 >99 98 S 
Table 6. ATH reduction of 49a using (S, S)-82 in IPA/KOH and FA/TEA. 
a 
The reaction 
was carried out at room temperature using a 0.1 M solution of ketone (5.0 mmol) in 
IPA, KOH (0.13 mmol) with S/C = 200.
 b
 The reaction was carried out at 28 °C using a 
ketone (5.0 mmol) in FA/TEA (5:2, 2.5 cm
3
) with S/C = 200. 
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The results show that both IPA and formic acid/triethylamine azeotrope can be utilized 
as hydrogen donors (Entry 1 and 2, Table 6), but the FA/TEA system using 82,
17i
 
usually obtained in situ by heating a mixture of [RuCl2(η
6
-mesitylene)]2 with 81 in IPA 
at 80 °C for 20 mins under argon, afforded excellent enantioselectivities (83-99% ee) 
for a wide range of substrates, as the method overwhelms the energetic requirement of 
the reduction process (irreversible), in comparison to using IPA as the hydrogen donor 
where an unfavourable thermodynamic balance is expected (reversible). The activity 
and the ability to carry out reductions enantioselectively with such catalysts are 
dependent on the steric and electronic properties of the arene ligand and the chiral 
diamine auxiliary. The reactivity decreases in the order benzene > p-cymene and 
mesitylene > hexamethylbenzene as ligand, while mesitylene or p-cymene displays a 
better enantioselection than unsubstituted benzene.
17i
 In the TsDPEN auxiliary, the 
presence of the NH2 terminus was crucial as the NHCH3 analogue gave much lower 
activity but comparable enantioselectivity; the N(CH3)2 derivative not only gave poor 
reactivity but also poor stereoselectivity.
17i
 Wills demonstrated that instead of forming 
the catalyst in situ, reductions with isolated N-alkylated TsDPEN Ru(II) complexes 
bearing a small alkyl group proved to be highly active and enantioselective for the ATH 
reduction of ketones (Scheme 26).
17j
 
 
Scheme 26. ATH reduction of 49a using Ru(II) complexes of N-alkylated TsDPEN 
ligands. 
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Entry Catalyst Time 
(hrs/days) 
% yield % ee Configuration 
1 (R,R)-83 26 hrs 99 95 R 
2 (R,R)-84 11 hrs 99 96 R 
3 (R,R)-85 3 days 99 96 R 
4 (R,R)-86 3 days 99 96 R 
5 (R,R)-87 7 days 88 98 R 
6 (R,R)-88 7 days 97 95 R 
7 (R,R)-89 7 days 97 96 R 
Table 7. ATH reduction of 49a using Ru (II) complexes of N-alkylated TsDPEN 
ligands. Reaction was carried out at room temperature using a ketone (1.0 mmol) in 
FA/TEA (5:2, 1.0 cm
3
) with S/C = 100 and C6D6 (0.05 cm
3
, for NMR studies). 
N-Methylated complex 84 (Entry 2, Table 7) showed superior catalytic activity than 
Noyori‟s 83 (Entry 1, Table 7) and equally enantioselective. These results suggest the 
despite having an alkyl group on the nitrogen, the complexes are still capable of 
reducing ketones through the six-membered transition state established for the parent 
non-alkylated catalyst (Section 1.4.4). The activity however was reduced when ligands 
contained bulkier substituents (Entry 5-7, Table 7).
17j
  
The use of a „roofed‟ cis-1,2-diamine-Ru(II) complex 90 which is both 
conformationally and sterically rigid developed by Matsunaga, proved to be an excellent 
catalyst for the ATH of ketones, and showed higher catalytic activity than 83 and 38 
(Scheme 27, Table 8), also giving higher enantioselectivity for certain bulky aromatic 
ketones.
17k
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Scheme 27. ATH reduction of 49a using catalyst 83, 90 and 38. 
Entry Catalyst Time (hrs) % yield % ee Configuration 
1 (S,R)-90 15 98 93 S 
2 (R,R)-83 16 98 96 R 
3 (R,R)-38 20 >99 98 R 
Table 8. ATH reduction of 49a using catalysts 83, 90 and 38. Reaction was carried out 
at 25 °C using a ketone (2.0 mmol) in FA/TEA (5:2, 1.0 cm
3
) with S/C = 200. 
The ATH of 49a using catalyst 90 completed the reduction process within 15 hrs, giving 
98% yield and 93% ee (Entry 1, Table 8). Although 83 and 38 were slightly more 
enantioselective in comparison to 90, catalyst 83 and 38 were less active, completing 
the reaction within 16 hrs and 20 hrs respectively.
17k
  
Another example of a highly active transfer hydrogenation ligand is 91, commonly 
known as TsCYDN, which was first employed in conjunction with [RuCl(p-cymene)]2 
forming 92, for the reduction of 49a, giving 49a’ in >99% conversion and 94 ee 
(Scheme 28). 
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Scheme 28. Knochel demonstrated the use of 91 with [RuCl(p-cymene)]2 for the ATH 
reduction of 49a. Reaction was carried out at 30 °C in FA/TEA (5:2) with the presence 
of [RuCl(p-cymene)]2 (0.5 mol%), and TsCYDN (2 mol%). 
Further investigations using 91 and 81 were carried out by Ikariya, forming new chiral 
rhodium and iridium complexes [Cp*MCl(Tsdiamine) (M = Rh, Ir) 93-95 for the ATH 
reduction of aromatic ketones. The structures of the rhodium and iridium complexes 
formed has a structure isoelectronic with the chiral Ru complex 83 (Scheme 29).
17l
 
 
Scheme 29. ATH reduction of 49a using new chiral rhodium and iridium complexes with 
chiral diamine ligands. 
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Entry Catalyst Time (hrs) % conv % ee Configuration 
1 83 12 92 94 R 
2 93 12 14 90 R 
3 94 12 85 97 R 
4 95 12 36 96 R 
Table 9. ATH reduction of 49a using catalyst 83, 93-95. Reaction was carried out at 30 
°C using a 0.1 M solution of the ketone in IPA. Ketone/cat./
t
BuOK = 200:1:1.2.  
The rate and enantioselectivity of the reaction are strongly affected by the metal used 
and the structure of the chiral diamine ligands (Table 9). The use of TsCYDN 91 was 
better utilized by Rh, with complex 94 giving 49a’ in 85% conv. and 97% ee (Entry 3, 
Table 9) within 12 hrs in comparison to 36% conv. and 96% ee (Entry 4, Table 9) 
obtained within 12 hrs for Ir complex 95. The enantioselectivity obtained with both 
complexes 94 and 95 were comparable, but the conversion obtained for 95 was fairly 
low. The use of 93, when TsDPEN (R,R-81) is combined with [Cp*RhCl2]2 for the 
reduction of 49a, gave 49a’ in 14% conv. and 90% ee (Entry 2, Table 9), showing it‟s 
reactivity isn‟t as high as the analogous Ru complex 83 (Entry 1, Table 9), and the 
enantioselectivity is lower. Complexes containing diamine TsCYDN 91 might not be as 
reactive as its competitor diamine 81, but the enantioselectivity obtained is higher 
(Entry 1, 3 and 4, Table 9).
17l
 
1.4.4     Mechanistic studies. 
The structural and mechanistic theory behind the successful new classes of β-
aminoalcohol and monotosylated complexes synthesized by Noyori et al became targets 
of intense research. Noyori had proposed the metal ligand bifunctional catalytic 
mechanism shown in Scheme 30, which functions through a concerted transfer of a 
hydride and proton. It is sometimes referred to as the “outer sphere” mechanism because 
of the substrate having no direct contact with the metal centre. The process is initiated 
by the elimination of HCl via an E1cb mechanism from the 18-electron “precatalyst” 
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complex 38, upon treatment with an appropriate base (KOH in IPA, or triethylamine 
when formic acid is used as hydrogen donor). This results in the formation of the active 
16 electron species 96, which abstracts two hydrogen atoms 97 from the donor 
(isopropanol or formic acid) via a six-membered pericyclic transition state forming the 
hydride 98.
18a
 The kinetic isotope effect for the dehydrogenation of isopropanol was 
investigated by Casey et al,
18b
 showing that hydride and proton transfer takes place 
simultaneously, which is in correspondence to what Noyori has shown. In a concerted 
process the hydride and proton is then transferred to the ketone asymmetrically via a 
six-membered transition state, giving the product and also regenerating the active 16-
electron species. Primary and secondary amines are usually very weak acids, but after 
complexation with a lewis acidic metal, the NH acidity is increased allowing the NH---
O=C hydrogen bond formation in the transition state TS-98. The rapid H/D exchange 
with CH3OD also confirms the acidity of the protons prior to complexation. 
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Scheme 30. ATH reduction mechanism of ketones, using Noyori‟s catalyst 38. 
 
Noyori et al. isolated and characterized the three key intermediates (38, 96 and 98) 
using X-ray crystallography. They also proved that the role of base is to only generate 
the active 16 electron species from 38,
18a
 as after isolation, 96 and 98 were both tested 
for the reduction of ketones, giving results comparable to in situ formed complex.  This 
also eliminated the possibility of a direct hydrogen transfer mechanism, as this would 
require the participation of a ruthenium isopropoxide intermediate. Further 
investigations carried out by Noyori
18c
 and Andersson
18d
 confirmed this. 
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1.4.5     Origin of Enantioselection. 
Noyori has demonstrated that both Ru(II) chloride 38 and Ru(II) hydride 98 exist 
predominantly in the diastereoisomeric form (via X-ray crystallography and molecular 
modelling). This preference also extends to the amino alcohol systems, which means the 
chiral ligand renders the metal center a single configuration. Andersson had mentioned 
that the generation of an enantiopure metal centre with the use of a suitable rigid ligand 
that disapproves other configurations of the coordinated NH group can help achieve 
good product enantioselectivity.
18c,18d,19a-19c
  
The absolute stereochemistry for each “2H” transfer process is controlled via a six-
membered transition state. The favoured approach of the substrate to the metal hydride 
is the conformation in which its aromatic ring is adjacent to the arene group on the 
metal. The aromatic group of acetophenone interacts with the η6-arene element on the 
catalyst through a favourable CH/π interaction (Si-TS-99) indicated in Figure 14, and is 
supported by DFT calculations carried out by Noyori, which also showed that the 
addition of six-electron-donating alkyl groups on the η6-arene further stabilises the TS, 
increasing the rate of the reaction with a drop in selectivity however (Si-TS-100).
19d-19g
 
This supports the observation that asymmetric reduction only takes place in high ee 
when aryl/alkyl ketones are used as substrates, but not with dialkyl ketones, as no CH/π 
interaction is present. 
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Figure 14. Stereocontrol in asymmetric transfer hydrogenation. 
Noyori also investigated the effects of having electron-donating/withdrawing groups on 
the aryl substituent of the substrate, and its effects on the enantioselectivity. It was 
discovered that electron-donating substituents on the aryl group increase the 
enantioselectivity due to an enhanced CH accepting ability by the electron rich aromatic 
ring, while electron withdrawing substituents reduce the enantioselectivity.
19d, 19f, 19g 
Wills‟ and co-workers had investigated the anti-orientation, and the importance of 1,2-
disubstitution pattern of phenyl groups in TsDPEN on the rate and the stereo-outcome 
of Ru(II) catalysed ATH reactions. It was discovered that 81 was the best ligand for 
Ru(II) catalysed transfer hydrogenation reduction in-terms of rate and enantioselectivity 
in comparison to ligands 101-103, giving 49a’ in 100% conv., 98% ee (R) at 28 °C in 
22 hrs. Identifying the importance of having matching stereogenic centres and trans 
orientation of the phenyl groups, providing extra element of stereo control and rate 
enhancement (Scheme 31).
19c
 
 
Scheme 31. ATH reduction of 49a, using ligands 81, 101-103 in conjunction with 
[Ru(p-cymene)Cl2]2 (S/C = 200). 
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1.4.6     Range of Substrates for Asymmetric Transfer Hydrogenation. 
1.4.6.1     Aryl Alkyl Ketones. 
The most commonly used substrate in asymmetric transfer hydrogenation reduction are 
aromatic ketones, especially using monotosylated diamine or β-amino alcohol ligands. 
A variety of aromatic ketones were reduced using catalyst (S,S)-82 (S/C = 200), in 
FA/TEA at 28 °C, giving the resulting secondary alcohols with excellent yields and 
enantioselectivities. The reason for why the reductions proceed with excellent kinetic 
enantioface discrimination, is due to the CH/π interaction between the Ru-arene ring 
and the aryl group on the ketone, along with the favourable diastereomeric transition 
state exerted by the monotosylated diamine ligand (Scheme 32, Table 10).
17i
 
 
Scheme 32. A range of aryl alkyl ketones were reduced using (S,S)-82. 
Ketone R
2
 R
1
 Time (hrs) Yield (%) ee (%) Config. 
49a H CH3 20 >99 98 S 
49b m-Cl CH3 21 >99 97 S 
49c p-Cl CH3 24 >99 95 S 
49d p-CN CH3 14 >99 90 S 
49e m-OCH3 CH3 50 >99 98 S 
49f p-OCH3 CH3 60 >99 97 S 
49g H C2H5 60 96 97 S 
49h H (CH2)3CO2C2H5 90 99 95 S 
Table 10. A range of aryl alkyl ketones were reduced using (S,S)-82. (S/C = 200) 
1.4.6.2     Dialkyl ketones. 
ATH reduction of dialkyl ketones have proved to be problematic with the use of β-
amino alcohol and monotosylated diamine ligands in conjunction with a metal 
precursor. This is due to the absence of the CH/π interaction, as the aromatic moiety 
isn‟t present, which earlier existed for aryl alkyl ketones. In effect, the difference in 
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energy between the two possible diastereomeric transition states are now narrow, 
resulting in poor enantioselectivity. 
Wills had recently reported the reduction of cyclohexymethyl ketone using 3C 
“tethered” dimethyl functionalized catalyst 168 (Section 1.4.7) in FA/TEA, giving the 
alcohol in 100% conversion and 90% ee,
20a
 which was the highest reported ee for a 
Ru/TsDPEN based catalyst. Other successful examples for the reduction of dialkyl 
ketones by ATH have been reported by Zhang
16i,16j 
and Hidai.
20b
 In Hidai‟s report, 
successful reduction of dialkyl ketones 104 and 105 was carried out, using ferrocene 
based complex [Ru(PPh3)(osazolinyl ferrocenylphosphine)Cl2] 106 and sodium 
isopropoxide in isopropanol at 50 °C. This gave 104’ in 99% ee and 81% conv., in 16 
hrs, and 105’ in 98% ee and 78% conv., in 3 hrs (Scheme 33).20b 
 
Scheme 33. ATH reduction of dialkyl ketone 104 and 105 using complex 106. 
1.4.6.3     Heterocyclic ketones. 
Optically active pyridyl alcohols are useful key compounds, not only as pharmaceutical 
intermediates, but also as useful chiral ligands and auxiliaries in asymmetric synthesis. 
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Ikariya reported the reduction of nitrogen-containing pyridyl ketones, using Ru(II) 
complex (S,S)-38 in FA/TEA, giving the corresponding optically active pyridylethanols 
with excellent conversions and enantioselectivities. ATH reduction of 2-acetylpyridine 
107a, using Ru(II) complex (S,S)-38 (S/C = 200) in a mixture of FA/TEA 
(acetylpyridine: FA: TEA molar ratio = 1:4.3:2.5) at 27 °C, gave (S)-1-(2-
pyridyl)ethanol 107a’ with 97% yield and 95% ee in 12 hrs. The reduction of various 
derivatives 107b-107e, gave good to excellent conversions (up to 100%) and ee‟s (up to 
99.6%), except for benzoylpyridine 107e, which gave a poor ee (9%) (Scheme 34, Table 
11).
21a
 
 
Scheme 34. ATH reduction of 107a-107e using catalyst (S,S)-38. Ketone/FA/TEA 
molar ratio = 1:4.3:2.5. 
Ketone S/C Temp (°C) Time (hrs) Yield (%) ee (%) Config. 
107a 200 27 12 97 95 S 
107a 200 50 12 99 91 S 
107a
a
 200 27 24 24 89 S  
107a 1000 27 24 91 93 S 
107a 1000 50 24 14 78 S 
107b 200 27 24 99 89 S 
107c 200 27 24 99 92 S 
107d 200 27 24 100 89 S 
107e 200 27 24 84 9 R 
107f
b
 200 10 24 95 86 S 
107g
b
 200 10 24 36 85 S 
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107h
c
 200 27 24 100 99.6 S, S 
Table 11. ATH reduction of 107a-107e using catalyst (S,S)-38. Ketone/FA/TEA molar 
ratio = 1:4.3:2.5. 
a
 Reaction in 2-propanol: (S,S)-Ru cat (38), 1.0 equiv 
t
BuOK, 
ketone:Ru = 200:1, 0.1 M in 2-propanol. 
b 
1.0 M in CH2Cl2. 
c 
Ketone/FA/TEA molar 
ratio = 1:8.6:5.0. 
Asymmetric transfer hydrogenation reduction of α, β-acetylenic ketones,21b cyclic α, β-
unsaturated ketones,
21c
 and for the synthesis of styrene oxides
21d
 and aziridines
21e
 has 
also been successfully carried out.  
1.4.6.4     Imines. 
The synthesis of chiral amines in pharmaceuticals and agrochemical substances is 
highly demanding, and requires efficient catalytic asymmetric reduction of imines.  
Noyori reported the first highly efficient asymmetric reduction of a range of imines, 
using suitably designed chiral Ru(II) complexes 38, 108a-108c in formic-acid-
triethylamine mixtures under mild conditions. The reactions worked best in aprotic 
solvents including MeCN, DMF, DMSO and CH2Cl2, but not in ethereal or alcoholic 
media, and neat FA/TEA (slow reaction rate).  The structure of the Ar group and the 
substitution pattern of η6-arene ligand on the Ru complex, were fine-tuned depending on 
the substrates used. The ATH reduction of imine 109a was most successful, using (S, 
S)-38 (S/C = 200) in FA/TEA (5:2) and acetonitrile at 28 °C, giving salsolidine 109a’ 
(R) in 95% ee and >99% yield in 3 hrs. Various other cyclic imine derivatives 109b-
109e were reduced, giving excellent conversions (up to >99%) and enantioselectivities 
(up to 95%). This method was further applied to the synthesis of indoles 110a-110b, 
giving good yields (up to 89%) and excellent enantioselectivities (up to 97%), and the 
reduction of acyclic imines 111-113, which gave good conversions (up to 90%) but 
were less stereoselective (ee‟s of up to 89%) (Scheme 35, Table 12).22 
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Scheme 35. ATH reduction of 109a-109e and 110-113, using catalyst 38, 108a-108c. 
Imine Catalyst S/C Solvent Time (hrs) Yield (%) ee (%) Config. 
109a (S,S)-38 200 CH3CN 3 >99 95 R 
109a (S,S)-38 1000 CH3CN 12 97 94 R 
109b (R,R)-108a 200 (CH3)2NCHO 7 90 95 S 
109c (R,R)-108a 200 CH2Cl2 12 99 92 S 
109d (S,S)-108c 200 CH2Cl2 8 99 84 R 
109e (R,R)-108c 100 CH2Cl2 12 >99 84 S 
110a (S,S)-38 200 (CH3)2NCHO 5 86 97 R 
110a (S,S)-38 1000 (CH3)2NCHO 12 89 93 R 
110b (S,S)-38 200 (CH3)2NCHO 5 83 96 R 
111 (S,S)-108b 200 CH2Cl2 36 72 77 S 
112 (S,S)-108c 100 CH2Cl2 6 90 89 S 
113a (S,S)-108c 100 CH3CN 12 82 85 S 
113b (S,S)-108c 100 CH3CN 5 84 88 S 
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Table 12. ATH reduction of 109a-109e and 110-113, using catalyst 38, 108a-108c. 
1.4.6.5     Quinolines. 
Asymmetric hydrogenation of quinolines, giving 1, 2, 3, 4-tetrahydroquinolines has 
been described earlier in Section 1.3.3.6, along with its synthetic importance.  The first 
example of a metal-free transfer hydrogenation reduction of quinolines was reported in 
2006.
23a
 Rueping used his expertise and extended his research from the already 
developed enantioselective Brønsted acid catalysed hydrogenation of imines,
23b,23c
 in to 
the enantioselective reduction of quinolines. 
Using Brønsted acid 114, 2-phenylquinoline 115a as a test substrate for reduction and 
dihyropyridine 116 as the source of hydride, the structure of catalyst 114 was studied 
(Scheme 36, Table 13). 
 
Scheme 36. Reduction of 2-phenylquinoline, using 114 and 116. 
Entry Cat. Ar ee (%) 
1 114a Phenyl 5 
2 114b 4-biphenyl 35 
3 114c 1-naphthyl 84 
4 114d 2-naphthyl 26 
5 114e 3,5-(CF3)-C6H3 72 
6 114f 9-phenanthryl 97 
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Table 13. Studying acid 114 for the cascade transfer hydrogenation of 2-
phenylquinoline. Reaction was carried out in benzene at 60 °C, with 115a, 116 (2.4 
equiv) and 114 (5 mol %). 
The results showed that sterically congested Brønsted acids were best catalysts for 
hydride transfer and gave good to excellent enantioselectivities, with the highest 
selectivity being obtained using 114f, providing 2-phenyltetrahydroquinoline 115a’ in 
97% ee. Investigation on various solvents was also carried out with nonpolar solvents 
(chlorinated: CH2Cl2, CHCl3, CCl4 and aromatic: benzene, toluene) proving to be 
crucial for high asymmetric induction. Benzene emerged to be the best solvent in this 
system giving the highest enantioselectivity.
23a
 
 
Scheme 37. Brønsted acid catalysed cascade transfer hydrogenation of 2-substitued 
quinolines under optimized conditions. 
Quinoline R Time (hrs) Yield (%) ee (%) 
115a phenyl 12 92 97 
115b 2-fluorophenyl 30 93 98 
115c 2-methylphenyl 48 54 91 
115d 2,4-dimethylphenyl 60 65 97 
115e 2-naphthyl 12 93             >99 
115f 3-bromophenyl 18 92 98 
115g 4-(CF3)-C6H3 30 91             >99 
115h 1,1‟-biphenyl-4-yl 12 91             >99 
115i 4-methoxyphenyl 12 90 98 
115j 2-furyl 12 93 91 
115k chloromethyl 12 91 88 
115l n-butyl 12 91 87 
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115m n-pentyl 12 88 90 
117a 2-phenylethyl 12 90 90 
117b 
 
12 94 91 
117c 
 
12 95 90 
Table 14. Transfer hydrogenation reduction of 2-substitued quinolines. Reaction was 
carried out in benzene at 60 °C with 115a-m and 117a-c, 116 (2.4 equiv) and catalyst 
114f (2 mol%). 
Bronsted acid catalysed cascade transfer hydrogenation reduction using the optimized 
conditions were carried out on a series of 2-substituted quinolines (Scheme 37, Table 
14). The results showed that high enantioselectivites (up to >99%) and good yields (up 
to 95%) of several tetrahydroquinolines, with aromatic, heteroaromatic residues as well 
as aliphatic substituents were obtained. The system was also compatible with 
halogenated aromatic and aliphatic residues.
23a
 
The proposed mechanism for this process: initiation with Brønsted acid catalyst 114 
protonating quinoline 115, forming the active iminium ion A. Subsequent transfer of 
hydride from 116, gives the enamine 118 and pyridinium salt B. Brønsted acid 114 is 
regenerated after proton transfer from B, forming Hantzsch pyridine 119. The desired 
tetrahydroquinoline is formed 115’, after the reaction of enamine 118 in a second cycle 
with Brønsted acid 114, forming iminium C which is subjected to hydride transfer from 
dihydropyridine 116 (Scheme 38).
23a
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Scheme 38. Proposed mechanism for the Brønsted acid catalysed cascade transfer 
hydrogenation. 
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The use of Hantzsch esters was further applied by Zhou in his system.
23d
 In 2007, Zhou 
reported the first metal catalysed asymmetric transfer hydrogenation of quinolines 120a-
f, 115a, 115l-m, 117a-c, using [Ir(COD)Cl]2/(S)-SegPhos 35/I2 and a Hantzsch ester 
121 (Scheme 39). 
 
Scheme 39. Ir-catalysed asymmetric transfer hydrogenation of quinolines. 
The optimized conditions for this system were obtained from studying the effects of 
solvents, different ligands, and different sizes of Hantzsch esters. In the study of solvent 
effects, solvents including THF, DME, toluene, DCM and dioxane were used. The two 
solvents that gave great results were toluene and dioxane, with the highest reactivity 
given by dioxane and highest enantioselectivity by toluene. Some commercially 
available ligands (Figure 15) were screened including (S)-MeO-BiPhep 31, (S)-SegPhos 
35, (S)-SynPhos 122, (R, R)-Me-DuPhos 123, (R)-Cl-MeOBiPhep 124 and (S)-BINAP 
125, with the best result given by (S)-SegPhos 35.
23d
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Figure 15. Commercially available chiral ligands screened. 
In the investigation of different Hantzsch ester sizes, dimethyl Hantzsch 121 ester out of 
diethyl-, di-
i
propyl- and di-
t
butyl gave the highest rate and enantioselectivity. The ATH 
reduction of 2-methylquinoline 120a was then carried out using [Ir(CODCl]2 / (S)-
SegPhos 35, dimethyl Hantzsch ester 121, 2/1 toluene/dioxane in presence of iodine at 
rt (Scheme 40), and the best overall result was obtained, giving 2-methyl-1,2,3,4-
tetrahydroquinoline 120a’ in 86% yield and 87% ee (Entry 1, Table 15). Once the 
optimal conditions were established, various quinolines were reduced (Entry 2-12, 
Table 15).
23d 
 
Scheme 40. Ir-catalysed asymmetric transfer hydrogenation of quinolines, using optimal 
conditions. 
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Entry R‟/R Yield (%) Time (hrs) ee (%) Config. 
1 H/Me 86 (120a) 42 87 (S) 
2 H/Et 92 (120b) 42 87 (S) 
3 H/n-Bu 98 (115l) 42 81 (S) 
4 H/n-Pentyl 94 (115m) 45 68 (S) 
5 F/Me 90 (120c) 45 86 (S) 
6 Me/Me 82 (120d) 56 86 (S) 
7 MeO/Me 43 (120e) 74 81 (S) 
8 H/Phenethyl 88 (117a) 45 87 (S) 
9 H/3,4-
Methylenedioxyphenethyl 
87 (117b) 46 87 (S) 
10 H/3,4-
(MeO)2C6H3(CH2)2- 
92 (117c) 46 88 (S) 
11 H/Ph2C(OH)CH2- 76 (120f) 79 78 (R) 
12 H/Ph 90 (115a) 69 10 (R) 
Table 15. Ir-catalysed asymmetric transfer hydrogenation of quinolines, using optimal 
conditions. Reaction was carried out at rt using quinoline (0.25 mmol), [Ir(COD)Cl]2 (1 
mol%), ligand (2.2 mol%), I2 (5 mol%), solvent (2.5 cm
3
) and Hantzsch ester (2.0 
equiv) 
The results showed that for 2-alkyl substituted quinolines, good yields (up to 98% 
yield), and enantioselectivities (up to 87%) were obtained, with the enantioselectivity 
decreasing when the length of the side chain is increased (Entry 1-4, Table 15). The 
reaction time had increased when having substituents at the 6-position (Entry 5-7, Table 
15), with low conversion also being obtained if the group at the 6-position is electron 
donating. 2-(2-Arylethyl)-substituted quinolines (Entry 8-11, Table 15) were reduced in 
good yields (up to 92% yield) and enantioselectivities (up to 88% ee), and the system 
can also withstand substrates that have a hydroxyl group present (Entry 11, Table 15). 
Good yield was obtained with 2-aryl substituted quinoline, but the enantioselectivity 
was poor (10% ee) (Entry 12, Table 15).
23d
   
ATH reduction using Hantzsch esters as the source of hydrogen have given excellent 
results with both metal-free and Ir/diphosphine-catalysed methods. Xiao et al. in 2010 
Introduction 
 
58 
 
reported the first ATH of quinolines in aqueous solution using a metal catalyst (Scheme 
41),
23e
 with the reaction being carried out in air, giving excellent enantioselectivities for 
a wide range of substrates. The use of water does not only offer new reactivity and 
selectivity patterns but also advantageous economic and ecological gains.
23e
 
 
Scheme 41. ATH of quinolines in water, and showing the possible reaction 
intermediate. 
Previously, ATH reduction of ketones and imines was studied in neat water,
23e
 using 
TsDPEN 81 with Ir [(Cp*IrCl2)2], Rh [(Cp*RhCl2)2] and Ru [{RuCl2(p-cymene)}2] 
metals, from which Rh-TsDPEN catalyst showed highest reactivity and selectivity.
23f
 
Due to this, initial studies for the reduction of 2-methylquinoline 120a were carried out 
using presynthesized Rh-TsDPEN catalyst
23g
 with HCOONa in water. This particular 
method gave a very poor conversion but excellent enantioselectivity. Xiao and co-
workers had previously studied the ATH of ketones in water, and had established that 
the rate of reaction was dependant on the pH of the solution.
23f,23h
 Taking this in to 
account, the pH effect of solution for the reduction of quinolines was examined, by 
monitoring the conversion at initial pH values of solution, from 3 up to 8 (via altering 
HCOOH/HCOONa ratio). The results showed that the highest conversion was obtained 
at initial pH of 5, which gets very close to the pKa of protonated quinoline 120a’’ (5.4), 
supporting the ionic mechanism pathway that has been previously suggested for the 
Introduction 
 
59 
 
reduction of quinolines in its protonated form.
 9g, 17j, 23a, 23i-l
 This also explains why such 
a low conversion was obtained in the earlier studies as the pH of the solution at the start 
of the reaction was 8 (Scheme 41). 
 
Scheme 42. The pH effect can be expressed with the two opposing equilibria shown: (1) 
and (2). 
The concentration of 120a’’ decreases at high pH values (pH > 5.4), and at low pH 
values (pH < 3.6) the concentration of formate becomes low. So having a pH between 
3.6 and 5.4 would be ideal for obtaining high reaction rates as it would provide a high 
concentration of both reactants (Scheme 42).
23e
 
The use of a buffered solution had resolved this issue, as it was able to maintain the pH 
of solution and avoid pH fluctuation. The buffer capacity of HCOOH/HCOONa pair 
with a pKa value of 3.6 was not sufficient, but the use of HOAc/NaOAc, having 
maximum buffer capacity of pH 5 proved to be ideal in this ATH system. ATH of 120a 
in 2 M HOAc/NaOAc buffer solution gave the resulting 1,2,3,4-tetrahydroquinoline 
120a’ with 95% conversion and 96% ee in 3 hrs.23e 
In the attempt to further improve the ATH efficiency, various metal precursors (Entry 1-
3, Table 16) and ligands (Entry 4-12, Table 16) were tested for the reduction of 120a 
using the optimized conditions (Scheme 43).  The metal precursor [(Cp*RhCl2)2], in 
comparison to the isoelectronic [{RuCl2(p-cymene)}2] and  [(Cp*IrCl2)2] (Entry 1-3, 
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Table 16), gave the best result with TsDPEN 81 as the ligand. Using [(Cp*RhCl2)2], 
various ligands were tested (Entry 4-12, Table 16) from which 122d gave the best 
reactivity and selectivity.
23e
 
 
Scheme 43. Reduction of 120a using different metal precursors and various ligands. 
Entry M Ligand R Conv. (%) ee (%) 
1 [{RuCl2(p-cymene)}2] 81 
 
32 90 
2 [(Cp*IrCl2)2] 81 
 
88 11 
3 [(Cp*RhCl2)2] 81 
 
95 96 
4 [(Cp*RhCl2)2] 81 
 
49 96 
5 [(Cp*RhCl2)2] 122a 
 
13 83 
6 [(Cp*RhCl2)2] 122b 
 
12 74 
7 [(Cp*RhCl2)2] 122c 
 
34 94 
8 [(Cp*RhCl2)2] 122d 
 
55 97 
9 [(Cp*RhCl2)2] 122e 
 
48 96 
10 [(Cp*RhCl2)2] 122f 
 
31 94 
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11 [(Cp*RhCl2)2] 122g 
 
39 90 
12 [(Cp*RhCl2)2] 122h CH3 27 94 
Table 16. Reduction of 120a using different metal precursors and various ligands. 
Reaction was carried out at 40 °C, using quinoline (0.5 mmol), metal precursor (2.5 
µmol), ligand (6 µmol), HCOONa (5 mmol) and 2 M HOAc/NaOAc buffer solution (5 
cm
3
). Reaction time was 12 hrs for entries 1-3 and 0.5 hrs for entries 4-12. 
As a result (Entry 8, Table 16), complex 123 (Scheme 44) was prepared using ligand 
122d and [(Cp*RhCl2)2], which was selected as the catalyst for the ATH reduction of a 
series of quinolines (Entry 1-25, Table 17) in an aqueous formate solution buffered to 
pH 5 with HOAc/NaOAc.
23e
 
Excellent enantioselectivities and yields were observed for a range of substrates, with 
the alkyl chain length in the 2-position, and substituents in 6- or 7- position having little 
effect on the enantioselectivity. The yield was however lowered with having electron-
rich substituents at the 6-position. 2-Phenyl-substituted quinolines were better reduced 
at a lowered pH value of 4, with the catalyst formed when ligand 122f was combined 
with [(Cp*RhCl2)2].
23e
 
 
Scheme 44. ATH reduction of a range of quinolines using catalyst 123. 
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Entry Product Product Yield (%) ee (%) 
1 120a’ 
 
96 97 
2 120b’ 
 
95 96 
3 124a’ 
 
93 97 
4 115l’ 
 
94 97 
5 115m’ 
 
95 97 
6 124b’ 
 
92 97 
7 120e’ 
 
96 96 
8 124c’ 
 
95 96 
9 124d’ 
 
96 95 
10 124e’ 
 
97 96 
11 120f’ 
 
91 96 
12 120g’ 
 
90 98 
13 124f’ 
 
86 91 
14 124g’ 
 
88 98 
15
a
 124h’ 
 
87 96 
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16 124i’ 
 
97 97 
17 124j’ 
 
84 97 
18 117b’ 
 
85 97 
19 124k’ 
 
80 96 
20 124l’ 
 
90 97 
21
b
 115a’ 
 
96 90 
22
b
 115i’ 
 
95 90 
23
b
 124m’ 
 
93 89 
24
a
 124n’ 
 
89 92 (4 : 1)
c
 
25 124o’ 
 
95 86 (99 : 1)
c
 
Table 17. ATH reduction of a range of quinolines using catalyst 123. Reaction was 
carried out at 40 °C, using quinoline (0.5 mmol), 123 (5 µmol), HCOONa (5 mmol) and 
buffer solution (5 cm
3
). Reaction time was between 6-24 hrs. [a] 2 mol% of 123 used. 
[b] ligand 122f used  at pH 4 in 2 M HOAc/NaOAc buffer solution (5 cm
3
) with EtOAc 
(0.3 cm
3
). [c] diastereoselectivity in brackets. 
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1.4.6.6     Synthesis of Biologically Active Compounds. 
1.4.6.6.1     (S)-Fluoxetin. 
(S)-Fluoxetin 126 is an anti-depressant used for the treatment of clinical depression. A 
practical method was reported by Ikariya using ATH for the synthesis of (S)-fluoxetin 
126. ATH reduction of 2-cyanoacetophenone 125 using catalyst (S,S)-38 in formic 
acid/triethylamine at 30 °C, gave the key intermediate 125’ for the formation of (S)-
fluoxetin 126 in 100% yield and 98% ee in 24 hrs (Scheme 45).
24a
 
 
Scheme 45. ATH reduction of 125 in FA/TEA (3.1:2.6), using catalyst (S,S)-38 (S/C = 
1000) gave the key product 125’, for the synthesis of (S)-fluoxetin 126.  
 1.4.6.6.2     (S)-MA-20565. 
(S)-MA-20565 128 is a wide-spectrum agricultural fungicide, and the formation of the 
key intermediate step can be carried out using ATH as reported by Tanaka et al.  The 
reduction of 1-(3-(trifluoromethyl)phenyl)ethanone 127, using (S,S)-38 (S/C = 5000) in 
FA/TEA (5:2) azeotrope at 50 °C, gave the key intermediate 127’ in 96% conv., and 
91% ee after 30 hrs (Scheme 46).
24b
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Scheme 46. ATH reduction of 127 in FA/TEA (5:2), using catalyst (S,S)-38 (S/C = 
5000) gave the key product 127’, for the synthesis of (S)-MA-20565 128. 
1.4.6.6.3     Aprepitant. 
Aprepitant 130 is an antimetic compound that belongs to a class of drugs called 
substance P antagonists. It mediates its effect by blocking the neurokinin 1 (NK1) 
receptor, and is used for the prevention of acute and delayed chemotherapy-induced 
nausea and vomiting. The key intermediate for this drug 129’ can be obtained by ATH. 
The reduction of 1-(3,5-bis(trifluoromethyl)phenyl)ethanone 129, using Ru(II) complex 
of (1S,2R)-cis-aminoindanol 75 combined with [Ru(p-cymene)Cl2]2 (S/C = 200) and 
KOH in IPA at rt, gave the key intermediate 129’ of Aprepitant 130 in 98% conv., and 
91% ee (R) after 4 hrs. The enantioselectivity of the product can be further enhanced by 
isolation of the alcohol 129’ as its DABCO complex 129’’, giving >99% ee (Scheme 
47).
24c
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Scheme 47. ATH of 129 using Ru(II) complex of 75, giving the key intermediate 129’ 
followed by 129’’ prior to isolation as a DABCO complex. 
ATH has also been applied for the synthesis of an intermediate of L-699,392 (LTD4 
antagonist)
17i
 and can also be used to reduce sulphur containing ketones in order to 
prepare the intermediate for MK-0417.
17i 
1.4.7     Asymmetric transfer hydrogenation using ruthenium(II) “tethered” 
catalysts. 
In recent years, successful structural modifications have been carried out on Noyori‟s 
catalysts, based on Ru(II) complexes of amino alcohols and monotosylated diamines 
such as complex 99 and 38 respectively. A new class of “tethered” Ru(II) catalysts was 
developed by Wills and co-workers in 2004, where the chiral amino alcohol or 
monosulfonylated diamine is covalently bound to the η6-arene group through a 
hydrocarbon bridge. The tether link allows “locking” of the otherwise freely rotating 
aryl group, and permits control over the spatial positions of the substituents on this ring. 
Furthermore, the stability of the catalyst is increased due to attachment of the ligand to 
the metal at three points, reducing ligand dissociation from the metal centre. 
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The synthesis of “tethered” amino alcohol catalyst 135 has been outlined in Scheme 48. 
The formation of chloro-bridged η6-arene ruthenium(II) complex 134, from the reaction 
of 133.HCl with RuCl3 under reflux in ethanol was the major step towards the formation 
of 135. The protonation of amine group in 133 is essential to form dimer 134, as the 
attempted reaction with free amine resulted in formation of complex product mixtures, 
possibly due to the chelation of Ru(III) by the free amine outpacing arene oxidation.
25a
 
 
a) Na, NH3, EtOH, -78 °C, 3 hrs; (b) (ClCO)2 (1.2 eq), DMSO (2.5 eq), Et3N (5.5 eq), 
DCM, -78 °C, 80 mins; c) i) 4Å molecular sieves, L-(-)-norephedrine (1 eq), DCM, rt, 
o/n, ii) NaBH4 (3 eq), MeOH, rt, o/n; d) HCl, Et2O, rt; e) RuCl3 hydrate, EtOH, reflux, 
21 hrs (two steps).  
Scheme 48. Synthetic route for the formation of dimer 134, forming 135 in situ under 
the ATH reduction conditions. 
Although Wills and co-workers were not able to isolate 135 from the treatment of 134 
with base, 135 however did form in situ during reduction of acetophenone 49a by dimer 
134 in IPA with KOH, giving the resulting alcohol in 96% yield and 66% ee after 1 hr 
(Scheme 49). The yield and ee obtained in this reaction is an improvement to what has 
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been obtained using analogous non-tethered catalyst derived from the combination of 
(1R,2S)-ephedrine and [Ru(benzene)Cl2]2 (86% yield, 58% ee). Dimer 134 failed to 
react in formic acid/triethylamine (5:2) azeotrope mixture, like other amino alcohol 
based catalysts previously mentioned (Section 1.4.3.1).
25a
 
 
Scheme 49. ATH reduction of 49a using dimer 134, and its non-tethered analogue. 
As well as amino alcohol, monosulfonylated diamine “tethered” catalysts such as 140 
can also be synthesized. But unlike 135, monosulfonylated diamine catalyst 140 can be 
isolated from the reaction of dimer 139, with Et3N, in refluxing IPA for 1 hr. The X-ray 
crystal structure of 140 confirmed the presence of the “tether” link, and showed that the 
ligand coordinates to the metal centre in a similar manner to the non-tethered analogue 
(Complex formed from the combination of [Ru(benzene)Cl2]2 with TsDPEN) (Scheme 
50).
25a
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a) CH3CO3H (36-40% in acetic acid) (3 eq), DCM, rt, 2 hrs; b) Na, NH3, EtOH, -78 °C, 
3 hrs; c) SOCl2 (20 eq), DMF (2 eq), DCM, 35 °C, 16 hrs; d) Et3N (2 eq), DCM, rt, o/n; 
e) HCl, Et2O, rt; f) RuCl3 hydrate, EtOH, reflux, 21 hrs, 66% (two steps); g) in situ 
during reaction or Et3N, 
i
PrOH, reflux, 1 hr (preparation of 140). 
Scheme 50. Synthetic route for the formation of 140, which can also be formed in situ 
using dimer 139 under ATH reaction conditions 
The reduction of 49a was successfully carried out using 140 in formic 
acid/triethylamine (5:2) azeotrope, giving 49a’ in >99% yield and 96% ee after 18 hrs. 
The result obtained was comparable to that obtained using the non-tethered analogue, 
with the same configuration of product formed when the same enantiomer of ligand is 
used. This shows that the mode of action of the catalyst is unaffected with the presence 
of the “tether”.25a 
 
Ruthenium dimer 139 can also be used directly for ATH reductions, as it forms 140 in 
situ. The formation of monomer from dimer involves neutralisation of the salt, splitting 
of the dimer and wrapping of the ligand around the metal. Reduction of 49a with dimer 
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139 in formic acid/triethylamine (5:2) azeotrope, gave 49a’ in >99% yield and 96% ee 
after 21 hrs (Scheme 51), showing same level of reactivity and enantioselectivity in 
comparison to 140, but with a slight increase in reaction time. This induction period is 
the time required for the conversion of dimer to the monomer. The increased stability 
given by the “three-point” ligand attachment to the metal was proved by the studies 
carried out to test the longetivity of 140. Acetophenone 49a in addition to formic 
acid/triethylamine (5:2) azeotrope mixture were added consecutively after completion 
of each reduction, and after 176 hrs, 3 batches of acetophenone were successfully 
reduced, without loss of enantioselectivity.
25a
  
 
Scheme 51. ATH reduction of 49a, using dimer 139 and monomer 140. 
The asymmetric reduction of alkyl/alkyl substituted ketones is known to be a 
challenging transformation, as the important interaction between the aryl ring of the 
catalyst and that of the substrate is absent (Section 1.4.5). Reduction of 
cyclohexylmethyl ketone 141 was carried out to determine whether the “tethering” 
might have an effect on the enantioselectivity of this process. Using catalyst 140, the 
reduction of 141 was successfully achieved in 84% yield after 63 hrs, but the ee 
obtained was very low (19%). An improved result was obtained using catalyst 135, 
giving the reduced product in 78% yield after 2 hrs, but with an improved ee of 69%. 
The reduction of 141 using the equivalent non-tethered complex [((1R,2S)-
ephedrine)Ru(p-cymene)Cl] under the same conditions gave product in 27% yield and 
6% ee. The tethering group clearly has a dramatic influence on the selectivity of the 
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reduction process. To probe this effect catalysts 142-143 were synthesized. The 
ephedrine unit in 143 was replaced with a pseudoephedrine unit, giving 144. Catalyst 
144 was worthy of investigation as the non-tethered analogue of 144 reported by Noyori 
([((1S,2S)-pseudoephedrine)Ru(C6Me6)Cl]), reduced 141, giving 141’ in 93% yield and 
75% ee (S) (Scheme 52).
25b
 
 
Scheme 52. ATH reduction of 141, using 140, 135 and non-tethered analogue of 135. 
The reduction of 141 was effective using catalyst 142 and 143, but 135 was better 
overall. Catalyst 144 however did give the highest ee of 70%, but the conversion was 
poor (5%) (Scheme 53). The reduction of 49a was also carried out using catalyst 142-
144, with 144 giving the best result (49a’ in 99% yield and 89% ee).25b 
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Scheme 53. ATH reduction of 49a and 141, using catalyst 142-144 (S/C = 200). 
The Wills group have previously reported the importance of trans-1,2-diphenyl 
substitution pattern of TsDPEN 81 on the rate and enantioselectivity of the Ru(II) 
catalysed ATH reactions (Section 1.4.5). Such modifications of complex 140 were 
examined by synthesizing complex 145-147 (Scheme 54).
25b
 
 
Scheme 54. ATH reduction of 49a, using complex “tethered” complex 145-147 (S/C = 
200). 
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Complexes 145-147 shown in Scheme 54 were all effective for the reduction of 49a, 
giving 49a’ in good conversions, but poor ee‟s, and long reaction times.25b 
Restriction of conformations available to the arene ring serves to be one of the major 
advantages of the “tethering” complex, as this allows selective functionalization to be 
inserted, with predictable spatial arrangement. Sterically hindered groups can be placed 
at the para position of the metal arene ring (Figure 16), changing the basis of 
enantiocontrol from electronic to steric in order to target challenging substrates such as 
141. Derivatives of the two “tethering” complex 135 and 140, containing an 
aminoalcohol and a sulfonylated diamine respectively were prepared 148-155. The 
conventional method approach to synthesize “tethered” catalyst has been to use Birch 
reduction to prepare the 1,4-cyclohexadiene ring, but for the synthesis of 148-155, an 
alternative approach based on [4 + 2] cycloaddition strategy between a diene and a 
functionalised alkyne was employed. (Scheme 55).
25c
 
 
Figure 16. Proposed transition state for the ATH of 141, using catalyst 148-155, with a 
sterically hindered group in the para position. 
Catalysts 148-151 and 152-155 were tested for the ATH reduction of 49a and 141. The 
reactivity and enantioselectivity obtained for 148-155 were much lower than its parent 
complexes, possibly due to the increased steric hinderance.
25c
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Scheme 55. ATH reduction of 49a and 141, using catalyst 148-155 (S/C = 200). 
Recently Wills and co-workers had discovered that the “tethered” catalyst based on 
monosulfonylated diamine, can be significantly improved by attaching the linking group 
from the “basic” amine rather than the sulfonyl group (as in 140). The preparation of 
complex 160, refered to as “reverse-tethered” has been shown in scheme 56.25d 
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-a) 4 Å mol. sieves, DCM, o/n then LiAlH4, THF, 2 hrs. 47% (over 2 steps); b) HCl, 
Et2O then RuCl3.H2O, EtOH, reflux, o/n, 89% (over 2 steps); c) Et3N, IPA or formed in 
situ under reduction conditions. 
Scheme 56. Synthesis of the “reverse-tethered” catalyst 160. 
Catalyst 160 proved to be highly active as the reduction of acetophenone 49a was 
achieved in just 3 hrs, at 40 °C (S/C= 200), giving 49a’ in 96% ee (Scheme 57). The 
catalyst was also active and equally enantioselective at a loading as low as 0.01 mol%, 
which is unheard of for this class of ATH catalyst.
25d
 
 
Scheme 57. ATH reduction of 49a, using dimer 159 forming 160 in situ (S/C = 200). 
1
H NMR studies for the reduction of acetophenone 49a was carried out at 40 °C using 
monomer 160, dimer 159 and untethered catalyst 38 (S/C = 200) in 5:2 formic 
acid/triethylamine. A mixture of the catalyst in FA/TEA was stirred for 20 mins, 
followed by the addition of the mixture to an NMR tube along with a small quantity of 
d6-benzene and the required quantity acetophenone 49a. The results showed that the 
reactivity of 160 and 159 is far greater than untethered catalyst 38, with the complete 
reduction of acetophenone 49a using untethered catalyst 38 being achieved after 18 hrs, 
159 after 3 hrs and 160 in 110 minutes. A close examination of the reaction using dimer 
159 indicates an initial lag at the start of the reaction, due to the incomplete in situ 
conversion of the dimeric species to the monomer. Repeating the reaction with the 
dimer 159 being stirred in FA/TEA for 3.5 hrs prior to the addition of ketone, gave 
complete conversion of acetophenone in 110 minutes, identical to monomer 160. The 
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longevity of 160 was also investigated, by consecutive addition of acetophenone 49a 
and FA/TEA after completion of each reaction. After seven cycles of acetophenone 49a 
addition, the catalyst remained consistently active throughout with no loss of ee.
25e
 
Investigation on the reduction of dialkyl ketone was next carried out using catalyst 160. 
Cyclohexylmethyl ketone 141 was fully reduced using dimer 159, giving 141’ in 69% 
ee at 28 °C (S/C = 200) in 10 hrs (Scheme 58).
25e
 In comparison to 140, which gave 
141’ in 84% conversion and 19% ee after 63 hrs at 28 °C.25b 
 
Scheme 58. ATH reduction of 141, using dimer 159 forming 160 in situ (S/C = 200). 
The “tethering” at the basic amine has tremendously enhanced the enantioselectivity of 
dialkyl ketones. The configuration obtained for the reduction of cyclohexylmethyl 
ketone was opposite to that of acetophenone reduction, which indicates that the large 
cyclohexyl substituent is directed away from the arene ring of the catalyst. It was 
possible that the “tether” lies in the region occupied by the group on the ketone, 
repelling the larger alkyl group away from the “tether” (Figure 17, 160-TS). In order to 
further investigate this possibility, complex 161 with a dimethyl-substituted “tether” 
was prepared (Figure 17, 161), in a similar way to 160. As the introduction of the 
dimethyl-substituent would further increase the steric repulsion (Figure 17, 161-TS), 
and therefore increase the enantioselectivity.
25e
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Figure 17. Possible reduction transition state of alkyl/alkyl ketones using 160, and the 
predicted transition state of complex 161. 
Introducing dimethyl substitution on the “tethered” monotosylated diamine gave a 
positive result for the reduction of 141, as a 5% improvement in ee over 160 to 74% ee 
was obtained under identical conditions. The rate of reduction was however diminished 
giving only 48% conversion after 2 days (Scheme 59).
25e
 
 
Scheme 59. ATH reduction of 141, using monomer 161 (S/C = 200). 
In order to increase the activity and versatility of catalyst 160, the effects of “tether” 
length and η6-arene ring substitution pattern was examined. Complexes 164-168 were 
identified as a series of systematically modified catalysts worthy of investigation. These 
complexes were synthesized in good yields via the route shown in Scheme 60.
20a
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a) i) HCl, Et2O, rt, ii) RuCl3 hydrate, EtOH, reflux, o/n; b) in situ during reaction or 
Et3N, 
i
PrOH, reflux, 1-18 hrs. 
Scheme 60. Synthesis of “tethered” catalysts 164-168. 
Precursors 162a-e were obtained after the Birch reduction of its corresponding arenes. 
The dimers 163a-e prepared from 162a-e, can be used directly in ATH reductions, as it 
forms monomer 164-168 in situ, but for accurate comparison and analysis monomer 
164-168 were isolated. With the exception of 166, which has the longest “tether”. 
Monomer formation took place within a few hours from the reaction of dimer with Et3N 
in refluxing IPA, but for 163c only a small quantity of 166 was produced even after 
extended reaction times. ATH reduction of 49a, using 160 and 164-168 were carried out 
at 40 °C (S/C = 200) in FA/TEA (5:2) azeotrope (Scheme 61, Table 18).
20a 
 
 
Scheme 61. ATH reduction of 49a, using catalyst 160, 164-168 (S/C = 200). 
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Catalyst Loading 
(mol%) 
Temp 
(°C) 
Ketone Time (hrs) Conv (%) ee (%) 
(R/S) 
(S,S)-160 0.5 40 49a 2 100 96 S 
(R,R)-164 0.5 40 49a 15 19 92 R 
(R,R)-165 0.5 40 49a 1.25 100 96 R 
(R,R)-166 0.5 40 49a 6 38 94 R 
(R,R)-167 0.5 40 49a 4 100 96 R 
(R,R)-168 0.5 40 49a 5 100 93 R 
Table 18. ATH reduction of 49a, using 160 and 164-168 (S/C = 200). 
The results obtained from the ATH studies showed that the most active catalyst for the 
reduction of 49a was 4C-“tethered” complex 165, giving full reduction within 75 min 
with an ee of 96% (R). Complex 165 proved to be faster than the previously reported 
3C-“tethered” complex 160, and significantly faster than the 5C 166 and the 2C 164 
“tethered” complexes. The ee‟s obtained using 166 and 164 were high, showing that 
they are still operating through the transition state expected for these compounds. As a 
result of this increased activity of 165, the catalyst loading can be reduced to as low as 
0.01 mol%, matching the level at which 160
25d
 has been used.
20a
 
Kinetic studies on 160, 83 and 164-168 were carried out at 40 °C using 1.62 M ketone 
in FA/TEA (S/C = 200), with the conversion being monitored by 
1
H NMR and chiral 
GC. The studies showed that catalysts 160, 164, 166, 167 and 168 for majority of the 
reaction displayed zero-order kinetics, whereas catalyst 165 showed mixed-order 
kinetics. Analysis of this data was carried out, assuming that ketone reduction by Ru-H 
species is second-order kinetics and the regeneration of Ru-H by formic acid is first 
order kinetics. The results revealed that the high rate obtained with catalyst 165 is due to 
increased rate of hydride regeneration combined with rapid ketone reduction. Noyori‟s 
untethered catalyst 83 also showed mixed-order kinetics similar to 165, but it took 20 
hrs to complete the reduction. For other “tethered” catalysts, the overall reduction is 
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restricted by the rate of hydride regeneration, until the ketone concentration has dropped 
to low levels. (Scheme 62).
20a
  
Figure 62. Kinetic data for the reduction of 49a. Reactions were carried out at 40 °C, 
[ketone] = 1.62 M, FA/TEA (5:2), S/C = 200. 
The reduction of a dialkyl ketone using catalyst 165 and 168 was carried out, with both 
catalysts fully reducing cyclohexylmethyl ketone 141 overnight. Catalyst 165 gave the 
product in 66% ee; however catalyst 168 gave a product in 90% ee with the 
configuration of product obtained in both cases being opposite to that of acetophenone, 
relative to the diamine configuration (Scheme 63).
20a
  
 
Scheme 63. ATH reduction of 141, using catalyst 165 and 168 (S/C = 200). 
This increased ee using 168 suggests that the extra methyl groups on the η6-arene ring 
forces the larger ketone substituent in to the less hindered region (Figure 18). This 
catalyst was the first example of a Ru/TsDPEN catalyst designed and demonstrated to 
have useful levels of enantioselectivity for non-aromatic substrates, with the 
replacement of electronic elements to steric ones.
20a
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Figure 18. Dimethyl substitution on the η6-arene ring 168 increases steric hinderance, 
which in effect increases the ee (left; 90% ee) for the reduction of cyclohexylmethyl 
ketone over 160 (right; 69% ee).  
Further investigation on “tethered” catalysts was conducted, where a benzylic “tether” 
169, in place of the aliphatic one was synthesized and tested along with complex 170, in 
which the diphenyl substituted diamine ligand 81 is replaced with a homochiral R,R-1,2-
diaminocyclohexane (R,R-TsCYDN) 91 (Figure 19). Derivatives of 1,2-
diaminocyclohexane have been reported to be effective for the reduction of ketones in 
the untethered form as mentioned earlier in Section 1.4.3.2.
25f
 
 
Figure 19. “Tethered” Ru(II) catalyst 169 and 170. 
Both catalysts demonstrated good activity for the ATH of ketones in FA/TEA, but 
neither gave an improved performance relative to catalyst 165. Reduction of 49a using 
169, gave the alcohol in 100% conv., 95% ee after 24 hrs at 40 °C, and using 170, in 
100% conv., 92% ee after 12 hrs at 28 °C (Scheme 64).
25f
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Scheme 64. ATH reduction of 49a, using catalyst 169 and 170 (S/C = 200). 
 
The use of ether-linked “tethered” catalysts 171-173 (Figure 20), which have a 
stereochemically well-defined structure, and in effect controls the configuration at the 
metal centre were also examined by the Wills group for ATH.
25g
  
 
Figure 20. Ether-linked “tethered” catalysts. 
The results obtained showed that out of all, 173b (S/C = 200) proved to be the most 
active for the ATH reduction of 49a in FA/TEA (5:2) azeotrope at 40 °C, giving 49a’ in 
100% conversion and 29% ee (R) after an overnight reaction. This shows that the 
“tether” length is not interfering with the catalytic mechanism, as the activity of the 
catalyst is unaffected. The catalyst was however lacking the elements which affect the 
enantioselectivity of ketone reductions.
25g
 
Wills‟ group have also synthesized “tethered” rhodium catalysts where the β-amino 
alcohol and monotosylated diamine is “tethered” to the cyclopentadienyl group. 
Although tetramethylcyclopentadienyl group is different in structure to the arene ligand, 
the same CH/π stabilising effect is known to operate through the methyl groups as 
shown previously in Section 1.4.5. The first rhodium “tethered” catalyst synthesized 
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was 174,
25h
 which proved to be a highly active catalyst for ketone reduction, but failed 
to remain stable under reaction conditions (Figure 21). The reduction of acetophenone 
49a using 1-5 mol% of catalyst 174 and KOt-Bu in IPA at rt gave ee of up to 75% and 
conversion of up to 98% (R), but with decreasing ee as the conversion was increasing. 
Rhodium “tethered” monotosylated diamine catalysts were later prepared 175-176, 
which were stable under reactions conditions (using FA/TEA) and showed excellent 
enantioselectivity and reactivity for a range of ketone reductions. The reduction of 49a 
using 175,
25i
 gave the alcohol 49a’ in 100% conv., 98% ee (R) within 10 hrs at 25 °C in 
FA/TEA (S/C = 200), and using 176 in 100% conv., 96% ee (R) in just 2 hrs at 28 °C in 
FA/TEA (S/C = 200).
25j
 
 
Figure 21. Structures of rhodium(III) “tethered” catalysts. 
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2.     Results and Discussion. 
2.1     Asymmetric transfer hydrogenation reduction of quinolines using Ru(II) 
“tethered” catalysts. 
Tetrahydroquinoline derivatives have attracted considerable attention owing to their 
importance as synthetic intermediates for drugs, agrochemicals, and dyes as described 
earlier in Section 1.3.3.6. Reduction of quinolines to tetrahydroquinolines represents a 
simple and promising methodology as quinoline derivatives are very easily available. A 
number of reports on the pressure hydrogenation of quinolines have been published, but 
very little research has been carried out on the transfer hydrogenation of quinolines 
(Section 1.4.6.5). It would be of great interest to know whether asymmetric transfer 
hydrogenation of quinolines can be successfully carried out using “tethered” and 
untethered Ru(II) catalysts in FA/TEA, as this method if successful, would ensure 
formation of the desired product under mild conditions. 
In the preliminary studies carried out for the ATH reduction of quinolines, Blackmond‟s 
reported method was used,
23j
 whereby formic acid was added in dropwise by syringe 
over a duration of 30 mins to a mixture of 4C „tethered‟ dimer 163b, triethylamine and 
the substrate 120a, 115a, 177-181 (Figure 22) dissolved in methanol.
 
 
Figure 22. Substrates that were used for preliminary studies. 
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In the previous studies, Wills group had demonstrated that monomer catalysts are 
formed in situ from their dimer precursors (Section 1.4.7). For this reason, a mixture of 
monomer and dimer catalysts was used (Figure 23), the selection of which depended on 
their availability and diversity of structure. However, most of the reductions that were 
conducted on quinolines employed the 4C „tethered‟ dimer 163b, which is converted in 
situ into the monomer 165.  
 
Figure 23. Ru(II) catalysts that were used for the ATH of quinolines. 
The first step in this project was to investigate the ATH reduction of isoquinoline, 
quinoline and quinoxaline rings using the 4C „tethered‟ dimer 163b. 
2.1.1     Preliminary studies. 
ATH reduction of isoquinolines. 
ATH reduction was carried out on 1-methylisoquinoline 177 using catalyst 163b, giving 
<5% conversion of a non-identified product after 24 hrs (Table 19, Scheme 65). This 
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result shows that the current method used is not suitable for the reduction of 
isoquinoline substrates. 
 
Scheme 65. ATH of 1-methylisoquinoline 177 using dimer 163b. 
Imine Catalyst Temp (°C) Time (hrs) Conversion (%) ee (%)/ Config. 
(R/S) 
177 (R,R)-163b rt 24 - - - 
Table 19. ATH reduction of 1-methylisoquinoline 177 to give 177’ or 177’’ 
(Concentration of 0.22 M with respect to imine, dropwise-method of FA employed, 
FA/TEA (5:2)); Using dimer 163b forming monomer in situ (S/C = 400). 
ATH reduction of quinolines. 
The next step was to carry out the ATH reduction on 2-methylquinoline 120a, which 
gave a positive result as 120a was reduced to give 2-methyl-1,2,3,4-tetrahydroquinoline 
120a’ in 47% conversion and 50% ee after 96 hrs (Scheme 66, Table 20).  
 
Scheme 66. ATH reduction of 2-methylquinoline 120a using dimer 163b. 
Imine Catalyst Temp (°C) Time (hrs) Conversion (%) ee (%)/ Config. 
(R/S) 
120a (R,R)-163b rt 96 47 50 R 
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Table 20. ATH reduction of 2-methylquinoline 120a to tetrahydroquinoline 120a’ 
(Concentration of 0.22 M with respect to imine, dropwise-method of FA employed, 
FA/TEA (5:2)); Using dimer 163b forming monomer in situ (S/C = 400). 
The result obtained was quite encouraging and represented a good starting point in this 
project. The racemic standard was obtained by injecting 120a in THF to a solution of 
[Ru(p-cymene)Cl2]2 and I2 dissolved in THF, after which pressure hydrogenation on the 
mixture was carried out at 700 psi for 24 hrs giving the racemic 2-methyl-1,2,3,4-
tetrahydroquinoline 120a’ in 50% yield (Scheme 67). The ee of the ATH product was 
obtained by GC, comparing the starting material 120a/racemic standard
10b
 with the 
asymmetric product 120a’. 
 
Scheme 67. Pressure hydrogenation of 120a giving a racemic product 120a’, using 
[Ru(p-cymene)Cl2]2. 
ATH reduction of 2-methylquinoline; increasing the quantity of formic acid. 
The next objective was to start optimizing the conditions using 2-methylquinoline as a 
model substrate to achieve a conversion that is acceptable before focusing on increasing 
the enantioselectivity. 
The first optimization was carried out by increasing the quantity of formic acid injected 
into the solution, as FA decomposes over time and may also act as a protonating source 
for the C=C bond, more acid may be required for the reaction to go to completion.  
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Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
120a (R,R)-163b 5:2 rt 72 36 48 R 
120a (R,R)-163b 10:2 rt 72 >99 50 R 
120a (R,R)-163b 15:2 rt 66.5 94 48 R 
Table 21. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.22 
M and 0.22 M with respect to imine, dropwise-method of FA employed, FA/TEA (5:2, 
10:2 and 15:2)); Using dimer 163b forming monomer in situ (S/C = 400). 
The results (Table 21) clearly show that changing the formic acid: triethylamine ratio 
from 5:2 to 10:2 leads to the complete conversion of 120a to give (R)-2-methyl-1,2,3,4-
tetrahydroquinoline 120a’ (Scheme 66) with 50% ee. Changing the ratio further to 15:2 
gives a respectable conversion of 94% and 48% ee after 67 hrs which would possibly 
reach >99% conversion by 72 hrs.  
ATH reduction of 2-methylquinoline; comparison of the 4C “tethered” catalyst 
163b with the untethered catalyst 38. 
The next task was to see how active the 4C “tethered” catalyst 163b is in comparison to 
the untethered catalyst 38, and whether or not the ee obtained using catalyst 38 is any 
different to that obtained using catalyst 163b (Scheme 68). 
 
Results and Discussion 
89 
 
Scheme 68. ATH reduction of 2-methylquinoline 120a using catalyst 163b and 38. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
120a (R,R)-163b 15:2 rt 186 >99 50 R 
120a (R,R)-38 15:2 rt 186 20 77 R 
Table 22. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.21M 
with respect to imine, dropwise-method of FA employed, FA/TEA (15:2)); Using dimer 
163b forming monomer in situ (S/C = 400) and catalyst 38 (S/C = 200). 
The two reactions (Scheme 68, Table 22) were carried out parallel to each other, and the 
result of the reduction of 120a with catalyst 163b using 15:2 FA:TEA shown previously 
(Table 21) is from this experiment (Table 22). 
The results (Table 23, Figure 24) show that catalyst 163b is much more active than 
catalyst 38 when it comes to conversion as >99% conversion was obtained after 186 
hours with catalyst 163b, and only 20% conversion was obtained after 186 hours with 
catalyst 38, but the ee obtained with catalyst 38 was much higher than that obtained 
with catalyst 163b, as 50% ee was obtained with catalyst 163b, but in a high 77% ee, 
was obtained with catalyst 38 (Table 22), meaning the 4C link is vital for rapid 
conversion but having a p-cymene arene group on the Ru is essential for achieving high 
enantioselectivity (Scheme 68). 
Time (hrs) Conversion (%) 
4C “tethered” catalyst 163b Untethered catalyst 38 
0.5 6 1 
17 33 2 
20 40 2 
23.25 45 2 
41 71 3 
46.5 79 4 
66.5 94 6 
186 >99 20 
Table 23. Conversion of catalyst 163b vs. 38 over time. 
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Figure 24. Comparing the conversion of 4C “tethered” catalyst 163b vs. untethered 
catalyst 38 over time. 
ATH reduction of 2-methylquinoline; 4C “tethered” catalyst 163b vs untethered 
catalyst 38 vs untethered catalyst 182. 
In the previous comparison it was obvious how active catalyst 163b was when 
compared to catalyst 38, so at this point it was decided to see whether or not the 
untethered catalyst 182,
17j, 26a
 which is known for reducing cyclic imines with great 
conversion and enantioselectivity and with a higher enantioselectivtiy than 38, shows 
any form of increased activity and enantioselectivity for quinoline reduction (Scheme 
69, Table 24). 
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Scheme 69. ATH reduction of 2-methylquinoline 120a using catalyst 182. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
120a (R,R)-163b 15:2 rt 23.25 45 50 R 
120a (R,R)-38 15:2 rt 23.25 2 - - 
120a (R,R)-182 10:2 rt 22.25 4 - - 
Table 24. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.21 
M with respect to imine, dropwise-method of FA employed, FA/TEA (15:2 and 10:2)); 
Using dimer 163b forming monomer in situ (S/C = 400) or catalyst 38/182 (S/C = 200). 
The results showed that catalyst 182, with a conversion of 4% after 22 hrs, is more 
active than catalyst 38 with a conversion of 2% after 23 hrs, but clearly catalyst 163b is 
even more active, giving a conversion of 45% after 23 hrs and 50% ee (Table 24, 
Scheme 69). 
ATH reduction of 2-methylquinoline; increasing the overall volume of formic 
acid:triethylamine. 
Since the formic acid: triethylamine ratio had been studied, seeing whether increasing 
the overall volume of triethylamine has any effect on the ATH reduction was examined 
(Scheme 66, Table 25). 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
120a (R,R)-163b 15:6 rt 176.5 96 42 R 
Table 25. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.19 
M with respect to imine, dropwise-method of FA employed, FA/TEA (15:6)); Using 
dimer 163b forming monomer in situ (S/C = 400). 
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The results (Table 25) show that increasing the amount of triethylamine gives a good 
conversion of 96% after 177 hrs, but an ee of 42% (drop of 8%) was obtained in 
comparison to the previously obtained ee of 50% (Table 21, 22). 
ATH reduction of 2-methylquinoline; using a different solvent. 
The final optimization involved the ATH reduction of 2-methylquinoline 120a using 
toluene instead of methanol and to use no solvent (Scheme 66, Table 26). 
Imine Catalyst Solvent FA/TEA 
ratio 
Temp 
(°C) 
Time 
(hrs) 
Conv. (%) ee (%)/ Config. 
(R/S) 
120a (R,R)-163b Toluene 10:2 rt 103.5 68 51 R 
120a (R,R)-163b - 10:2 rt 103.5 61 46 R 
Table 26. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.21M 
and 1.48 M with respect to imine, dropwise-method of FA employed, FA/TEA (10:2)); 
Using dimer 163b forming monomer in situ (S/C = 400). 
In this final optimization it was quite clear that methanol is a better solvent for ATH 
reduction of quinolines, as the ee obtained with toluene (51%) and no solvent (46%) is 
comparable with methanol (50%), the conversion using methanol however is much 
faster (>99% conversion, 72 hrs, Table 21) than using toluene (68% conversion, 104 
hrs, Table 26) or no solvent (61% conversion, 104 hrs, Table 26). 
ATH reduction of 2-phenylquinoline. 
ATH reduction was next carried out on a bulkier substituted quinoline 115a, as some 
work has now been carried out on optimizing the reactions (Scheme 70, Table 27). 
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Scheme 70. ATH reduction of 2-phenylquinoline 115a using dimer 163b. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
115a (R,R)-163b 10:2 rt 107.3 84 64 S 
Table 27. ATH reduction of 115a to tetrahydroquinoline 115a’ (Concentration of 0.21 
M with respect to imine, dropwise-method of FA employed, FA/TEA (10:2)); Using 
dimer 163b forming monomer in situ (S/C = 400). 
Reduction of 2-phenylquinoline 115a was carried out successfully to give (S)-2-phenyl-
1,2,3,4-tetrahydroquinoline 115a’ with 84% conversion and 64% ee after 107 hrs (Table 
27). This is a positive result in addition to what has been obtained with the ATH 
reduction of 2-methylquinoline 120a. The configuration was determined by HPLC data 
comparison with literature.
10d 
ATH reduction of 2-tert-butylquinoline. 
ATH was carried out on 2-tert-butylquinoline 178, synthesized successfully by cleanly 
converting o-nitrobenzaldehyde to o-aminobenzaldehyde using iron metal (10 eq.) in 
the presence of aq. HCl (20 mol%) in refluxing EtOH for 30 mins. The solids were 
removed by filtration and the filtrate was treated with 3,3-dimethylbutan-2-one and 
powdered KOH (3 eq.). After stirring at reflux for 40 mins, 2-tert-butylquinoline was 
obtained with >99% yield.
26b
 As 178 is another bulky substrate like 115a, it was 
considered interesting to establish whether ATH gives a similar result to what was 
obtained for the reduction of 115a (Scheme 71, Table 28). 
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Scheme 71. ATH reduction of 2-tert-butylquinoline 178 using dimer 163b. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
178 (R,R)-163b 10:2 rt 120.75 77 0 - 
Table 28. ATH reduction of 178 to tetrahydroquinoline 178’ (Concentration of 0.21 M 
with respect to imine, dropwise-method of FA employed, FA/TEA (10:2)); Using dimer 
163b forming monomer in situ (S/C = 400). 
2-tert-Butylquinoline 178 was successfully reduced to give 2-tert-butyl-1,2,3,4-
tetrahydroquinoline 178’ with 77% conversion after 121 hrs, but unfortunately a 
racemic product was obtained (Table 28). 
ATH reduction of methylquinoline-2-carboxylate. 
The next task was to examine methylquinoline-2-carboxylate 179 reduction by ATH 
(Scheme 72, Table 29). 
 
Scheme 72. ATH reduction of methylquinoline-2-carboxylate 179 using dimer 163b. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
179 (R,R)-163b 10:2 rt 96 0 - - 
Table 29. ATH reduction of 179 to tetrahydroquinoline 179’ (Concentration of 0.21 M 
with respect to imine, dropwise-method of FA employed, FA/TEA (10:2)); Using dimer 
163b forming monomer in situ (S/C = 400). 
Results and Discussion 
95 
 
Reduction of 179 was unsuccessful (Table 29), possibly due to the interaction of the 
carboxylate group with the catalyst 163b, preventing the catalyst 163b from carrying 
out the reduction. 
ATH reduction of 2-phenylpyridine. 
As it was established that quinoline type substrates can be reduced via ATH, attention 
turned to a test of ATH on the pyridine substrate 2-phenylpyridine 180 (Scheme 73, 
Table 30). 
 
Scheme 73. ATH reduction of 2-phenylpyridine 180 using dimer 163b. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
180 (R,R)-163b 10:2 rt 96 0 - - 
Table 30. ATH reduction of 180 to piperidine 180’ (Concentration of 0.21 M with 
respect to imine, dropwise method of FA employed, FA/TEA (10:2)); Using dimer 
163b forming monomer in situ (S/C = 400). 
The reduction on 180 was unsuccessful (Table 30), possibly due to the substrate being 
far too stable and is able to restore its aromaticity. 
ATH reduction of quinoxaline. 
Another substrate on which ATH was evaluated was quinoxaline 181. Although the 
reaction does not give an asymmetric product, a successful application could be 
extended to a prochiral substrate. (Scheme 74, Table 31). 
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Scheme 74. ATH reduction of quinoxaline 181 using dimer 163b. 
Imine Catalyst FA/TEA 
ratio 
Temp (°C) Time (hrs) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
181 (R,R)-163b 10:2 rt 96 17 - - 
Table 31. ATH reduction of 181 to tetrahydroquinoxaline 181’ (Concentration of 0.21 
M with respect to imine, dropwise-method of FA employed, FA/TEA (10:2)); Using 
dimer 163b forming monomer in situ (S/C = 400). 
Reduction on 181 was partially successful giving 1,2,3,4-tetrahydroquinoxaline 181’ in 
17% conversion (Table 31). 
The preliminary studies carried out above was using the dropwise addition of formic 
acid, and as complete conversion was taking up to 72 hrs, the Noyori method was tested 
for comparison (Scheme 66, Table 32). In this method, the azeotrope is used from the 
outset of the reaction.
22
 
Imine Catalyst Solvent FA/TEA 
ratio 
Temp 
(°C) 
Time 
(hrs) 
Conv. (%) ee (%)/ Config. 
(R/S) 
120a (R,R)-163b MeOH 5:2 28 24 96 46 R 
Table 32. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). 
Imine Catalyst Solvent FA/TEA 
ratio 
Temp 
(°C) 
Time 
(hrs) 
Conv. (%) ee (%)/ Config. 
(R/S) 
120a (R,R)-163b MeOH 10:2 rt 72 >99 50 R 
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Table 33. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.21 
M with respect to imine, dropwise-method of FA employed, FA/TEA (10:2)); Using 
dimer 163b forming monomer in situ (S/C = 400). 
The results show (Table 32, 33) that changing the concentration of solution from 0.21 M 
to 0.45 M with respect to the imine speeds up the reaction rate and the 
tetrahydroquinoline is formed with complete conversion within 24 hrs. 
It is after this point where all the ATH reductions that were carried out were using the 
non-dropwise method, since it is practically easier and more efficient. 
2.1.2     ATH reduction of 2-methylquinoline; optimization of solvent. 
In order to optimize the outcome of the reaction, systematic variation of the conditions 
was carried out using 120a as a model substrate and 163b as catalyst (Scheme 66). The 
results of solvent variation are shown (Table 34). 
Imines Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
120a MeOH 28 (R,R)-163b 5:2 24 96 46 R 
120a ACN 28 (R,R)- 163b 5:2 24 79 36 R 
120a Water 28 (R,R)- 163b 5:2 24 23 32 R 
120a EtOH 28 (R,R)- 163b 5:2 24 96 37 R 
120a DCM 28 (R,R)- 163b 5:2 24 92 25 R 
120a Et2O 28 (R,R)- 163b 5:2 24 98 17 R 
120a Acetone 28 (R,R)- 163b 5:2 24 8 8 R 
120a Toluene 28 (R,R)- 163b 5:2 24 73 22 R 
120a IPA 28 (R,R)- 163b 5:2 24 98 31 R 
120a EtOAc 28 (R,R)- 163b 5:2 24 74 18 R 
Table 34. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). 
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The results clearly show that methanol overall proved to be the best solvent giving a 
respectable conversion of 96% and 46% ee after 24 hrs (Table 34). The reaction 
conversions were monitored after 2,4,6 and 24 hrs (Table 36, Figure 25). 
ATH of quinolines was also carried out using ionic liquid as solvent instead of methanol 
to see if that has any effect on the conversion or enantioselectivity (Scheme 66, Table 
35). Chan in 2008 reported the reduction of quinolines using Ru(II) catalysts where 
ionic liquid (Section 1.3.3.6) was used as solvent and up to 99%> conversion and ee 
was obtained with pressure hydrogenation. 
Imines Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(days) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
120a [BMIM]PF6 28 (R,R)-163b 5:2 3 88 41 R 
120a MeOH/[BMIM]PF6 28 (R,R)-163b 5:2 5 91 52 R 
Table 35. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). 
 
Ionic liquid as solvent and using a 50:50 mixture of ionic liquid and methanol gave 
good results, but methanol alone proved to be the better solvent (Table 35). 
Time  
(hrs) 
Conversion (%) 
MeOH ACN   H2O EtOH DCM Et2O Acetone Toluene IPA EtOAc 
0 0 0 0 0 0 0 0 0 0 0 
2 27 47 16 30 51 68 6 34 25 38 
4 52 58 23 59 70 73 6 47 52 51 
6 76 66 23 79 78 82 6 55 74 58 
24 96 79 23 96 92 98 8 73 98 74 
 46% 
ee 
36% 
ee 
32%  
ee 
37%  
ee 
25% 
ee 
17% 
ee 
8%  
ee 
22%  
ee 
31% 
ee 
18%  
ee 
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Table 36. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). Conversion monitored after 2,4,6 and 24 
hrs. 
 
Figure 25. A graph to show conversion vs. time when using different solvents for the 
ATH reduction of 2-methylquinonline 120a to tetrahydroquinoline 120a’. 
2.1.3     ATH reduction of 2-methylquinoline; optimization of temperature. 
Since methanol was confirmed to be the best solvent, the reactions were next carried out 
at different temperatures (Scheme 66, Table 37). 
Imines Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
120a MeOH 28 (R,R)-163b 5:2 24 96 46 R 
120a MeOH 40 (R,R)-163b 5:2 24 94 44 R 
120a MeOH 50 (R,R)-163b 5:2 24 94 43 R 
120a MeOH 60 (R,R)-163b 5:2 24 96 43 R 
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Table 37. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). 
The results show that the reduction of 120a to the tetrahydroquinoline 120a’ is most 
rapid when the reaction is carried out at 60 °C with a drop of 3% ee (Table 37). The 
reaction conversions were monitored after 2,4,6 and 24 hrs (Table 38, Figure 26).  
Time (hrs) Conversion (%) 
28 °C 40 °C 50 °C 60 °C 
0 0 0 0 0 
2 27 74 87 88 
4 52 89 89 90 
6 76 91 90 91 
24 96 94 94 96 
 46% ee 44% ee 43% ee 43% ee 
Table 38. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). Conversion monitored after 2,4,6 and 24 
hrs. 
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Figure 26. A graph to show conversion vs. time when carrying out ATH reduction of 2-
methylquinoline 120a to tetrahydroquinoline 120a’ at different temperatures. 
2.1.4     ATH reduction of 2-methylquinoline; using different catalysts. 
As now the optimization with temperature was carried out, it was worth testing out 
ATH using various catalysts (Scheme 75, Table 39) at 60 °C, as this will increase the 
rate of conversion even for the less active catalysts quite rapidly with only a loss of 3% 
ee. This would give a good picture for the final conversion/ee that could be obtained 
with the catalysts 38, 159, 160, 163b-c, 164, 182 and 183. 
 
Scheme 75. ATH reduction of 2-methylquinoline 120a, using catalysts 38, 159, 160, 
163b-c, 164, 182 and 183. 
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Imines Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
120a MeOH 60 (R,R)-163b 5:2 24 96 43 R 
120a MeOH 60 (R,R)-38 5:2 24 17 80 R 
120a MeOH 60 (R,R)-182 5:2 24 66 29 R 
120a MeOH 60 (R,R)-163c 5:2 24 87 44 R 
120a MeOH 60 (S,S)-159 5:2 24 62 43 S 
120a MeOH 60 (R,R)-164 5:2 24 27 68 R 
120a MeOH 60 (R,R)-160 5:2 24 59 43 R 
120a MeOH 60 (R,R)-183 5:2 24 30 46 R 
Table 39. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
159, 163b-c and 183 forming monomer in situ (S/C = 400) and catalyst 38, 160, 164 
and 182 (S/C = 200). 
The results obtained are very encouraging and similar to what was observed in the 
preliminary studies. Catalyst 163b is the most active catalyst when compared to the 
other catalysts used, giving the fastest and the most conversion. The reaction 
conversions were monitored after 2, 4, 6 and 24 hrs (Table 40, Figure 27). Catalyst 38 
however gave the best ee of 80% (Table 39), and yet again it is worth pointing out the 
fact that it is the only catalyst in the list to have a functionalized aromatic ring on the 
Ru. In view of the high conversion in the reduction of 120a achieved using the 4C 
„tethered‟ complex 163b, but the high ee of 80% achieved using the p-cymene 
containing untethered complex 38, catalyst 183 was synthesized,  which contains 
elements of each in order to achieve both high activity and enantioselectivity. This 
catalyst contains a methyl group in the arene ring, intended to mimic the p-cymene ring 
in 38, which was considered to be important for high enantioselectivity. Catalyst 183 
however proved to be unsuccessful as it did not prove to be as active as catalyst 163b 
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and it was not able to achieve enantioselectivity near enough catalyst 38 as a conversion 
of 30% and an ee of 46% was obtained after 24 hrs at 60 °C (Table 39). 
Time 
(hrs) 
Conversion (%) 
 
 
4C 
dimer  
163b 
Unteth. 
catalyst 
38 
Unteth. 
catalyst 
182 
5C 
dimer 
163c 
3C 
dimer 
159 
2C 
monomer 
164 
3C 
monomer 
160 
4C DiMe 
dimer 
183 
0 0 0 0 0 0 0 0 0 
2 88 13 46 45 47 3 50 18 
4 90 15 58 77 51 5 53 21 
6 91 16 61 83 53 8 54 24 
24 96 17 66 87 62 27 59 29 
 43%  
ee 
80%  
ee 
29%  
ee 
44%  
ee 
43%  
ee 
68%  
ee 
43%  
ee 
42% 
ee 
Table 40. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
159, 163b-c and 183 forming monomer in situ (S/C = 400) and catalyst 38, 160, 164 
and 182 (S/C = 200). Conversion monitored after 2,4,6 and 24 hrs. 
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Figure 27. A graph to show conversion vs. time when carrying out ATH reduction of 2-
methylquinoline 120a to tetrahydroquinoline 120a’ using different catalysts at 60 °C. 
2.1.5     Synthesis of catalyst 183 for the ATH reduction of quinolines. 
Dimer 183 was prepared successfully by firstly protecting 4-bromo-1-butanol 184 using 
tert-butyldiphenylsilyl chloride and imidazole in THF giving (4-bromobutoxy)(tert-
butyl)diphenylsilane
26c
 185 with 31% conversion. The next step was a Br/Li exchange 
on 5-bromo-m-xylene 186 and reaction with 185 in THF giving tert-butyl(4-(3,5-
dimethylphenyl)butoxy)diphenylsilane
26d
 187 with 70% yield, followed by deprotection 
of the silyl group using tetrabutylammonium fluoride in THF giving 4-(3,5-
dimethylphenyl)butan-1-ol
26e
 188 in 91% conversion. Birch reduction was then carried 
out to reduce the aromatic ring on 188 with sodium and ethanol in liquid ammonia to 
form 4-(3,5-dimethylcyclohexa-1,4-dienyl)butan-1-ol
 
189 as a red oil in 74% yield. The 
second step was a Swern oxidation to oxidize 189 to 4-(3,5-dimethylcyclohexa-1,4-
dienyl)butanal 190 using oxalyl chloride, dimethyl sulfoxide and triethylamine in DCM. 
Aldehyde 190 was afforded as a clear yellow oil in 96% yield. Thirdly, reductive 
amination was carried out in dry methanol using 190, R,R-TsDPEN 81 and glacial 
acetic acid to form an imine as an intermediate, which then was reduced using sodium 
cyanoborohydride to give N-((1R,2R)-2-(4-(3,5-dimethylcyclohexa-1,4-
dienyl)butylamino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 191 as a white 
solid in 37% yield. The final step was the complexation of 191 with via 191.HCl salt 
formed from the reaction of 191 with 2M HCl in Et2O in DCM, followed by the 
reaction of the salt with ruthenium(III) trichloride hydrate in refluxing ethanol 
overnight, forming 183 as a black solid in 21% yield. Dimer 183 then forms the 
monomer 192 in situ under ATH reaction conditions (Scheme 76). 
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Scheme 76. Synthesis of the DiMe 4C “tethered” dimer 183. 
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2.1.6     ATH reduction of ketones using catalyst 183. 
The reduction of substrate 120a was not successful using catalyst 183, so it was 
considered valuable to establish how well catalyst 183 reduces ketones in comparison to 
other catalysts, as „tethered‟ complexes that have been made in the Wills group have 
given good results for the reduction of certain ketones as shown in Section 1.4.7 
(Scheme 77, Table 41). 
 
Scheme 77. ATH reduction of ketones 49a and 141 giving alcohols 49a’ and 141’ 
respectively, using dimer 183. 
Ketone Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
49a - 28 (R,R)-183 5:2 24 89 97 R 
141 - 28 (R,R)-183 5:2 168 >99 74 S 
Table 41. ATH reduction of 49a and 141 giving alcohols 49a’ and 141’ respectively, 
(Concentration of 1.62 M with respect to ketone, non-dropwise i.e. 5:2 azeotropic 
mixture used); Using dimer 183 forming monomer 192 in situ (S/C = 400). 
The reductions were successful and some good results were obtained. Acetophenone 
49a was reduced to the alcohol 49a’ giving 89% conversion and an impressive ee of 
97% after 24 hrs, this reaction would possibly have reached >99% conversion if it was 
left to continue. Cyclohexylmethyl ketone 141 was reduced to the alcohol 141’ giving 
>99% conversion after 7 days with an ee of 74% (Table 41). Both the reductions are 
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comparable to the results obtained previously in the Wills‟ group for the reduction of 
ketones using untethered and „tethered‟ complexes. 
ATH reduction of 6, 7-dimethoxy-2-methylquinoline 193. 
Synthesis of 6,7-dimethoxy-2-quinoline 193 follows the same procedure as 178, via the 
Friedlander reaction, giving 193 in 76% yield.
26b
 This reaction was a test to see whether 
having electron donating groups on the aromatic ring of the substrate has any effect on 
the conversion or enantioselectivity (Scheme 78, Table 42). 
 
Scheme 78. ATH reduction of 6, 7-dimethoxy-2-methylquinoline 193 to 193’ using 
catalyst 38, 159 and 163b. 
Imine Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(days) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
193 MeOH 28 (R,R)-163b 5:2 6 53 48 R 
193 MeOH 28 (S,S)-159 5:2 4 23 48 S 
193 MeOH 28 (R,R)-38 5:2 4 >5 - - 
Table 42. ATH reduction of 193 to tetrahydroquinoline 193’ (Concentration of 0.45 M 
with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 159 
and 163b forming monomer in situ (S/C = 400) and catalyst 38 (S/C = 200).  
The results obtained showed that having electron-donating groups on the aromatic ring 
of the quinoline slows the reaction down as quinoline 193 was reduced to the 
tetrahydroquinoline 193’ using catalyst 163b with only 53% conversion after 6 days 
with an ee of 48%, and catalysts 159/38 were much slower as only 23% conversion was 
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obtained with an ee of 48% after 4 days for catalyst 159, and only >5% conversion 
obtained using catalyst 38, not enough conversion for determining the ee (Table 42). 
2.1.7     ATH reduction of 2-methylquinoline; Using Rh “tethered” catalysts 175 
and 176.  
Reductions were carried out using „tethered‟ Rh(III) 175 and analogue 176 catalyst for 
comparison with Ru(II) catalysts (Scheme 79, Table 43), as recently Xiao et al disclosed 
the use of Rh-based catalyst in aqueous solution (Section 1.4.6.5), and gave impressive 
results that required careful control of pH for full reduction to occur.
 
 
Scheme 79. ATH reduction of 2-methylquinoline 120a, using catalyst 175 and 176. 
Imine Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%) 
ee (%)/ 
Config. (R/S) 
120a MeOH 28 (R,R)-175 5:2 24 68 93 R 
120a MeOH 28 (R,R)-176 5:2 24 93 82 R 
Table 43. ATH reduction of 120a to tetrahydroquinoline 120a’ (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using catalyst 
175 and 176 (S/C = 200).  
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ATH reduction using “tethered” Rh(III) catalysts proved be successful with catalyst 175 
giving the best ee of 93%, and catalyst 176 giving the best conversion of 93% out of the 
two Rh(III) “tethered” catalyst‟s after 24 hours (Table 43). 
2.1.8     ATH reduction of quinolines; using catalyst 163b and 175. 
A series of quinoline substrates 115l, 117a, 120b, 124a, 194-195 (Figure 28) were 
synthesized 
26b, 26f, 26g
, from the initial reaction of 2-methylquinoline with 
n
BuLi in dry 
THF at -78 °C followed by the addition of iodo/bromo containing starting materials. 
ATH reduction of quinolines 115l, 117a, 120b, 124a, 194-195 along with 115a and 178 
was carried out using the most active Ru(II) “tethered” catalyst 163b and the most 
stereoselective Rh(II) “tethered” catalyst 175 tested (Scheme 80, Figure 28). 
 
Scheme 80. ATH reduction of quinolines shown in Figure 28, using catalyst 163b and 
175. 
 
Figure 28. Substrates used for ATH reduction using catalyst 163b and 175. 
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Imine Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%) 
ee (%)/ Config. 
(R/S) 
120a MeOH 28 (R,R)-163b 5:2 24 96 46 R 
115a MeOH 28 (R,R)-163b 5:2 168 68 73 S 
178 MeOH 28 (R,R)-163b 5:2 48 57 0 - 
120b MeOH 28 (R,R)-163b 5:2 30 95 41 R 
124a MeOH 28 (R,R)-163b 5:2 144 94 42 R 
115l MeOH 28 (R,R)-163b 5:2 144 93 41 R 
117a MeOH 28 (R,R)-163b 5:2 48 90 50 R 
  194* DCM 28 (R,R)-163b 5:2 48 86 47 R 
195 MeOH 28 (R,R)-163b 5:2 48 93 67 R 
Table 44. ATH reduction of quinolines to tetrahydroquinolines (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using dimer 
163b forming monomer in situ (S/C = 400). *Substrate 194 did not dissolve in MeOH, 
EtOH, ACN and IPA. 
The results show that the reductions to tetrahydroquinoline for all the substrates were 
carried out successfully and with high conversions, with substrate 120a giving the highest 
conversion of 96% and substrate 178 giving the lowest conversion of 57%. The ee‟s 
obtained for the tetrahydroquinolines were not so high, with substrate 115a giving the 
highest ee of 73% (Table 44).  
As “tethered” Rh(III) catalysts showed good activity and great stereoselectivity for the 
reduction of quinolines, it was further employed for the reduction of a series of quinolines 
(Scheme 80, Figure 28). 
Imine Solvent Temp 
(°C) 
Catalyst FA/TEA 
ratio 
Time 
(hrs) 
Conv. 
(%)** 
ee (%)***/ 
Config. (R/S) 
120a MeOH 28 (R,R)-175 5:2 24 68 (85) 93 R 
115a MeOH 28 (R,R)- 175 5:2 48 30 (35) 86 S 
178 MeOH 28 (R,R)- 175 5:2 48 16 (43) 0 - 
120b MeOH 28 (R,R)-175 5:2 48 67 (76) 91 R 
124a MeOH 28 (R,R)-175 5:2 48 65 (73) 90 R 
115l MeOH 28 (R,R)-175 5:2 48 64 (76) 92 R 
117a MeOH 28 (R,R)-175 5:2 48 57 (65) 93 R 
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  194* DCM 28 (R,R)-175 5:2 48 30 (29) 81 R 
195 MeOH 28 (R,R)-175 5:2 48 58 (69) 94 R 
Table 45. ATH reduction of quinolines to tetrahydroquinolines  (Concentration of 0.45 
M with respect to imine, non-dropwise i.e. 5:2 azeotropic mixture used); Using catalyst 
175 (S/C = 200). *Substrate 194 did not dissolve in MeOH, EtOH, ACN and IPA. 
**Figures in parenthesis indicate conversion after 2 days using 2 mol% catalyst. ***ee 
of product of 0.5 mol% catalyst loading reaction. 
The results show that the reductions of quinolines to tetrahydroquinolines for all the 
substrates were carried out successfully and with high ee‟s, with substrate 195 giving 
the highest ee of 94% (Table 45). As the reactions were not going to completion the 
catalyst loading was changed to 2 mol%** from 0.5 mol%, and this gave an increase in 
% conversion for all the substrates, with the highest conversion given by substrate 120a 
of 85%, but the reductions still did not go to completion. 
In summary, it has now been demonstrated that Ru(II) and Rh(II) complexes are 
effective catalysts for the ATH reduction of substituted quinolines, which are generally 
regarded as challenging substrates for this application. Also as seen for ketone 
reductions (Section 1.4.7), the increased reactivity of “tethered” complexes over the 
untethered catalysts appears to be key to their capacity to work as effective catalysts in 
this application.  
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2.2     Synthesis of ether-linked “tethered” catalyst for the ATH reduction of 
ketones. 
The objective of this project was the synthesis of an ether-linked “tethered” catalyst. 
Wills and co-workers had previously reported the synthesis of a stereochemically well 
defined catalyst 173b that controlled the configuration of the metal with the use of a 
ether-linked “tether”, showing good activity but lacked elements which affect the 
enantioselectivity of ketone reductions (Section 1.4.7). The ether-linked “tethered” 
catalyst 207 represented an interesting target to synthesize and includes all the necessary 
features for making it a desirable catalyst in terms of its promise for rate and 
enantioselectivity for ketone reductions. The “tether” is linked to the “basic” amine 
which has proved to be vital for achieving high activity, and the “tether” chain has 4 
substituents (-CH2CH2OCH2-), as the 4C alkyl chain “tethered” catalyst 165 having 4 
substituents had proved to be the most active catalyst among the rest of its class (160 
and 165, Figure 29) (Section 1.4.7). TsDPEN 81, with matching stereocentres and a 
trans orientation of the phenyl groups was also employed for the synthesis of this 
catalyst (Section 1.4.5), which in effect will help enhance the rate and enantioselectivity 
of an ATH reaction.  
 
Figure 29. Ru(II) “tethered” catalyst. 
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2.2.1     Synthesis of the ether-linked “tethered” catalyst 207. 
The initial step in the route for synthesizing 207, using Birch reduction on 2-
(benzyloxy)ethanol 196 was unsuccessful as it resulted in the cleavage of the ether 
(Scheme 81). 
 
Scheme 81. Attempted Birch reduction on 2-(benzyloxy)ethanol 196. 
With the Birch reduction step being problematic, an alternative approach was devised to 
gain access to the 1, 4-cyclohexadienyl moiety. In the synthesis of catalyst 207 (Scheme 
81), the Diels-Alder cycloaddition was employed to attain the 1,4-cyclohexadienyl 
containing compound. Cycloaddition of isoprene 197 with propiolic acid 198 in THF at 
reflux temperature furnished 4-methylcyclohexa-1,4-dienecarboxylic acid 199
27a
 in 54% 
yield as a white solid, which then was reduced using LiAlH4 in THF giving (4-
methylcyclohexa-1,4-dienyl)methanol 200
17j
 in 81% yield as a colourless oil. The 
coupling of 200 with tert-butylbromoacetate 201 in NaOH solution and using TBAB led 
to the formation of 2-((4-methylcyclohexa-1,4-dienyl)methoxy)acetic acid 202
27b
 in 
75% yield as a light yellow solid. Compound 202 was reduced with LiAlH4 in THF 
giving 2-((4-methylcyclohexa-1,4-dien-1-yl)methoxy)ethanol 203
17j
 in >99% yield 
(quant.) as a yellow oil, and oxidised via Swern oxidation to form 2-((4-
methylcyclohexa-1,4-dienyl)methoxy)acetaldehyde 204
20a
 in >99% yield (quant.) as an 
orange oil. Reductive amination was carried out in methanol using 204, R,R-TsDPEN 
81
27c
 and glacial acetic acid to form an imine as an intermediate, which then was 
reduced to give 4-methyl-N-((1R,2R)-2-(2-((4-methylcyclohexa-1,4-
dienyl)methoxy)ethylamino)-1,2-diphenylethyl)benzenesulfonamide 205
20a
 as a white 
Results and Discussion 
114 
 
solid in 29% yield using sodium cyanoborohydride. The final step was the complexation 
of 205 with ruthenium(III) trichloride hydrate in refluxing IPA, after formation of 
205.HCl using HCl (1.25 M in EtOH) in anhydrous DCM, giving 206
20a
 as a black solid 
in 88% yield (if carried out in ethanol gives a low yield of 14%). The dimer 206 could 
be directly used in ATH reactions, as it forms 207 under reaction conditions, in common 
with related complexes that are converted from their dimer forms to monomer in situ. 
The formation of monomer 207
20a
 using Et3N in IPA at 80 °C, was successful as 
confirmed by mass spectroscopy, and 
1
H NMR spectroscopic analysis of the crude 
product. The isolation of the pure complex 207, was however challenging in contrast to 
the alkyl chain complexes which were universally stable to purification by 
chromatography. Decomposed material was obtained in the attempt to purify 207. For 
this reason monomer 207 was either used in crude form, or more conveniently, the 
dimeric precursor 206 was employed directly in ATH reactions. 
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Scheme 82. Synthesis of ether-linked “tethered” catalyst 207. 
Problems encountered during the synthesis of 207. 
The formation of 202 was successful after 200 was coupled with tert-butylbromoacetate 
201 in NaOH solution and using TBAB. This method was employed as the coupling of 
200 using NaH proved to be unsuccessful. A test reaction was first carried out (A, 
Scheme 83) in which benzyl alcohol 208 was coupled to bromoacetic acid 209 using 
NaH, with the addition of 208, 209 followed by sodium methoxide and 
methylchloroformate in to a solution of NaH in DMF were carried out at 0 °C, then 
allowed to stir at rt overnight resulting in a successful formation of 210.
27d
 The reaction 
was repeated using 200, and proved to be unsuccessful (B, Scheme 83), also failing 
when using 201 (C, Scheme 83), tert-butyl(2-iodoethoxy)diphenylsilane 211
26c
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(prepared by the drop wise addition of tert-butyl-chlorodiphenylsilane to a solution of 2-
iodoethanol and imidazole dissolved in THF) (D, Scheme 83), and when experimenting 
with temperature. 
 
Scheme 83. Failed coupling attempts using NaH. 
Further work on the synthesis of the ether-linked “tethered” catalyst. 
In an attempt to form aldehyde 204 in a one-pot reaction, alcohol 200 was reacted with 
2-bromomethyl-1,3-dioxolone 212 and TBAB in NaOH solution at 0 °C. Stirring the 
reaction at 70 °C for 1 day had given 213 with 30% yield, and leaving the reaction for 3 
days had further increased the yield to 80%. The addition of 1 M HCl and 5 M HCl to 
213 had showed changes in the 
1
H NMR, but the product had decomposed after the 
addition of conc. HCl. Further investigations need to be carried out for this step as 
removing the reduction step for the synthesis of the ester-linked “tethered” catalyst, 
could be highly beneficial when synthesized on a large scale in industry (Scheme 84) 
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Scheme 84. Synthesis of the aldehyde 204 in a one-pot reaction. 
2.2.2     Reduction of imine with ether-linked “tethered” dimer 206. 
After the successful formation of catalyst 206, it was worth carrying out an ATH 
reduction on 6,7-dimethoxy-1-methyl-3,4-dihydroisoquinoline 109a to see how active 
and stereoselective the catalyst is for this substrate (Scheme 85, Table 46). 
 
Scheme 85. ATH reduction of 109a using catalyst 206. 
Imine Catalyst Temp (°C) Time (days) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
109a (R,R)-206 
 
28 4 100 87 S 
Table 46. ATH reduction of 109a to tetrahydroisoquinoline 109a’ (Concentration of 
0.45 M with respect to imine, non-dropwise i.e. azeotropic mixture used); Using dimer 
206 forming monomer 207 in situ (S/C = 400). 
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The results showed that catalyst 206 was successful for the reduction of 109a, giving 
6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline 109a’ in 90% conv., and a 
respectable 87% ee (S) after 4 days (Table 46).  
2.2.3     Reduction of quinoline with ether-linked “tethered” dimer 206. 
The next task was to carry out the ATH reduction with catalyst 206 on 2-
methylquinoline 120a (Scheme 86, Table 47). 
 
Scheme 86. ATH reduction of 2-methylquinoline 120a using catalyst 206. 
Imine Catalyst Temp (°C) Time  
(days) 
Conversion (%) ee (%)/ Config. 
(R/S) 
120a (R,R)-206 28 6 65 61 R 
Table 47. ATH reduction of 2-methylquinoline 120a to tetrahydroquinoline 120a’ 
(Concentration of 0.45 M with respect to quinoline, non-dropwise i.e. azeotropic 
mixture used); Using dimer 206 forming monomer 207 in situ (S/C = 400). 
The reduction of 120a was successful giving the 2-methyl-1,2,3,4-tetrahydroquinoline 
120a’ in 65% conv., 61% ee (R) (Table 47). After 24 hrs, the conversion was 57%, and 
after 6 days it was 65%. The ee obtained for the reduction of 120a is the highest to have 
been achieved with any Ru(II) “tethered” catalyst.  
2.2.4     Reduction of ketones with ether-linked “tethered” dimer 206. 
ATH reductions have now been tested out on an imine and a quinoline with catalyst 
206. The next step was to focus on the ATH reduction of ketones to alcohols with 
catalyst 206 (Scheme 87). The majority of substrates tested were reduced successfully, 
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giving the alcohols with excellent conversions (in the best cases >99%) and 
enantioselectivities in some cases of >99%). ATH reduction of acetophenone 
derivatives containing para- 49c and meta-chloro substituents 49b, and bicyclic 
derivatives such as α-tetralone 214 and 4-chromanone 215 were reduced in similar 
conversions and enantioselectivities to acetophenone itself. The ortho-chloro substituted 
acetophenone derivative 216 however gave a reduced ee of 87%, which has been 
observed previously for reduction of this substrate with a similar catalyst (Scheme 87, 
Figure 30, Table 48).
17e, 17i, 18a, 20a, 21b, 25a, 25c-e, 25i, 27e-27h 
 
 
Scheme 87. ATH reduction of ketones, using catalyst 206. 
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Figure 30. ATH reduction of a series of ketones. 
Ketones Catalyst Temp (°C) Time (days) Conversion 
(%) 
ee (%)/ Config. 
(R/S) 
49a (R,R)-206 28 o/n >99 99 R 
49c (R,R)-206 28 o/n >99 96 R 
49b (R,R)-206 28 2  >99 94 R 
214 (R,R)-206 28 2  >99 >99 R 
215 (R,R)-206 28 o/n >99 >99 R 
216 (R,R)-206 28 2  100 87 R 
49g (R,R)-206 28 2  >99 >99 R 
217 (R,R)-206 28 2   11 27 R 
218 (R,R)-206 28 2  6 14 R 
219 (R,R)-206 28 o/n >99 98 S 
220 (R,R)-206 28 o/n >99 96 S 
221 (R,R)-206 28 o/n >99 97 S 
222 (R,R)-206 28 o/n >99 95 S 
129 (R,R)-206 28 o/n >99 60 R 
224 (R,R)-206 28 4  22 17 R 
225 (R,R)-206 28 10  99 >99 S 
107a (R,R)-206 28 4  0 0 - 
141 (R,R)-206 28 4  >99 0 - 
226 (R,R)-206 28 13  >99 71 R 
Table 48. ATH reduction of ketones to alcohols (Concentration of 1.62 M with respect 
to ketone, non-dropwise i.e. azeotropic mixture used); Using dimer 206 forming 
monomer 207 in situ (S/C = 400). 
Propiophenone 49g was reduced successfully, giving 49g’ in excellent conversion, and 
ee. Increasing the size of the alkyl group to isopropyl and tert-butyl however resulted in 
an extreme drop in activity and enantioselectivity, giving 217’ and 218’ in poor conv., 
and ee. This is dissimilar to the alkyl “tethered” complex 160, which is more versatile in 
this respect. Excellent results were obtained for α-chloroacetophenones 219-221, which 
lead to alcohols 219’-221’, and are useful intermediates for the formation of epoxides 
and other chiral building blocks. Related substrates 222 and 225 that contain an O and N 
heteroatom on the alkyl substituent side can also be reduced successfully in excellent 
conversions and ee‟s. Introducing electron-withdrawing trifluoromethyl groups in to the 
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substrate appeared to be detrimental to the enantioselectivity, as 129’ was formed in just 
60% ee whilst the ortho-substituted 224 was reduced in just 22% conversion and 17% 
ee. An unexpected result was obtained for 2-acetylpyridine 107a, which was not 
reduced at all by catalyst 206 under the reaction conditions used. The reduction of 223 
was unsuccessful as the starting material was decomposing over time. 
The reduction of 2-acetylpyridine 107a was carried out using catalyst 165, with 
identical conditions to when catalyst 206 was employed previously in the reaction. 
Reduction of 107a was successful giving 107a’ in >99% conv., and 88% ee, which is in 
agreement with another alkyl-“tethered” catalyst 160 previously used for this reduction 
(Scheme 88, Table 49).
20a
 
 
Scheme 88. ATH reduction of 107a, using catalyst 206 and 163b. 
Ketone Catalyst Temp (°C) Time (days) Conversion (%) ee (%)/ Config. 
(R/S) 
107a (R,R)-206 28 4 0 0 - 
107a (R,R)-163b 28 o/n >99 88 R 
Table 49. ATH reduction of 107a to 107a’ (Concentration of 1.62 M with respect to 
ketone, non-dropwise i.e. azeotropic mixture used); Using dimer 206 forming monomer 
207 in situ also dimer 163b (forming 165) (S/C = 400). 
At this stage it was worth investigating to see whether or not the substrate was 
inhibiting the reaction. To test this, the reduction of a 1 : 1 mixture of 2-acetylpyridine 
107a and acetophenone 49a was attempted with catalyst 206 (Scheme 89). 
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Scheme 89. ATH reduction of a 1 : 1 mixture of 107a and 49a, using catalyst 206 (S/C 
= 400). 
The results showed that neither of the ketones were reduced (Scheme 89), suggesting 
that 2-acetylpyridine 107a is inhibiting the catalysis of the reaction, by a mechanism 
which is presently unclear but may involve an interaction of the protonated N atom of 
the pyridine with the oxygen atom on the “tether”. This would stabilise the complex 
between the catalyst and both the substrate and product to the point where product is not 
released (Figure 31), hence preventing catalyst turnover as reflected in the competition 
experiment. This additional interaction is not available to 165 and 160, and so is not 
inhibited by this substrate. 
 
Figure 31. 107a inhibits catalysis due to an additional interaction of the protonated 
pyridine with the O atom on the “tether” in catalyst 207 (formed from dimer 206).  
The reduction of cyclohexylmethyl ketone 141, which is a useful test ketone for dialkyl 
substrates, was catalysed by 206 with full conversion however racemic alcohol 141’ 
was obtained. This is in contrast to the 69% ee achieved for this substrate using alkyl-
“tethered” catalyst 160 (Section 1.4.7). The reduction of a structurally similar but 
unsaturated ketone 226, in contrast, was achieved in full conversion in 71% ee but after 
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13 days of reaction. The reduction to form 226’ could be directed by a similar CH/π 
interaction as for acetophenone derivatives (Figure 32). 
 
Figure 32. CH/ π interaction between η6-arene ring of the catalyst and the aromatic ring 
of the substrate. 
2.2.5     Comparative studies. 
A comparison in activity and selectivity using catalyst 206 (forming 207), 163b 
(forming 165) and 159 (forming 160) was carried out for the reduction of 225, which 
showed that catalyst 206, 163b and 159 all demonstrated similar activity and reactivity 
for the reduction of 225 (Scheme 90, Table 50). 
 
Scheme 90. ATH reduction of 225, using catalyst 206, 163b and 159. 
Ketone Catalyst Temp (°C) Time (days) Conversion (%) ee (%)/ Config. 
(R/S) 
35 (R,R)-206 28 10 >99 >99 S 
35 (R,R)-163b 28 8 >99 >99 S 
35 (S,S)-159 28 10 >99 >99 R 
Table 50. ATH reduction of 225 to 225’ (Concentration of 1.62 M with respect to 
ketone, non-dropwise i.e. azeotropic mixture used); Using dimer 206 forming monomer 
207 in situ and dimers also for 163b (forming 165) and 159 (forming 160) (S/C = 400). 
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In conclusion, the results suggest that the interaction of certain ketones with the ether-
linked “tethered” catalyst 206 (forming monomer 207 in situ) is somewhat different to 
their interaction with the alkyl-chain version such as catalysts 165 and 160. The sense of 
reduction in each case however shows that the catalyst 206 operates through a 
mechanism which is analogous to that of complex 165 and 160. This involves a key 
stabilising CH/π interaction between η6-arene ring of the catalyst and the aromatic ring 
of the substrate. 
During the preparation of this thesis, Ikariya et al, published
27i
 a synthesis of catalyst 
207 via a route different to that in this thesis and tested it in the ATH of a range of 
ketones distinct from the selection in this thesis. The 
1
H NMR spectroscopic data of the 
monomeric complex obtained by Ikariya matched that of the crude material obtained 
from dimer 206 in this project. 
2.3     N-Alkylated TsDPEN ligands for ATH reductions. 
As now it was established that ether-linked “tethered” catalysts were capable of 
reducing ketones, it was worth investigating the effects of having an ether- or alcohol-
containing chain on the “basic” nitrogen atom without it being “tethered” to the η6-arene 
ring. This transformation can provide means for attaching the catalyst to a 
hetereogeneous support. As mentioned in Section 1.4.3.2, catalyst 84 can be 
monosubstituted without the loss of catalytic activity or selectivity, provided that the 
subsituent is a linear alkyl group, as branched or sterically-hindered substituents cause a 
sharp reduction of activity. In contrast to extensive studies on the primary amine-
containing TsDPEN, a relatively small number of successful applications of N-alkylated 
TsDPEN-derived catalysts have been reported.
28a-f
 These include applications to C=C 
reduction
28a
 and use in reversible formate decarboxylation studies.
28b,28c
 In addition, the 
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application of N‟-alkylated derivatives of N-tosyl-1,2-diaminocyclohexane (TsDAC) to 
ketone and imine ATH has been reported.
28d, 28e
 Although oxygen-containing chains has 
not been previously studied, one report on the successful use in ATH of a TsDPEN 
ligand containing a PEG chain has been published.
28f
 There appear to be no published 
studies on the use of N-hydroxy-functionalised substituents, which have the potential to 
interact with the ruthenium atom in an analogous manner to a previously-reported 
catalyst 227 (Figure 33) containing a 2-hydroxyethyl group on the η6-arene ring.28g In 
other related examples published by Ikariya, and NHTf group at the end of a 3-carbon 
chain from the η6-arene ring, i.e. in 228 (Figure 33), was reported to give improved 
results in the asymmetric hydrogenation during the catalytic cycle.
28h, 28i
 
 
Figure 33. Previously reported functionalized Ru(II) catalysts. 
2.3.1     Preparing N-alkylated ligands. 
N-Alkylated ligands were prepared by via the route shown in Scheme 91. Diols 229a-c 
were first of all mono protected with the use of tert-butyldiphenylchlorosilane 
(TBDPSCl) and imidazole in THF at rt.
26c
 In order to prevent diprotection, solvent for n 
=2 and n =3 in 229b-c was replaced with DCM,
28j
 having a saturated solution 
(protecting group in excess). The monosilylated diols 230a-c were then oxidized to give 
the aldehydes 231a-c via Swern oxidation,
29a
 followed by aminal formation 232a-c with 
(R,R)-TsDPEN 81 using glacial acetic acid in dry methanol (Scheme 91).
29a
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Scheme 91. Synthesis of hydroxy N-alkylated ligands. 
 Reduction of the aminals 232a-c using LiAlH4, resulted in the formation of 233
29a
 and 
234 through aminal reduction coupled with desilylation under the same conditions. 
Ligands 235 and 236 both containing a linear 4C groups, were prepared by an 
analogous sequence to 233-234, with the difference that the LiAlH4 treatment at the end 
of the sequence did not simultaneously remove the silyl group, i.e. the product was silyl 
ether 235. The silyl group was however removed in a subsequent step using TBAF to 
furnish 236.
29a
 
2.3.2     Ester-containing ligands. 
The ester-containing ligands 240-241 were prepared by reaction of N-
hydroxyethylTsDPEN 233 and 236 with acids 238 and 199, using a combination of 
DCC and DMAP as the coupling reagent in DCM. DCC was however replaced with 
ethyl-(N‟,N‟-dimethylamino)propylcarbodiimide hydrochloride (EDC), as this 
carbodiimide reagent and its urea by-product 237 are water soluble, so the by-product 
and any excess reagent are removed by aqueous extraction. Dicyclohexylurea, the by-
product formed from DCC is nearly insoluble in most organic solvents and precipitates 
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from the reaction mixture as the reaction progresses (Scheme 92).
29b
 The coupling of 
233, with propiolic acid 198 was unsuccessful, with both starting materials obtained 
unreacted. 
 
Scheme 92. Synthesis of ester-linked N-alkylated ligands. 
Dimeric ligands 242 and 243 were prepared by an analogous process, starting from the 
1,4-dicarboxylic acid 239. The initial attempts to form ester-linked N-alkylated ligands 
had failed considerably with the reaction of alcohol 233 to the carboxylic acid 199 
transformed in to acid chloride in DCM.
29c
 Also with another alcohol and acid coupling 
method using methanesulfonic acid, aluminium oxide, sodium bicarbonate in ethyl 
acetate.
29d
  
2.3.3     N-Alkylated Ru(II) complex formation. 
A number of isolated complexes 244-247 were also prepared by the reaction of 233-236 
with [RuCl2(benzene)]2 in IPA at 80 °C for 1 hr (noting that the use of η
6
-benzene gives 
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significantly improved results over other η6-arenes when N-alkylated TsDPENs are 
employed in ATH reactions) (Scheme 93).
17j
 
 
Scheme 93. Synthesis of N-alkylated complexes 244-247.  
Complexation of ester-linked ligands 240, 242 and 243 proved problematic as long 
reaction times were required, or else starting ligand was still present. However, after 
long reaction times the products were formed in small quantities and were quite 
unstable, along with large quantities of decomposed material. The complexation of 
dimeric ligand 243, gave a mixture of two products 248 + 249 as suggested by 
1
H NMR 
and LR MS, along with the starting unreacted ligand 243 (Figure 34). 
 
 
Results and Discussion 
129 
 
 
Figure 34. Products formed after complexation of ligand 243 with [RuCl2(benzene)]2. 
An attempt to form a “trimeric” ligand 251 was also carried out using acid 250, proving 
to be unsuccessful, as an unknown product that couldn‟t be identified with very broad 
1
H NMR peaks was formed (Scheme 94). Further work was not conducted using the 
ester-linked ligands.   
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Scheme 94. Attempted synthesis of “trimeric” ligand 251 using 236 and 250 had failed. 
Attempted formation of Ester-linked “tethered” catalyst 252 (dimer). 
As attempts to form the ester with a 1,4-cyclohexadienyl moiety were successful, it was 
considered worth testing whether an ester-linked “tethered” catalyst could be formed. 
Complexation using 240, first forming the ligand salt 240.HCl using HCl in DCM, 
followed by refluxing of the salt in IPA gave a black solid product 252. Product analysis 
using 
1
H NMR, LR MS and HR MS showed no signs of product formation. It was still 
however tested for the ATH reduction of acetophenone 49a and cyclohexylmethyl 
ketone 141, but no conversion was observed and no presence of the monomeric catalyst 
was seen by LR MS. Monomer formation was also attempted separately by heating 252 
with Et3N in IPA at 80 °C, but no product was formed as confirmed by 
1
H NMR and LR 
MS (Scheme 95). 
 
Scheme 95. Attempted formation of ester-linked “tether” dimer 252 had failed. 
Results and Discussion 
131 
 
2.3.4     Ether-linked N-alkylated ligands. 
The synthesis of ether-linked N-alkylated ligand was unsuccessful using NaH in THF 
with 236 and 1,3,5-tris(bromomethyl)benzene 253 at rt (Scheme 96).
29e
 In the attempt to 
not waste ligand 236, 4-phenyl-1-butanol 255 was first used in order to optimize 
conditions for coupling with 253.  
 
Scheme 96. Attempted synthesis of a “trimeric” ether-linked ligand 254 using 236 and 
253 failed.  
Using NaH in THF, the coupling was repeated as previously shown, but using 4-phenyl-
1-butanol 255 with 1,3,5-tris(bromomethyl)benzene 253. The reaction was carried out at 
rt and at 60 °C, but the coupling was unsuccessful on both occasions (Scheme 97).  
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Scheme 97. Attempted synthesis of a “trimeric” ether-linked test ligand 256 using 255 
and 253 failed. 
However when the coupling of 255 with 253 was carried out using K2CO3 in acetone at 
0 °C,
29f
 the coupling was successful (Scheme 98, Figure 35). However due to lack of 
time further studies were not conducted in this area. 
 
Scheme 98. Synthesis of a “trimeric” ether-linked test ligand 256 using 255 and 253. 
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Figure 35. 
1H NMR of “trimeric” ether-linked test ligand 256. 
2.3.5     Aymmetric transfer hydrogenation reduction using Ru(II) N-alkylated 
complexes and ligands. 
In the ATH of acetophenone, each of the catalysts, both pre-prepared, and formed in 
situ, proved to be effective and gave a product of high enantiomeric excess (Table 51). 
The N-alkylated complexes were somewhat less active than the unsubstituted and 
“tethered” complexes, however, with a typical reaction time of 4 days being required for 
full reduction at rt at 0.5 mol% catalyst loading. Catalyst 244, with the shortest chain, 
was the least active, requiring 10 days to achieve >99% conversion to product. This 
may indicate that there is some reversible interaction of the OH group with the Ru(II) 
atom, thereby reducing its effective concentration in the reaction. This would have a 
close analogy to the effect observed by White for hydroxyethyl-substituted complex 
227.
28g
 As the chain becomes longer, this reduction in activity is attenuated and, for the 
4C complex, there is essentially no difference in activity between the silylated 247 and 
the free OH complex 246, as would be expected on entropic grounds. In general, the 
isolated complexes were more active than the complexes formed in situ (Scheme 99, 
Table 51). 
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Scheme 99. ATH reduction of acetophenone 49a, using complex 244-247 and ligands 
233-236 and 240-243 in conjunction with [RuCl2(benzene)]2 (S/C = 200). 
Entry Catalyst Time (days) Conv. (%) ee (%)/ Config. 
(R/S) 
1 233/Ru 13 >99 92 R 
2 234/Ru 8 31 92 R 
3 235/Ru 6 >99 95 R 
4 236/Ru 6 93 94 R 
5 244 3 88 93 R 
6 245 2 >99 94 R 
7 246 2 >99 95 R 
8 247 2 >99 95 R 
9 240/Ru 5 98 95 R 
10 241/Ru 5 97 96 R 
11 242/Ru 5 92 96 R 
12 243/Ru 8 >99 95 R 
Table 51. ATH reduction of acetophenone 49a, using complex 244-247 and ligands 
233-236 and 240-243 in conjunction with [RuCl2(benzene)]2 (S/C = 200). 
The ester-terminated complexes formed 240-243 were also efficient catalyst for the 
ATH of acetophenone, giving products of 95-96% ee in high conversion. The presence 
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of a nearby ester appears entirely compatible with catalyst activity. It should be noted 
that all of the reactions in Table 51 were followed over time order to confirm that no 
racemisation was taking place during their course (Table 52-63). 
In conclusion, complexes containing a straight-chain substituent attached to a hydroxyl, 
ether or ester function also act as effective catalysts. This may represent a useful means 
for the attachment of the catalyst to a heterogeneous support. 
Conversions and enantioselectivities of complexes 244-247 and ligands 233-236 and 
240-243 over time. 
Catalyst 244 
Time Conversion Enantiomeric excess (%) 
1 hr 1.3 - 
5 hrs 40 mins 6.4 92 
24 hrs 10 mins 28 92 
48 hrs 40 mins 63 93 
72 hrs 40 mins 88 93 
Table 52. 
Catalyst 245 
Time Conversion Enantiomeric excess (%) 
16 hrs 40 mins 87 94 
25 hrs 10 mins 96 95 
42 hrs 10 mins >99 94 
Table 53. 
Catalyst 246 
Time Conversion Enantiomeric excess (%) 
16 hrs 40 mins 93 95 
25 hrs 10 mins 98 95 
42 hrs 10 mins >99 95 
Table 54. 
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Catalyst 247 
Time Conversion Enantiomeric excess (%) 
16 hrs 40 mins 94 95 
25 hrs 10 mins 98 96 
42 hrs 10 mins >99 95 
Table 55. 
Ligand 233 
Time Conversion Enantiomeric excess (%) 
2 hrs 50 mins - - 
23 hrs 5 mins 7.8 91 
94 hrs 20 mins 60 90.4 
141 hrs 50 mins 89 91 
311 hrs 50 mins >99 92 
Table 56. 
Ligand 234 
Time Conversion Enantiomeric excess (%) 
17 hrs 45 mins 10 93 
41 hrs 45 mins 20.5 93 
116 hrs 45 mins 30 92 
138 hrs 45 mins 30 92 
185 hrs 45 mins 31 92 
Table 57. 
Ligand 235 
Time Conversion Enantiomeric excess (%) 
17 hrs 45 mins 24 94 
41 hrs 45 mins 73.4 95 
116 hrs 45 mins >99 95 
138 hrs 45 mins >99 95 
Table 58. 
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Ligand 236 
Time Conversion Enantiomeric excess (%) 
17 hrs 45 mins 25 93 
41 hrs 45 mins 67.3 94 
116 hrs 45 mins 93 94 
138 hrs 45 mins 93 94 
185 hrs 45 mins 93 93.4 
Table 59. 
Ligand 240 
Time Conversion Enantiomeric excess (%) 
16 hrs 51 96 
41 hrs 88 97 
113 hrs 98 95 
Table 60. 
Ligand 241 
Time Conversion Enantiomeric excess (%) 
16 hrs 46 96 
41 hrs 86 95 
113 hrs 97 96 
Table 61. 
Ligand 242 
Time Conversion Enantiomeric excess (%) 
4 hrs 4 89 
23 hrs 48 95 
46 hrs 30 mins 78 97 
119 hrs 30 mins 92 96 
Table 62. 
Ligand 243 
Time Conversion Enantiomeric excess (%) 
17 hrs 45 mins 11 94 
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41 hrs 45 mins 40.1 95 
116 hrs 45 mins 93 95 
138 hrs 45 mins 96 95 
185 hrs 45 mins >99 95 
Table 63. 
2.4     Further work on the synthesis of “tethered” Ru(II) catalysts. 
Further work that was carried out during the course of this PhD project, included the 
attempted synthesis of catalysts 257-261 (Figure 36). 
 
Figure 36. Attempted synthesis of the Ru(II) “tethered” catalysts 257-261. 
2.4.1     Synthesis of the N-linked “tethered” catalyst 257. 
The synthesis of the N-linked “tethered” catalyst was the next task in this project after 
the successful synthesis of the ether-linked catalyst 207, as bulkier groups can be 
functionalized on the “tether”, and its effects on ATH reductions is worth investigating 
(Section 1.4.7). In order to proceed with the synthesis, it was vital that 200 was 
converted into a good leaving group for the successful insertion of benzylamine. The 
attempts to tosylate and mesylate proved to be unsuccessful as the products formed 
262/263
20a
 were very sensitive and possibly reacted with other sources/impurities 
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present in solution. To overcome this problem, 200 was successfully converted in to an 
aldehyde so that reductive amination with benzylamine could be carried out. 4-
methylcyclohexa-1,4-dienecarbaldehyde 264 via swern oxidation
20a
 with the use of 
oxalylchloride, dimethylsulfoxide and triethylamine in dichloromethane at -78 °C was 
successfully formed in >99% yield (quant.) (Scheme 100). 
 
Scheme 100. Attempted conversion of the alcohol 200 in to a good leaving group. 
Reductive amination was carried out in methanol using 264, benzylamine and glacial 
acetic acid to form an imine, which then was reduced to give N-Benzyl (4-
methylcyclohexa-1,4-dienyl) methanamine
20a
 265 as a yellow oil in 75% yield using 
sodium cyanoborohydride. The steps that need to be carried out for the completion of 
this catalyst will now be outlined. The amine 265 needs to be coupled with tert-
butylbromoacetate 201 in NaOH solution and using TBAB to give 266,
27b
 which would 
then be reduced with LiAlH4 in THF to give 267
17j
, and oxidised via Swern oxidation to 
form 268
20a
. Reductive amination in methanol would then be carried out using 268, R,R-
TsDPEN 81 and glacial acetic acid to form an imine, then reduced to give 269
20a
 using 
sodium cyanoborohydride. The final step would then be the complexation of 269.HCl 
salt which is formed by the addition of hydrochloric acid in DCM, and then 
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complexation with ruthenium(III) trichloride hydrate in IPA at reflux temperature, to 
form 270
20a
, which in situ would form 257 or can isolate the monomer 257 by the 
reaction of dimer 270 with Et3N in IPA for 1 hr
20a 
(Scheme 101). Due to insufficient 
time, the synthesis could not be completed. 
 
Scheme 101. Proposed synthesis of the N-linked “tethered” catalyst 257. This synthesis 
was not completed. 
2.4.2     Synthesis of the ether-linked “tethered” Ru(II) catalyst with functionalized 
arene ring. 
Investigations into the modification of the η6-arene ring have been carried out 
previously in the Wills group, preparing derivatives of “tethered” catalysts 148-151 and 
152-155 with a variety of functional groups on the arene ring using a [4 + 2] 
cycloaddition step. This area was further investigated, with the replacement of the alkyl 
“tether” with the ether-linked “tether” and having monotosyl diamine ligand replacing 
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the previously used amino alcohol and sulfonylated diamine. It was previously 
demonstrated by Noyori that mesitylene or p-cymene arene ligands were less reactive 
than unsubtituted benzene, but gave better enantioselectivities. For this reason, the 
mesitylene functionality was incorporated in to the original ether-linked “tethered” 
catalyst 206 (forming 207 in situ) to give 258. The synthesis of catalysts 259-261 were 
carried out as they seemed interesting, and because useful information could be 
generated with the use of these catalysts for the ATH reduction of aromatic and dialkyl 
ketones.  
The attempted synthesis of the isoprenes required for the cycloaddition step has been 
shown in Scheme 102. Substrate 272 and 274-275 were readily available; however 273 
had to be prepared by the reaction of 271 with AcOK in refluxing ethanol, giving 273 in 
31% yield.
30a
 The conversion of the C=O group to C=C was unsuccessful with 272 
using methyltriphenylphosphonium bromide, sodium hexamethyldisilazide in 1,4 
dioxane at 60 °C,
30b
 as it was very volatile and difficult to isolate. The same reaction 
using 273 had formed a mixture of 280 and 281 instead of 277. It was however 
successful for the formation 278 and 279 (Scheme 102).  
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Scheme 102. Synthesis of the required isoprene 276-279, with successful product 
formation of 278-279, but unsuccessful for 276-277. 
Cycloaddition reaction of 278 and 279 using 282 and hydroquinone in refluxing toluene 
had failed to deliver the expected products, instead giving decomposed material 
(Scheme 103).  
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Scheme 103. Attempted cycloaddition reaction of 278 and 279 with 282. These 
reactions were unsuccessful. 
3.     Appendix; Additional studies completed within the project. 
3.1     Asymmetric transfer hydrogenation reductions of imines derived from β-
tetralone 223. 
An early objective in this project was to synthesize a series of useful acyclic imine 
substrates derived from β-tetralone 223 (Figure 37), and then examine their asymmetric 
reduction using Ru(II) untethered and “tethered” complexes. Synthesizing acyclic 
imines derived from 223 is unusual, rare and it produces some interesting amine targets 
as shown in Scheme 104 and Scheme 105.  
 
Figure 37. Structure of β-tetralone 223. 
In mammals, melatonin (N-acetyl-5-methoxytryptamine, MLT) 286, a neurohormone 
modulates a variety of cellular, neuroendocrine and physiological processes through the 
activation of atleast two high-affinity G-protein coupled receptors, named MT1 and 
MT2.
31a
 Piersanti
31b
 developed a novel, efficient and diastereoselective procedure for the 
gram-scale synthesis of cis-4-phenyl-2-propionamidotetralin (4-P-PDOT) 289, a 
selective MT2 melatonin receptor antagonist. The synthetic strategy involved the 
conversion of 4-phenyl-2-tetralone 287 derived from 223 to enamide 288 by refluxing 
under nitrogen, 287 with propionamide and p-toluenesulfonic acid in toluene using 
Dean-Stark apparatus affording 288 as a light yellow oil in 95% yield after column 
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chromatography and recrystallisation. A diastereoselective reduction of 288 was carried 
out by cooling down a solution of 288 in trifluoroacetic acid  to -10 °C followed by the 
dropwise addition of triethylsilane affording 289 in 71% yield after column 
chromatography and recrystallisation
31c
 (Scheme 104). 
 
Scheme 104. Synthesis of 4-P-PDOT 289, a selective MT2 melatonin receptor 
antagonist. 
The pharmacological importance of the 2-aminotetralin (2-amino-1,2,3,4- 
tetrahydronaphthalene) 294 structure has been known for a long time. Initially, 
aminotetralins were characterized by their sympathomimetic action (causing mydriasis, 
contraction of the uterus, changes in blood pressure and respiration, and increased 
intestinal motility in test animals). During the late sixties the dopaminergic activity of 2-
aminotetralins was identified which led to an active synthesis program. For the 
synthesis of a complex 294 carried out by Hans-Jurgen Federsel (Astrazeneca), the 
nitrogen at the stereogenic centre was introduced by a reductive amination of 8-bromo-
5-methyl-3,4-dihydronaphthalen-2(1H)-one 290 derived from 223 with 
phenylethylamine, firstly forming the intermediate imine 291 with the addition of p-
toluenesulfonic acid, and then forming the resulting amine 292 with a sodium 
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borohydride reduction. The Buchwald-Hartwig approach with palladium acetate in the 
presence of BINAP afforded the piperazine coupled product 293. Finally carrying out a 
hydrogenation followed by the addition of benzoic acid resulted in the formation of the 
complex 294 in 88% yield
31d
 (Scheme 105). 
Scheme 105. Synthesis of a complex 2-Aminotetralin 294, with „pharmaceutical 
significance‟ 
A series of β-tetralone derived imines that were considered worthy of investigation are 
shown in Figure 38. 
 
Figure 38. C=N reduction substrates 
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Attempted synthesis of (E)-1-(3,4-dihydronaphthalen-2(1H)-ylidene)-2-
phenylhydrazine 295. 
The first objective was to synthesize 295, however the reaction of a phenylhydrazine 
with 223 initially forms 295, but this can then isomerize to the respective enamine 295’ 
(or 'ene-hydrazine'). After protonation, a cyclic [3,3]-sigmatropic rearrangement can 
occur producing an imine. The resulting imine can form a cyclic aminoacetal (or 
aminal), which under acid catalysis eliminates NH3, resulting in the energetically 
favorable aromatic indole 295’’ (Scheme 106). This is the Fischer indole synthesis. Care 
must be taken to stop at the imine stage. 
 
Scheme 106. Reaction of 223 with phenylhydrazine to give 295’’ instead of 295. 
In the event, the condensation reaction under acidic conditions resulted in the formation 
of the aromatic indole 295’’ (in 91% Yield as an orange-red oil) and not the desired 
295. This particular reaction proved to be unsuccessful without acidic conditions and 
using heat in an attempt to avoid the Fischer indole reaction (Scheme 107). 
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Scheme 107. Reaction of 223 with phenylhydrazine, with heat and without acidic 
conditions. 
Synthesis of Methyl [3,4-dihydro-2(1H)-naphthalen-ylidene]-hydrazinecarboxylate 
296. 
The next objective was to successfully synthesize 296 using a method in the literature 
published by Beam.
31e 
The reaction was carried out by the addition of 
methylhydrazinocarboxylate and 223 in methanol, stirring at 50 °C overnight affording 
296 as orange-white crystals in 66% yield
31f
 (Scheme 108). As there were distinctive 
impurities present in the crude product as shown by NMR analysis, purifying the crude 
product was necessary before any reductions were carried out. 
 
Scheme 108. Reaction of 223 with methylhydrazinocarboxylate to give 296. 
Purification methods such as Column chromatography, Kugelrohr distillation and 
recrystallization all proved unsuccessful.  
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The structural properties of 296 were worthy of further investigation, therefore a 
variable temperature NMR of 296 was recorded at 25 °C, 40 °C and 50 °C (Figure 39). 
 
Figure 39. NMR analysis of 296 at various temperatures. 
The results were informative, as the peaks marked with an arrow are increasing in 
height as the temperature is increased. This indicates that the speed of rotation about the 
C-N bond is increasing with increasing temperature, as the NMR machine is unable to 
differentiate between the two different isomers causing a compressed tall peak to 
appear. The large energy barrier between E/Z isomers clearly eliminates the possibility 
of „flipping‟ of the E form to the Z form (rotation about the N-N bond) and vice versa. 
Rotation about the C-N bond is of low energy barrier, and can be held responsible for 
the change in NMR with increasing temperature (Figure 39-40). 
ppm (t1)
2.503.003.504.004.505.005.506.006.507.00
ppm (t1)
2.503.003.504.004.505.005.506.006.507.00
ppm (t1)
2.503.003.504.004.505.005.506.006.507.00
NMR Analysis of 296 
25 °C 
40 °C 
50 °C 
Rotation about the C-N bond is 
faster as the temperature  
increases. 
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Figure 40. The four different isomers of 296. 
This substrate was proving to be quite problematic and so it was not further used as part 
of this project. 
Synthesis of (R,E)-N-(3,4-dihydronaphthalen-2(1H)ylidene)-1-phenylethanamine 
297. 
The synthesis of 297 was carried out using (R)--methylbenzylamine and 223, which 
was difficult at first as various procedures from previous literature were tested out, all 
proving to be unsuccessful. But the procedure published by Carlson, Larsson and 
Hansson
31g
 in 1992 proved to be successful giving 297 which is in equilibrium with 
enamine 297’, using titanium tetrachloride as the water trapping agent, deoxygenating 
every reagent/solvent used, and keeping the reaction under argon at all times, even 
while filtering out the precipitate formed. The dark green crude product formed was 
purified using Khugelrohr distillation, giving a clear yellow oil in 36% yield (Scheme 
109). This particular product is highly air sensitive, light sensitive and has to be stored 
at low temperatures in order to avoid colour change and decomposition. 
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Scheme 109. Reaction of 223 with (R)-alpha-methylbenzylamine giving 297. 
Reductions using sodium cyanoborohydride and the untethered catalyst 38 were carried 
out on 297 to try and obtain N-((R)-1-phenylethyl)-1,2.3,4-tetrahydronaphthalen-2-
amine 301. 
Sodium cyanoborohydride reduction was successfully carried out to give a standard 
sample of both diastereoisomers of 301 in 83% yield, as confirmed by 
1
H NMR and MS 
analysis (Scheme 110, Figure 41). 
 
Scheme 110. Reduction of 297 using NaBH3CN, giving the amine 301. 
 
Appendix 
 
151 
 
 
Figure 41. LR MS of amine 301. 
Reduction using the untethered catalyst 38 was unsuccessful as shown by LR MS 
(Figure 42) and 
1
H NMR analysis (Scheme 111), giving a ~50 : 50 mixture of β-
tetralone 223 and an unknown product, which couldn‟t be identified. The result was also 
quite similar when a few attempted reductions were carried out using “tethered” catalyst 
163b instead of the untethered catalyst 38. 
 
Scheme 111. Reduction of 297 using the untethered catalyst 38 (S/C = 200). 
 
301 
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Figure 42. LR MS of the unknown product formed from the reduction of 297 with the 
untethered catalyst 38. 
Synthesis of (E)-1-(3,4-dihydronaphthalen-2(1H)-ylidene)semicarbazide 298. 
The preparation of 298 was quite straight forward and followed a literature precedent 
published by Dimmock and Pandeya.
31h
 Reacting a mixture of semicarbazide 
hydrochloride, sodium acetate and water with a solution of 223 in ethanol gave 298 as 
white crystals in 70% yield (Scheme 112). The reductions carried out with 298 were 
unsuccessful as a lot of solvent was required to dissolve 298. The two recommended 
solvents for ATH reductions giving best yields and conversion rates are acetonitrile and 
methanol, however neither was able to dissolve the product using recommended 
quantities.  
 
Scheme 112. Reaction of 223 with semicarcarbazide, giving 298. 
The racemic standard of 298 was however successfully prepared using NaBH3CN, 
acetic acid in methanol, giving 302 after column chromatography (Scheme 113). 
Unknown product 
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Scheme 113. Reduction of 298 using NaBH3CN giving 302. 
Synthesis of (1E,5E)-1,5-bis(3,4-dihydronaphthalen-2(1H)-
ylidene)carbonohydrazide 299. 
Synthesis of 299 was successfully carried out using the same literature published by 
Dimmock and Pandeya
31h
 for synthesis of 298. The addition of carbohydrazide in 
methanol to 223 in methanol, and after the solution was stirred for 20 mins, 299 had 
formed as grey crystals in 46% yield (Scheme 114). The crude product contained some 
impurities, which even after recrystallisation had remained. 
 
Scheme 114. Reaction of 223 with carbohydrazide, giving 299. 
Product 299 encountered similar solubility issues that were previously observed for 298.  
Synthesis of (Z)-N-(3,4-dihydronaphthalen-2(1H)-ylidene)benzenamine 300. 
The final objective was to successfully synthesize 300. The synthesis of 300 was carried 
out by following the same procedure as for making 297 as this substrate has not been 
synthesised before.
31g
 An orange-red oil was formed in 75% yield (Scheme 115). 
1
H 
NMR and LR MS analysis of the crude product showed the presence of 300. Distillation 
and various purification methods such as column chromatograph had proved to be 
unsuccessful, giving decomposed material. 
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Scheme 115. Reaction of 223 with aniline, giving 300. 
Due to a series of implications in this project, work in this area was not further carried 
out. 
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4.     General Experimental. 
All the air sensitive reactions were carried out under an argon or nitrogen atmosphere. 
Room temperature (rt) refers to ambient temperature (20-22 °C), 0 °C refers to an ice 
slush bath and -78 °C refers to a dry ice acetone bath. Heated experiments were 
conducted using thermostatically controlled oil baths or Asynt aluminium heating 
blocks. Reactions were monitored by Thin Layer Chromatography (TLC) using 
aluminium backed silica gel 60 (F254) plates, visualised using UV254 nm, PMA, iodine, 
potassium permanganate and ninhydrin dips as appropriate. 
13
C-NMR spectra were 
recorded on a Bruker DPX-300 (300 MHz) or a Bruker DPX-400 (400 MHz). All 
chemical shifts are reported in ppm downfield from TMS (Me4Si). Coupling constants 
(J) are reported in Hz. Multiplicity in 
1
H-NMR is reported as singlet (s), doublet (d), 
triplet (t), quartet (q), quintet (quin), octet (oct), double doublet (dd), triple triplet (tt), 
broad singlet (br s), broad multiplet (br m) and multiplet (m). Mass spectra were 
recorded on an Esquire 2000. High resolution mass spectra were recorded on Bruker 
Micro ToF. Infrared spectra were recorded on PerkinElmer spectrum100. The optical 
rotations were measured on Optical Activity Ltd. AA-1000 Polarimeter. The Chiral 
HPLC measurements were carried out on HPLC consisting of a Gilson 811B Dynamic 
Mixer, a Gilson 805 Monometer Module, a Gilson 305 Piston Pump, Merck-Hitachi L-
4000 UV detector linked to HEWLETT PACKARD 3396 Series II integrator with 
CHIRAL PAK IA/IB column (0.46 cm x 25 cm) or CHIRAL CEL OD-H/OD column 
(0.46 cm x 25 cm). The chiral GC measurements were done on HEWLETT PACKARD 
5890 linked to HEWLETT PACKARD HP3396A integrator or PERKIN-ELMER 8500 
chromatography linked to PC running DataApex Clarity software with Chrompak CP-
Chirasil Dex Cβ column. Melting points were determined on a Stuart scientific melting 
point apparatus and are uncorrected. Purification of compounds was carried out by 
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using flash column chromatography using silica gel of mesh size 230-400/ Florisil of 
mesh 100-200 or Kugelrohr distillation using BÜCHI GKR-51.  
4.1     Procedures from Section 2.1 
Synthesis of 4-(cyclohexa-1,4-dienyl)butan-1-ol (303). 
 
This is a known compound and has been fully characterised.
20a 
A solution of 4-phenylbutan-1-ol (3.30 g, 3.39 cm
3
, 22 mmol) in ethanol (10 cm
3
) was 
slowly added to a refluxing solution of ammonia (250 cm
3
) containing ethanol (70 cm
3
) 
at -78 °C while stirring. Small cleaned (with hexane) sodium pieces were added to the 
reaction mixture until the blue colour persisted. After the addition of sodium over the 
course of 7 hours with regular additions of ethanol (5-10 cm
3
) to facilitate stirring, the 
reaction mixture was then left overnight to allow the remaining ammonia to evaporate. 
Saturated NH4Cl(aq) (100 cm
3
) was added to the reaction, which was then extracted 
using DCM (3 x 30 cm
3
). The combined organic layers were dried (MgSO4), filtered 
and concentrated under reduced pressure to afford 303 as a light orange oil (3.30 g, 
21.68 mmol, >99%); δH (400 MHz, CDCl3) 5.75-5.67 (2 H, m, HC=CH), 5.48-5.40 (1 
H, m,  C=CH), 3.65 (2 H, t, J 6.3, CH2OH), 2.70-2.67 (2 H, m, C=CCH2C=C), 2.60-
2.55 (2 H, m, C=CCH2C=C), 2.00 (2 H, t, J 7.0, CH2CH2CH2CH2OH), 1.65-1.45 (4 H, 
m, CH2CH2CH2CH2OH) and 1.31 (1 H, br s, OH); δC (101 MHz, CDCl3) 134.74 (C), 
124.31 (CH), 124.27 (CH), 118.45 (CH), 62.63 (CH2), 37.16 (CH2), 32.33 (CH2), 28.86 
(CH2), 26.73 (CH2) and 23.43 (CH2). The data matched that previously reported. 
Synthesis of 4-(cyclohexa-1,4-dienyl)butanal (304).  
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This is a known compound and has been fully characterised.
20a 
The solution of oxalylchloride (2 M in DCM, 7.78 cm
3
, 15.55 mmol) in anhydrous 
DCM (20 cm
3
) was cooled to -78 °C, and to this was slowly added DMSO (2.21 cm
3
, 
31.10 mmol) in DCM (10 cm
3
) by syringe. The solution was stirred for 30 minutes at -
78 °C before  4-(cyclohexa-1,4-dienyl)butan-1-ol 303 (1.82 g, 11.96 mmol) in DCM (30 
cm
3
) was slowly added at the same temperature. After stirring for 45 minutes at -78 °C, 
Et3N (10 cm
3
, 71.69 mmol) was added, and the reaction mixture was allowed to warm 
up to rt. After 60 minutes, water (75 cm
3
) was added, and the mixture was extracted 
with DCM (3 x 40 cm
3
). The combined organic layers were dried (MgSO4), filtered and 
concentrated under reduced pressure to give 304 as a light orange oil (1.82 g, 12.12 
mmol,  >99% quantitative conversion, includes traces of solvent); δH (400 MHz, CDCl3) 
9.77 (1 H, s, CH=O), 5.74-5.66 (2 H, m, HC=CH), 5.42 (1 H, br s, C=CH), 2.72-2.63 (2 
H, m, C=CCH2C=C), 2.62-2.55 (2 H, m, C=CCH2C=C), 2.42 (2 H, t, J 7.3, 
CH2CH2CH2CHO), 1.99 (2 H, t, J 7.3, CH2CH2CH2CHO) and 1.75 (2 H, quin, J 7.3, 
CH2CH2CH2CHO); δC (101 MHz, CDCl3)  202.63 (CH=O), 133.78 (C), 124.32 (CH), 
124.23 (CH), 119.46 (CH), 43.26 (CH2), 37.16 (CH2), 28.86 (CH2), 26.71 (CH2) and 
20.00 (CH2). The data matched that previously reported for this compound. 
Synthesis of (R, R)-N-(4-cyclohexa-1,4-dienyl)butyl)-1,2-diphenyl-N’-tosylethane-
diamine (162b).  
 
Experimental 
 
158 
 
This is a known compound and has been fully characterised.
20a 
To a suspension of powdered molecular sieves (4 Å, 0.50 g) in dry methanol (30 cm
3
) 
was added 4-(cyclohexa-1,4-dienyl)butanal 304 (265 mg, 1.76 mmol),  (R, R)-TsDPEN 
81 (712 mg, 1.94 mmol) and glacial acetic acid (4 drops). The reaction mixture was 
stirred at rt and monitored by TLC. After 2 hrs, the imine had formed (observed by 
TLC), and sodium cyanoborohydride (528 mg, 8.44 mmol) was added. The reaction was 
left to stir overnight at rt. Molecular sieves were removed by filtration, and the solution 
was concentrated under reduced pressure. The residue was re-dissolved in DCM (40 
cm
3
). The organic phase was washed with saturated NaHCO3 (40 cm
3
) and brine (40 
cm
3
), dried (MgSO4), filtered and concentrated under reduced pressure. The resulting 
residue was purified by flash chromatography (10→30 % v/v ethyl acetate/hexane) to 
afford 162b as a white solid (265 mg, 0.53 mmol, 30 %); δH (400 MHz, CDCl3) 7.37 (2 
H, d, J 8.5, 2 x NHSO2Ar-o-CH), 7.16-7.11 (3 H, m, 3 x Ar-H), 7.08-7.01 (5 H, m, 5 x 
Ar-H), 6.97-6.89 (4 H, m, 4 x Ar-H), 6.29 (1 H, br s, NHTs), 5.74-5.67 (2 H, m, 
HC=CH), 5.35 (1 H, br s, C=CH), 4.24 (1 H, d, J 8.0, TsNHCH), 3.60 (1 H, d, J 8.0, 
NHCH), 2.72-2.65 (2 H, m, C=CCH2C=C), 2.59-2.51 (2 H, m, C=CCH2C=C), 2.43-
2.35 (2 H, m, NHCH2CH2CH2), 2.32 (3 H, s, TsCH3), 1.90 (2 H, t, J 6.5, 
NHCH2CH2CH2CH2), 1.41-1.30 (5 H, m, NHCH2CH2CH2CH2 + NH);  δC (101 MHz, 
CDCl3) 142.69 (C), 139.40 (C), 138.41 (C), 137.09 (C), 134.70 (C), 129.09 (2 x CH), 
128.30 (2 x CH), 127.90 (2 x CH), 127.59 (2 x CH), 127.44 (CH), 127.40 (2 x CH), 
127.25 (CH), 127.15 (2 x CH), 124.35 (CH), 124.32 (CH), 118.49 (CH), 67.86 (CH), 
63.08 (CH), 47.03 (CH2), 37.20 (CH2), 29.64 (CH2), 28.87 (CH2), 24.76 (CH2), 23.44 
(CH2) and 21.44 (CH3). The data matched that previously reported for this compound. 
Synthesis of N-[(1R, 2R)-1,2-Diphenyl-2-(4-phenylbutylamino)-ethyl]-4-
methylbenzenesulfonamide ammonium chloride ruthenium dimer
 
(163b).  
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This is a known compound and has been fully characterised.
 20a 
To a stirred solution of (R,R)-N-(4-cyclohexa-1,4-dienyl)butyl)-1,2-diphenyl-N’-
tosylethane-diamine 162b (265 mg, 0.53 mmol) in anhydrous DCM (8 cm
3
) was added 
hydrochloric acid (2 M in diethyl ether, 0.80 cm
3
, 1.59 mmol) at 0 °C. The reaction 
mixture was stirred at rt for 20 minutes, and subsequently concentrated under reduced 
pressure to give a white residue. To a suspension of the residue in ethanol (10 cm
3
) was 
added ruthenium (III) trichloride hydrate (112 mg, 0.42 mmol). The reaction mixture 
was refluxed overnight. The precipitate was collected by filtration and washed with cold 
ethanol to give N-[(1R,2R)-1,2-diphenyl-2-(4-phenylbutylamino)-ethyl]-4-
methylbenzenesulfonamide ammonium chloride ruthenium dimer 163b (200 mg, 0.14 
mmol, 54 %) as green-brown crystals; δH (400 MHz, DMSO-d6) 9.47 (2 H, br s, 2 x 
NH(1)H(2)
+
Cl
-
), 9.02 (2 H, br s, 2 x NH(1)H(2)
+
Cl
-
),  8.60 (2 H, d, J 9.5, 2 x NHTs), 7.30-
6.81 (28 H, m, 2 x (14 x Ar-H)), 6.02-5.72 (10 H, m, 2 x (5 x Ru-Ar-H)), 4.82 (2 H, m, 
2 x PhCHNHTs), 4.58-4.51 (2 H, m, 2 x PhCHNH2
+
Cl
-
), 2.74-2.66 (4 H, m, 2 x 
NH2
+
Cl
-
CH2CH2CH2CH2), 2.45-2.39 (4 H, m, 2 x CH2NH2
+
Cl
-
), 2.21 (6 H, s, 2 x 
TsCH3), 1.78-1.67 (4 H, m, 2 x NH2
+
Cl
-
CH2CH2CH2CH2), 1.58-1.47 (4 H, m,  2 x 
NH2
+
Cl
-
CH2CH2CH2CH2); δC (101 MHz, DMSO-d6) 142.14 (2 x C), 137.67 (2 x C), 
135.48 (2 x C), 131.49 (2 x C), 129.15 (2 x CH), 129.07 (2 x CH), 128.84 (2 x (2 x CH), 
128.65 (2 x (2 x CH), 127.71 (2 x (2 x CH), 127.54 (2 x (2 x CH), 127.14 (2 x CH), 
126.33 (2 x (3 x CH), 107.22 (2 x C), 88.87 (2 x (2 x CH), 84.84 (2 x CH), 84.82 (2 x 
CH), 83.09 (2 x CH), 64.29 (2 x CH), 60.58 (2 x CH), 45.25 (2 x CH2), 31.72 (2 x CH2), 
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25.58 (2 x CH2), 24.38 (2 x CH2) and 20.82 (2 x CH3). The data matched that 
previously reported for this compound. 
Synthesis of N-((1R, 2R)-2-(benzylamino)-1,2-diphenylethyl)-4-
methylbenzenesulfonamide (305).  
 
This is a known compound and has been fully characterised.
32a, 32b 
To a stirred solution of (R, R)-TsDPEN 81 (0.60 g, 1.64 mmol) and molecular sieves (4 
Å, 2.0 g) in dried methanol (16 cm
3
), was added benzaldehyde (0.20 cm
3
, 1.96 mmol) 
followed by glacial acetic acid (6 drops). The reaction was followed by TLC until the 
imine was formed (3 hrs), and then sodium cyanoborohydride (0.30 g, 4.8 mmol) was 
added and the reaction was left overnight at rt. The molecular sieves were filtered 
through filter paper and the solution was then concentrated under reduced pressure to 
remove the methanol. The residue was dissolved in chloroform (100 cm
3
), and was 
washed with saturated NaHCO3 solution (60 cm
3
). The organic layer was then dried 
(MgSO4), filtered and concentrated under reduce pressure to give a crude solid which 
was purified by flash chromatography (10→30 % v/v ethyl acetate/hexane) to afford the 
product 305 as a while solid (430 mg, 0.94 mmol, 57 %); δH (400 MHz, CDCl3) 7.36 (2 
H, d, J 8.2, 2 x Ar-H o to SO2NH), 7.32-7.22 (3 H, m, 3 x Ar-H), 7.19-7.12 (5 H, m, 5 x 
Ar-H), 7.09-6.88 (9 H, m, 9 x Ar-H), 6.13 (1 H, br s , NHTs), 4.31 (1 H, dd, J 7.7, 2.9, 
CH(1)H(2)Ph), 3.68 (1 H, d, J 7.7, CH(1)H(2)Ph), 3.62 (1 H, d, J 13.2, TsNHCH), 3.41 (1 
H, d, J 13.2, CHNH), 2.31 (3 H, s, CH3Ts) and 1.68 (1 H, br s, NHCH2Ph); δC (101 
MHz, CDCl3) 142.72 (C), 139.37 (C), 138.90 (C), 138.25 (C), 136.99 (C), 129.10 (2 x 
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CH), 128.48 (2 x CH), 128.43 (2 x CH), 128.04 (2 x CH), 127.95 (2 x CH), 127.62 
(CH), 127.55 (2 x CH), 127.51 (2 x CH), 127.32 (CH), 127.18 (CH), 127.11 (2 x CH), 
66.80 (CH), 63.09 (CH), 50.88 (CH2) and 21.44 (CH3). The data matched that 
previously reported for this compound. 
Synthesis of NBn untethered catalyst (182).  
 
This is a known compound and has been fully characterised.
17j 
A mixture of benzeneruthenium(II) chloride dimer (0.16 g, 0.33 mmol), N-((1R, 2R)-2-
(benzylamino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 305 (0.20 g, 0.44 
mmol) and triethylamine (0.24 cm
3
, 1.7 mmol) in IPA (10 cm
3
) was heated at 80 °C for 
1 hr. The solution was then cooled to rt, and concentrated under reduced pressure. The 
residue was dissolved in CHCl3 (20 cm
3
) and then washed with water (10 cm
3
) with 
vigorous stirring for 3 minutes. The organic phase was separated, dried (Na2SO4), 
filtered and then concentrated under reduced pressure  giving the crude product, which 
was then purified by column chromatography (3: 3: 1 v/v/v ethyl acetate/ hexane/ 
methanol) providing 182 as a brown solid (189 mg, 0.28 mmol, 64 %); δH (400 MHz, 
CDCl3) 7.40-6.50 (19 H, m, 19 x Ar-H), 5.60 (6 H, s, 6 x Ru-Ar-H), 4.50-4.40 (1 H, m, 
CHNTs), 4.29-4.20 (1 H, m, CHNH), 4.16 (1 H, d, J 10.7, CH(1)H(2)Ph), 3.93 (1 H, t, J 
10.7, CH(1)H(2)Ph) and 2.24 (3 H, s, CH3); δC (101 MHz, CDCl3) 141.55 (C), 138.72 
(C), 138.55 (C), 136.26 (C), 135.04 (C), 130.29 (2 x CH), 128.50 (2 x CH), 128.21 (3 x 
CH), 127.89 (2 x CH),  127.57 (CH), 127.40 (2 x CH), 127.11 (CH), 126.90 (CH), 
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126.71 (2 x CH), 126.22 (2 x CH), 125.66 (CH), 83.47 (6 x CH), 80.51 (CH), 68.96 
(CH), 59.52 (CH2) and 20.61 (CH3). The data matched that previously reported for this 
compound. 
Synthesis of (4-bromobutoxy)(tert-butyl)diphenylsilane
 
(185).  
 
This is a known compound and has been fully characterised.
32c 
tert-Butyl-chlorodiphenylsilane (7.96 g, 7.53 cm
3
, 28.97 mmol) was added to a stirred 
solution of 4-bromo-1-butanol (4.03 g, 26.34 mmol) and imidazole (3.95 g, 57.95 
mmol) in THF (150 cm
3
) under an argon atmosphere. The resulting mixture was stirred 
over the weekend at rt and quenched with water (150 cm
3
) followed by the addition of 
Et2O (150 cm
3
). After phase separation and extraction of the aqueous phase with Et2O 
(3 x 150 cm
3
), the combined organic phases were dried (MgSO4), filtered, concentrated, 
and purified by flash chromatography (0→10 % v/v ethyl acetate/hexane) to afford the 
silyl alcohol 185 as a colourless oil (3.23g, 8.25 mmol, 31%); δH (300 MHz, CDCl3) 
7.52-7.51 (4 H, m, 4 x Ar-H), 7.45-7.30 (6 H, m, 6 x Ar-H), 3.75 (2 H, t, J 6.1, 
CH2OSi), 3.50 (2 H, t, J 6.8, BrCH2), 2.06-1.93 (2 H, m, BrCH2CH2), 1.73-1.65 (2 H, 
m, CH2CH2OSi) and 1.09 (9 H, s, 3 x CH3); δC (75 MHz, CDCl3) 135.58 (CH), 133.84 
(2 x C), 129.65 (3 x CH), 127.69 (6 x CH), 62.93 (CH2), 33.91 (CH2), 31.07 (CH2), 
29.48 (CH2), 26.90 (3 x CH3) and 19.24 (C). The data matched that previously reported 
for this compound. 
Synthesis of tert-butyl(4-(3,5-dimethylphenyl)butoxy)diphenylsilane (187).  
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This compound is novel.  
A Schlenk tube was dried with a heat gun under vacuum, and flushed with argon. 5-
Bromo-m-xylene (1.53 g, 1.12 cm
3
, 8.25 mmol) was injected into the tube followed by 
freshly distilled THF (16.5 cm
3
). The tube was then degassed 3 times followed by the 
reinsertion of argon. 
t
BuLi (1.7 M in pentane, 12.14 cm
3
, 20.63 mmol) was added 
dropwise at -78 °C and the tube was again degassed and flushed with argon. The 
mixture was then stirred at room temperature for 1 hr, and then re-cooled to -78 °C. (4-
Bromobutoxy)(tert-butyl)diphenylsilane (3.23 g, 8.25 mmol) was added dropwise to the 
reaction mixture and then degassed and flushed with argon. The solution was then 
heated up to 40 °C and allowed to stir at this temperature for 4 days. The mixture was 
then allowed to cool to room temperature and then was partitioned between diethyl 
ether (33 cm
3
) and water (25 cm
3
). The aqueous phase was extracted with Et2O (2 x 
16.5 cm
3
), and then the combined organic phases were dried (MgSO4), filtered and then 
evaporated in vacuo to give 187  as a light yellow oil (2.4 g, 5.76 mmol, 70 %); υmax 
3071, 2931, 2858, 1606, 1472, 1462, 1428, 1390, 1361, 1261, 1189, 1105, 1008, 998, 
975, 939, 846, 822, 739 and  699 cm
-1
; 
 δH (400 MHz, CDCl3) 7.70-7.62 (3 H, m, 3 x 
Ar-H), 7.45-7.30 (7 H, m, 7 x Ar-H), 6.85 (1 H, s, Ar-H), 6.80 (2 H, s, 2 x Ar-H), 3.65 
(2 H, t, J 6.2, CH2OSi), 2.53 (2 H, t, J 7.8, ArCH2), 2.25 (6 H, s, 2 x CH3), 1.70 (2 H, m, 
ArCH2CH2), 1.60 (2 H, m, CH2CH2OSi) and 1.05 (9 H, s, 3 x SiCCH3); δC (101 MHz, 
CDCl3) 142.60 (C), 137.69 (2 x C), 135.60 (3 x CH), 134.12 (2 x C), 129.52 (2 x CH), 
127.60 (5 x CH), 127.28 (CH), 126.28 (2 x CH), 63.76 (CH2), 35.46 (CH2), 32.25 
(CH2), 28.92 (C), 27.62 (CH2), 26.89 (3 x CH3) and 21.34 (2 x CH3); m/z (ESI-MS) 
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439.0 [M+Na]
+
. Found (ESI-HR-MS): 439.2419 [M+Na]
+
, C28H36NaOSi requires 
439.2428 (1.86 ppm error). 
Synthesis of 4-(3,5-dimethylphenyl)butan-1-ol
 
(188).  
 
This compound is novel.  
Tetrabutylammonium fluoride was added as a 1 M solution in THF (24 cm
3
) to a 
solution of tert-butyl(4-(3,5-dimethylphenyl)butoxy)diphenylsilane (2.0 g, 4.8 mmol) in 
THF (65 cm
3
). The mixture was allowed to stir for 3 days at 23 °C and the conversion 
was checked by TLC. After completion the solution was concentrated under reduced 
pressure and the crude product was purified by flash chromatography (10→50 % v/v 
ethyl acetate/hexane) to afford 188 as a colourless oil (776 mg, 4.35 mmol, 91 %); υmax 
3326, 3014, 2928, 2860, 1606, 1459, 1377, 1060, 1036, 985, 933, 894, 843 and 700 cm
-
1; δH (400 MHz, CDCl3) 6.82 (1 H, s, Ar-H), 6.80 (2 H, s, 2 x Ar-H), 3.65 (2 H, t, J 6.2, 
CH2OH), 2.59 (2 H, t, J 7.6, ArCH2), 2.30 (6 H, s, 2 x CH3) and 1.72-1.56 (4 H, m, 
CH2CH2CH2OH); δC (101 MHz, CDCl3) 142.28 (C), 137.77 (2 x C), 127.41 (CH), 
126.27 (2 x CH), 62.91 (CH2), 35.51 (CH2), 32.46 (CH2), 27.62 (CH2) and 21.29 (2 x 
CH3); m/z (ESI-MS) 201.1 [M+Na]
+
. Found (ESI-HR-MS): 201.1247 [M+Na]
+
, 
C12H18NaO requires 201.1250 (1.5 ppm error) 
Synthesis of 4-(3,5-dimethylcyclohexa-1,4-dienyl)butan-1-ol (189).  
 
Experimental 
 
165 
 
This compound is novel.  
A solution of 4-(3,5-dimethylphenyl)butan-1-ol (513 mg, 2.8 mmol) in ethanol (2.5 
cm
3
) was slowly added to a refluxing solution of ammonia (50 cm
3
) containing ethanol 
(10 cm
3
) at -78 °C while stirring. Small cleaned (with hexane) sodium pieces were 
added to the reaction mixture until the blue colour persisted. After the addition of 
sodium over the course of 7 hours with regular additions of ethanol (2.5 cm
3
), the 
reaction mixture was left overnight to evaporate ammonia. The reaction mixture was 
quenched carefully with saturated ammonium chloride (20 cm
3
), and extracted using 
DCM (3 x 6 cm
3
). The combined organic layers were dried (MgSO4) filtered and 
concentrated under reduced pressure to afford crude 189 as an orange red oil (374 mg, 
3.07 mmol, 74%) which appeared to be a ca 1:1 mixture of isomers D1 and D2. The 
product was analyzsed as a 1:1 mixture of D1 and D2; δH (300 MHz, CDCl3) 5.32 (2 H, 
br s, 2 x HC=C), 3.60-3.55 (2 H, m, CH2OH), 2.71 (1 H, br s, OH), 2.45-2.40 (2 H, m, 
=C-CH2-C=), 2.10-2.05 (1 H, m, =C-CH-C=), 1.65 (4.5 H, br s, CH3), 1.50-1.20 (6 H, 
m, (CH2)3) and 0.95 (1.5 H, d, J 7.6, CHCH3). This material was directly used in the 
next step, and 90 % conversion was obtained after multiple reduction attempts on 
the same product. 
Synthesis of 4-(3,5-dimethylcyclohexa-1,4-dienyl)butanal (190).  
 
This compound is novel.  
A solution of oxalylchloride (2 M in DCM, 1.35 cm
3
, 2.69 mmol) in anhydrous DCM (3 
cm
3
) was cooled to -78 °C, and to this was slowly added a solution of dimethylsulfoxide 
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(0.38 cm
3
, 5.38 mmol) in DCM (1.5 cm
3
) by syringe. The solution was stirred for 30 
minutes at -78 °C before a solution of 4-(3,5-dimethylcyclohexa-1,4-dienyl)butan-1-ol 
(375 mg, 2.07 mmol) in DCM (5 cm
3
) was slowly added at the same temperature. After 
stirring for 45 minutes at -78 °C, Et3N (1.73 cm
3
, 12.40 mmol) was added and the 
reaction mixture was allowed to warm up to rt. After 60 minutes, water (10 cm
3
) was 
added, and the mixture was extracted with DCM (3 x 5 cm
3
). The combined organic 
layers were dried (MgSO4), filtered and concentrated under reduced pressure to give 
crude 190 as a light orange oil (355 mg, 1.99 mmol, 96 %) which appeared to be a ca. 
1:1 mixture of isomers D1 and D2. The product was analyzsed as a 1:1 mixture of D1 
and D2; δH (400 MHz, CDCl3) 9.88 (0.5 H, s, CH=O), 9.85 (0.5 H, s, CH=O), 5.30-5.20 
(2 H, m, -CH=), 2.35-2.30 (4 H, m, =C-CH2-C=), 2.05-2.00 (0.5 H, m, =C-CH-C=), 
1.80-1.70 (0.5 H, m, =C-CH-C=), 1.68 (4.5 H, br s, CH3), 1.65-1.55 (2 H, m, CH2), 
1.40-1.30 (2 H, m, CH2), 1.00 (1.5 H, d, J 7.7, CH3); This material was directly used 
in the next step. 
Synthesis of N-((1R,2R)-2-(4-(3,5-dimethylcyclohexa-1,4-dienyl)butylamino)-1,2-
diphenylethyl)-4-methylbenzenesulfonamide (191).  
 
This compound is novel.  
To a suspension of powdered molecular sieves (4 Å, 0.50 g) in dry methanol (30 cm
3
) 
was added 4-(3,5-dimethylcyclohexa-1,4-dienyl)butanal 190 (355 mg, 2.00 mmol),  (R, 
R)-TsDPEN (806 mg, 2.20 mmol) and glacial acetic acid (4 drops). The reaction 
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mixture was stirred at rt and monitored by TLC. After 2 hrs, the imine had formed 
(observed by TLC), and sodium cyanoborohydride (590 mg, 9.38 mmol) was added. 
The reaction was left overnight at rt The molecular sieves were then removed by 
filtration, and the solution was concentrated under reduced pressure. The residue was 
redissolved in DCM (40 cm
3
). The organic phase was washed with saturated NaHCO3 
(40 cm
3
) and brine (40 cm
3
), dried (MgSO4), filtered and concentrated. The resulting 
residue was purified by flash chromatography (10→30 % v/v ethyl acetate/hexane) to 
afford 191 as a colourless oil (390 mg, 0.74 mmol, 37 %) which appeared to be a ca. 1:1 
mixture of isomers D1 and D2. The product was analyzsed as a 1:1 mixture of D1 and 
D2; [α]D
35 
-5.3 (c 0.5, CHCl3); υmax 3299, 3030, 2926, 2856, 2257, 1600, 1495, 1455, 
1433, 1380, 1352, 1327, 1305, 1184, 1160, 1119, 1093, 1054, 1020, 909, 846, 807, 755, 
731, 698 and 667 cm
-1; δH (400 MHz, CDCl3) 7.37 (2 H, d, J 8.2, 2 x Ar-H), 7.15-7.10 
(3 H, m, 3 x Ar-H), 7.05-7.00 (5 H, m, 5 x Ar-H), 6.95-6.85 (4 H, m, 4 x Ar-H), 5.35-
5.25 (2 H, br s, HC=C), 4.26-4.21 (1 H, m, CHTs), 3.62-3.57 (1 H, m, CHNH), 2.80-
2.59 (1 H, m, CH3CH), 2.43-2.36 (2 H, m, CH2C(CH3)=C), 2.35 (3 H, s, TsCH3), 2.34-
2.25 (2 H, m, NHCH2), 1.70 (4.5 H, s, CH3), 1.56-1.14 (6 H, m, NHCH2CH2CH2CH2) 
and 1.05 (1.5 H, d, J 7.2, CH3); δC (101 MHz, CDCl3) 142.67 (C), 139.43 (C), 138.42 
(C), 137.09 (C), 131.05 (2 x C), 129.08 (2 x CH), 128.30 (2 x CH), 127.90 (2 x CH), 
127.58 (2 x CH), 127.43 (CH), 127.39 (2 x CH), 127.25 (CH), 127.15 (2 x CH), 125.18 
(CH), 124.98 (CH), 123.40 (CH), 67.86 (CH), 63.06 (CH), 47.20 (CH2), 36.12 (CH2), 
34.02 (CH2), 30.35 (CH2), 29.63 (CH2), 23.09 (CH3) and 21.44 (2 x CH3); m/z (ESI-
MS) 529.3 [M+H]
+
. Found (ESI-HR-MS): 529.2899 [M+H]
+
, C33H41N2O2S requires 
529.2883 (-2.9 ppm error). 
Synthesis of N-((1R,2R)-2-(4-(3,5-dimethylphenyl)butylamino)-1,2-diphenylethyl)-
4-methylbenzenesulfonamide ammonium chloride dimer (183).  
Experimental 
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This compound is novel.  
To a stirred solution of N-((1R,2R)-2-(4-(3,5-dimethylcyclohexa-1,4-
dienyl)butylamino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 191 (200 mg, 0.38 
mmol) in anhydrous DCM (5.5 cm
3
) was added hydrochloric acid (2 M in diethyl ether, 
0.57 cm
3
, 1.14 mmol) at 0 °C. The reaction mixture was stirred at rt for 20 minutes, and 
subsequently concentrated under reduced pressure to give a white residue. To a 
suspension of the residue in ethanol (7.2 cm
3
) was added hydrate ruthenium (III) 
trichloride hydrate (62 mg, 0.30 mmol). The reaction mixture was refluxed overnight. 
The precipitate was collected by filtration and washed with ethanol to give 183 (54 mg, 
0.04 mmol, 21 %) as black crystals; Mp 240-250°C (dec.); υmax 3054, 1597, 1456, 1323, 
1156, 1091, 1030, 925, 813, 763, 700 and 669 cm
-1; δH (400 MHz, DMSO-d6) 9.36 (2 
H, br s, 2 x NH(1)H(2)
+
Cl
-
), 8.95 (2 H, br s, 2 x NH(1)H(2)
+
Cl
-
), 8.50 (2 H, br s, 2 x 
NHTs), 7.33-6.70 (28 H, m, 2 x (14 x Ar-H)), 5-55.5.50 (6 H, m, 2 x (3 x Ru-Ar-H)), 
4.74-4.66 (2 H, m, 2 x CHNHTs)), 4.50-4.40 (2 H, m, 2 x CHNH2
+
), 2.80-2.70 (4 H, m, 
2 x NH2
+
CH2), 2.55 (12 H, br s, 2 x (2 x CH3)), 2.40-2.35 (4 H, m, 2 x CH2Ar), 2.20 (6 
H, s, SO2ArCH3), 1.83-1.50 (8 H, m, 2 x (2 x CH2)); δC (101 MHz, DMSO-d6) 142.24 
(2 x C), 137.50 (2 x C), 135.35 (2 x C), 131.41 (2 x C), 129.22 (2 x CH), 129.07 (2 x (2 
x CH)), 128.92 (2 x (2 x CH)), 128.70 (2 x (2 x CH)), 127.70 (2 x (2 x CH)), 127.57 (2 
x (2 x CH)), 127.19 (2 x CH), 126.38 (2 x (2 x CH)), 107.10 (2 x C), 104.11 (2 x (2 x 
C)), 82.80 (2 x CH), 82.16 (2 x CH), 82.11 (2 x CH), 64.37 (2 x CH), 60.49 (2 x CH), 
45.40 (2 x CH2), 31.55 (2 x CH2), 26.12 (2 x CH2), 24.51 (2 x CH2), 20.90 (2 x CH3) 
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and 18.30 (2 x (2 x CH3); m/z 1321, 1307, 627 (0.5M-2HCl-Cl), 353 (Molecular ion not 
observed; fragmentation ions with Ru isotope patterns observed). Found (ESI-HR-MS): 
627.1631 C33H37N2O2
102
RuS (monomer formed in situ from dimer) requires 627.1622 
(1.4 ppm error), 314.0841, C33H38N2O2
102
RuS(2+) requires 314.0847 (1.9 ppm error). 
Optical rotation could not be obtained due to the product being highly coloured. 
General procedure for making quinolines. 
2-Methylquinoline and 2-phenylquinoline were purchased from Sigma-Aldrich and Alfa 
Aesar. 
 
Synthesis of 2-tert-butylquinoline (178).  
 
This is a known compound and has been fully characterised.
26b 
 
To a solution of 6-nitrobenzaldehyde (3.02 g, 20 mmol) in ethanol (60 cm
3
) was added 
iron power (<10 μm, aldrich, 4.47 g, 80 mmol) followed by 0.1 N aq HCl (10 cm3, 1 
mmol) and the resulting mixture was vigorously stirred at 95 °C (oil bath) for 2 hrs. 
TLC analysis revealed that the reduction reaction was complete so 3,3-dimethyl-2-
butanone (2.0 g, 2.5 cm
3
, 20 mmol) and powdered KOH (1.35 g, 24 mmol) were added 
successively in portions (Caution! Potential exotherm; add KOH slowly). The reaction 
mixture was stirred at 95 °C, then cooled to rt, diluted with DCM (600 cm
3
), and filtered 
through a celite pad. The filtrate was washed with water (100 cm
3
) and the aqueous 
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phase was back-extracted with DCM (2 x 40 cm
3
). The combined organic phases were 
dried (MgSO4), filtered, and concentrated in vacuo to give 178 as an orange red oil (3.7 
g, 20 mmol,>99 %); δH (400 MHz, CDCl3) 8.08-8.01 (2 H, m, (4)-CH + (8)-CH), 7.73 
(1 H, d, J 7.0, (5)-CH), 7.65 (1 H, t, J 7.0, (7)-CH), 7.50 (1 H, d, J 8.6, (3)-CH), 7.45 (1 
H, t, J 7.0, (6)-CH) and 1.49 (9 H, s, (2)-3 x CH3);  δC (101 MHz, CDCl3) 169.28 (C), 
147.47 (C), 135.86 (CH), 129.45 (CH), 128.99 (CH), 127.24 (CH), 126.47 (C), 125.63 
(CH), 118.24 (CH), 38.16 (C) and 30.18 (3 x CH3).  The data matched that previously 
reported for this compound. 
Synthesis of 6,7-dimethoxy-2-methylquinoline
 
 (193).  
 
This is a known compound and has been fully characterised.
32d
 
To a solution of 6-nitroveratraldehyde (2.11 g, 10 mmol) in ethanol (30 cm
3
) was added 
iron power (<10μm, aldrich, 2.23 g, 40 mmol) followed by 0.1 N aq HCl (5 cm3, 0.5 
mmol) and the resulting mixture was vigorously stirred at 95 °C (oil bath) for 2 hrs. 
TLC analysis revealed that the reduction reaction was complete so acetone (0.58 g, 0.73 
cm
3
, 10 mmol) and powdered KOH (0.67 g, 12 mmol) were added successively in 
portions (Caution! Potential exotherm; add KOH slowly). The reaction mixture was 
stirred at 95 °C, then cooled to rt, diluted with DCM (300 cm
3
), and filtered through a 
celite pad. The filtrate was washed with water (50 cm
3
) and the aqueous phase was 
back-extracted with DCM (2 x 20 cm
3
). The combined organic phases were dried 
(MgSO4), filtered, and concentrated in vacuo to give 193 as brown crystals (1.55 g, 7.63 
mmol, 76 %); δH (400 MHz, CDCl3) 7.88 (1 H, d, J 8.3, (4)-CH), 7.38 (1 H, s, (8)-CH), 
7.10 (1 H, d, J 8.3, (3)-CH), 6.95 (1 H, s, (5)-CH), 4.01 (3 H, s, (7)-OCH3), 3.99 (3 H, s, 
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(6)-OCH3) and 2.70 (3 H, s, (2)-CH3); δC (101 MHz, CDCl3) 156.53 (C), 152.30 (C), 
149.06 (C), 144.75 (C), 134.46 (CH), 121.70 (C), 120.08 (CH), 107.54 (CH), 105.09 
(CH), 56.05 (CH3), 55.95 (CH3) and 24.97 (CH3). The data matched that previously 
reported for this compound. 
Synthesis of 2-ethylquinoline
  
(120b). 
 
This is a known compound and has been fully characterised.
32e
  
Quinaldine (1.40 g, 1.4 cm
3
,10 mmol) was dissolved in dry THF (20 cm
3
). The reaction 
vessel was cooled to -78 °C and 
n
BuLi in hexane (1.6 M, 6.3 cm
3
, 10 mmol) was added. 
After 30 mins, methyl iodide (1.90 g, 0.8 cm
3
, 13 mmol) was added via syringe. The 
mixture was allowed to gradually warm to room temperature while being stirred 
overnight. The resulting light yellow solution was concentrated, diluted with water (40 
cm
3
) and brine (10 cm
3
), and extracted with DCM (3 x 40 cm
3
). The combined organic 
layers were dried (MgSO4), filtered and concentrated to give 120b as an yellow oil (1.46 
g, 9.29 mmol, 93 %); δH (400 MHz, CDCl3) 8.05 (1 H, d, J 8.5, (8)-CH), 7.99 (1 H, d, J 
8.5, (4)-CH), 7.70 (1 H, d, J 8.5, (5)-CH), 7.61 (1 H, t, J 7.0,  (7)-CH), 7.39 (1 H, t, J 
7.0, (6)-CH), 7.25 (1 H, d, J 8.5, (3)-CH), 2.88 (2 H, q, J 7.7, (2)-CH2CH3) and 1.30 (3 
H, t, J 7.7 Hz, (2)-CH2CH3); δC (101 MHz, CDCl3) 163.95 (C), 147.88 (C), 136.30 
(CH), 129.31 (CH), 128.81 (CH), 127.47 (CH), 126.72 (C), 125.63 (CH), 120.82 (CH), 
32.32 (CH2) and 14.50 (CH3). The data matched that previously reported for this 
compound. 
Synthesis of 2-propylquinoline (124a).  
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This is a known compound and has been fully characterised.
32f
  
This compound was prepared as for 2-ethylquinoline using quinaldine (1.40 g, 1.4 cm
3
, 
10 mmol), 
n
BuLi in hexane (1.6 M, 6.3 cm
3
, 10 mmol) and ethyliodide (2.0 g, 1.0 cm
3
, 
13 mmol) and was isolated as a yellow oil (1.53 g, 8.93 mmol, 89 %); δH (400 MHz, 
CDCl3) 8.05 (1 H, d, J 8.5, (8)-CH), 7.96 (1 H, d, J 8.4, (4)-CH), 7.78 (1 H, d, J 8.4, 
(5)-CH), 7.68 (1 H, t, J 7.0, (7)-CH), 7.49 (1 H, t , J 7.0, (6)-CH), 7.25 (1 H, d, J 8.4, 
(3)-CH), 2.99 (2 H, t, J 7.4, (2)-CH2CH2CH3), 1.90 (2 H, sext, J 7.4, (2)-CH2CH2CH3) 
and 1.05 (3 H, t, J 7.4, (2)-CH2CH2CH3); δC (101 MHz, CDCl3) 162.80 (C), 147.92 (C), 
136.08 (CH), 129.25 (CH), 128.82 (CH), 127.45 (CH), 126.70 (C), 125.59 (CH), 121.33 
(CH), 41.26 (CH2), 23.24 (CH2) and 14.00 (CH3). The data matched that previously 
reported for this compound. 
Synthesis of 2-butylquinoline
 
(115l).  
 
This is a known compound and has been fully characterised.
32g
 
This compound was prepared as for 2-ethylquinoline using quinaldine (1.40 g, 1.4 cm
3
, 
10 mmol), 
n
BuLi in hexane (1.6 M, 6.3 cm
3
, 10 mmol)  and iodopropane (2.21 g, 1.27 
cm
3, 13 mmol) and was isolated as a yellow oil (1.70 g,  9.18 mmol, 92 %); δH (400 
MHz, CDCl3) 8.06 (1 H, d, J 8.5, (8)-CH), 7.99 (1 H, d, J 8.4, (4)-CH), 7.71 (1 H, d, J 
8.4, (5)-CH), 7.64 (1 H, t, J 7.0, (7)-CH),  7.43 (1 H, t, J 7.0, (6)-CH), 7.23 (1 H, d, J 
8.4, (3)-CH), 2.98 (2 H, dd, J 7.6, 8.0, (2)-CH2CH2CH2CH3), 1.83 (2 H, quin, J 7.6, (2)-
CH2CH2CH2CH3), 1.43 (2 H, sext, J 7.6, (2)-CH2CH2CH2CH3) and 0.95 (3 H, t, J 7.6, 
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(2)-CH2CH2CH2CH3); δC (101 MHz, CDCl3) 163.05 (C), 147.94 (C), 136.11 (CH), 
129.27 (CH), 128.84 (2 x CH), 126.70 (C), 125.59 (CH), 121.34 (CH), 39.10 (CH2), 
32.17 (CH2), 22.69 (CH2) and 14.00 (CH3). The data matched that previously reported 
for this compound. 
Synthesis of 2-phenylethylquinoline
 
(117a).  
 
This is a known compound and has been fully characterised.
32h
 
This compound was prepared as for 2-ethylquinoline using quinaldine (1.40 g, 1.4 cm
3
, 
10 mmol), 
n
BuLi in hexane (2.5 M, 4.0 cm
3
, 10 mmol)  and benzyl bromide (2.22 g, 
1.55 cm
3
, 13 mmol) and was isolated as a yellow oil (1.90 g, 8.14 mmol, 81 %); δH (400 
MHz, CDCl3) 8.23 (1 H, d, J 8.4, (8)-CH), 7.97 (1 H, d, J 8.4, (4)-CH), 7.77-7.69 (2 H, 
m, (5)-CH + (7)-CH), 7.49 (1 H, t, J 7.8, (6)-CH), 7.38-7.23 (5 H, m, (2)-
CH2CH2C6H5), 7.18 (1 H, d, J 8.4, (3)-CH), 3.36 (2 H, dd, J 10.1, 9.2, (2)-
CH2CH2C6H5) and 3.24 (2 H, dd, J 10.1, 9.2, (2)-CH2CH2C6H5); δC (101 MHz, CDCl3) 
161.81 (C), 148.12 (C), 141.63 (C), 136.24 (CH), 129.01 (CH), 128.64 (3 x CH), 128.55 
(3 x CH), 126.89 (C), 126.15 (CH), 125.88 (CH) 121.63 (CH), 41.05 (CH2) and 35.98 
(CH2). The data matched that previously reported for this compound. 
Synthesis of 2-(3,5-dimethoxyphenethyl)quinoline (195).  
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This compound is novel. 
This compound was prepared as for 2-ethylquinoline using quinaldine (1.40 g, 1.4 cm
3
,  
10 mmol), 
n
BuLi in hexane (1.6 M, 6.3 cm
3
, 10 mmol) and 3,5-dimethoxybenzyl 
bromide (3.0 g, 13 mmol) and was isolated as an orange oil (2.29 g, 7.8 mmol, 78 %); 
υmax 3057, 2998, 2935, 2837, 1735, 1594, 1563, 1504, 1459, 1427, 1349, 1310, 1295, 
1204, 1147, 1115, 1065, 826, 750 and 690 cm
-1
; δH (300 MHz, CDCl3) 8.10-8.02 (2 H, 
(8)-CH + (4)-CH), 7.77 (1 H, dd, J 8.1, 1.5, (5)-CH), 7.69 (1 H, dd, J 15.3, 1.5, (7)-CH), 
7.49 (1 H, dd, J 15.3, 1.5, (6)-CH), 7.24 (1 H, d, J 8.5, (3)-CH), 6.43 (2 H, d, J 2.3, (2)-
CH2CH2Ar(o-CH‟s)), 6.32 (1 H, t, J 2.3, (2)-CH2CH2Ar(p-CH)), 3.74 (6 H, s, (2)-
CH2CH2Ar(m-OCH3‟s)), 3.31-3.26 (2 H, m, (2)-CH2CH2Ar) and 3.12-3.07 (2 H, m, (2)-
CH2CH2Ar); δC (75 MHz, CDCl3) 161.12 (C), 160.16 (2 x C), 147.36 (C), 143.32 (C), 
135.64 (CH), 128.81 (CH), 128.23 (CH), 126.93 (CH), 126.20 (C), 125.21 (CH), 120.98 
(CH), 105.90 (2 x CH), 97.56 (CH), 54.63 (2 x CH3), 40.21 (CH2) and 35.64 (CH2);  
m/z (ESI-MS) 294.0 [M+H]
+
. Found (ESI-HR-MS): 294.1486 [M+H]
+
, C19H20NO2 
requires 294.1489 (1.0 ppm error). 
Synthesis of 2-(2-(6-bromobenzo[d][1,3]dioxol-5-yl)ethyl)quinoline (194).  
 
This is a known compound and has been fully characterised.
26g
 
This compound was prepared as for 2-ethylquinoline using quinaldine (1.40 g, 1.4 cm
3
,  
10 mmol), 
n
BuLi in hexane (1.6 M, 6.3 cm
3
, 10 mmol) and 5-bromo-6-bromomethyl-
1,3-benzodioxole (3.8 g, 13 mmol) and was isolated as white crystals (1.65 g, 4.63 
mmol, 46 %); δH (300 MHz, CDCl3) 8.08-8.00 (2 H, m, (8)-CH + (4)-CH), 7.77 (1 H, 
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dd, J 1.5, 8.3, (5)-CH), 7.68 (1 H, dd, J 15.3, 1.5, (7)-CH), 7.48 (1 H, dd, J 15.3, 1.5, 
(6)-CH), 7.27 (1 H, d, J 8.3, (3)-CH), 7.00 (1 H, s, (2)-CH2CH2Ar(m-CH)), 6.72 (1 H, s, 
(2)-CH2CH2Ar(o-CH)), 5.91 (2 H, s, (2)-CH2CH2Ar(O2CH2)) and  3.24-3.15 (4 H, m, 
(2)-CH2CH2Ar); δC (75 MHz, CDCl3) 160.75 (C), 147.34 (C), 146.69 (C), 146.15 (C), 
135.70 (CH), 133.15 (C), 128.81 (CH), 128.27 (CH), 126.93 (CH), 126.23 (C), 125.23 
(CH), 120.95 (CH), 113.79 (C), 112.10 (CH), 109.57 (CH), 100.93 (CH2), 38.72 (CH2) 
and 35.53 (CH2). The data matched that previously reported for this compound. 
Synthesis of methyl quinoline-2-carboxylate (179).  
 
This is a known compound and has been fully characterised.
32i 
 
To a suspension of quinaldic acid (1.73 g, 10.00 mmol) in MeOH (20 cm
3
) was added a 
solution of HCl in MeOH (1.25 M, 20 cm
3
). The resulting solution was refluxed for 15 
hrs. The mixture was then cooled to rt and concentrated in vacuo. The residue was 
partitioned between saturated aqueous NaHCO3 solution (25 cm
3
) and EtOAc (3 x 20 
cm
3
). The combined organic extracts were further washed with saturated aqueous 
NaHCO3 solution  (7 cm
3
) and water (7 cm
3
), dried (Na2SO4), filtered and concentrated 
in vacuo to give 179 as a white solid (1.43 g, 7.64 mmol, 76 %); δH (400 MHz, CDCl3) 
8.35-8.26 (2 H, m, (4)-CH + (8)-CH), 8.21 (1 H, d, J 8.4, (5)-CH), 7.89 (1 H, d, J 8.4, 
(3)-CH), 7.80 (1 H, t, J 7.4, (7)-CH), 7.66 (1 H, t, J 7.4, (6)-CH) and 4.09 (3 H, s, 
OCH3); δC (101 MHz, CDCl3) 166.00 (C=O), 147.92 (C), 147.56 (C), 137.35 (CH), 
130.74 (CH), 130.33 (CH), 129.38 (C), 128.66 (CH), 127.58 (CH), 121.06 (CH) and 
53.24 (CH3). The data matched that previously reported for this compound. 
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General procedure for the ATH of Quinolines.
22
 
A solution of ruthenium dimer (0.0025 mmol) and imine (1 mmol) in methanol (1.6 
cm
3
) was stirred in a flame dried Schlenk tube at 28 °C for 10 minutes. Formic acid / 
triethylamine (5:2) azeotrope (0.5 cm
3
) was then added (The Schlenk tube was degassed 
and purged with argon 3x before and after the addition of reagents). The reaction 
mixture was stirred at 28°C and monitored by TLC or GC, for which a drop of sample 
was filtered through a small plug of silica in a glass pipette using ethyl acetate and 
maybe a few drops of methanol depending on the polarity of the compound. After 
completion, NaHCO3 solution (5 cm
3
) was added, and the mixture was extracted with 
dichloromethane (3 x 10 cm
3
). The organic phase was dried (MgSO4), filtered and 
concentrated under reduced pressure to give the desired amine.  
General procedure for formation of the racemic mixture.
10b
 
To reaction vessel (A) was added [Ru(p-cymene)Cl2]2 (0.0028 g, 0.0045 mmol) and 
undistilled THF (2 cm
3
). The mixture was stirred until the solution was homogeneous. 
At the same time, to reaction vessel (B) was added quinoline (0.13 g, 0.12 cm
3
, 0.89 
mmol) and I2 (0.012 g, 0.045 mmol), followed by THF (1 cm
3
). The mixture was stirred 
until the iodine was dissolved. Then to the reaction bottle (B) was added the solution of 
[Ru(p-cymene)Cl2]2 in THF from vessel (A). The final mixture in a glass vessel was 
pressurised to 600 psi hydrogen in a pressure hydrogenator and stirred at 20 °C for 20 
hrs. The reaction mixture was concentrated to afford the crude product, which was then 
filtered through silica before being used for enantiomeric excess analysis on the 
GC/HPLC. 
 (R)-2-Methyl-1,2,3,4-tetrahydroquinoline (120a’).  
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This is a known compound and has been fully characterised.
10h
 
Reduction of 120a using catalyst 163b; 46% ee and 96% conversion, reduction of 120a 
using catalyst 175; 93% ee and 68% conversion: Enantiomeric excess and conversion 
by GC analysis (Chrompac cyclodextrin-β-236M-19 50m, T = 125°C, P = 15 psi, He, 
imine 43.9 min., S isomer 67.5 min (minor),. R isomer 68.6 min (major)); *[α]D
27
 +46.7 
(c 0.5, CHCl3) 43% ee (R) (lit.
10h
 [α]D
25 
-78.3 (c 0.76, CHCl3) 91% ee (S));
  δH (300 
MHz, CDCl3) 6.98-6.95 (2 H, m, (7)-CH + (5)-CH), 6.61 (1 H, td, J 7.2, 1.2, (6)-CH), 
6.48 (1 H, dd, J 8.1, 1.3, (8)-CH), 3.70 (1 H, br s, (1)-NH), 3.44-3.38 (1 H, m, (2)-CH), 
2.85-2.74 (2 H, m, (4)-CH2), 1.94-1.91 (1 H, m, (3)-CH), 1.64-1.55 (1 H, m, (3)-CH) 
and 1.22 (3 H, d, J 6.3, (2)-CHCH3); δC (75 MHz, CDCl3) 144.20 (C), 128.67 (CH), 
126.09 (CH), 120.50 (C), 116.37 (CH), 113.40 (CH), 46.56 (CH), 29.50 (CH2), 26.00 
(CH2) and 22.02 (CH3). The data matched that previously reported for this compound. 
*[α]D determined on sample with 43% ee. 
(R)-2-Ethyl-1,2,3,4-tetrahydroquinoline (120b’).  
 
This is a known compound and has been fully characterised.
10h
 
Reduction of 120b using catalyst 163b; 41% ee and 95% conversion: Enantiomeric 
excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-19 50m, T = 
115°C, P = 15 psi, He, imine 94.6 min., S isomer 174.0 min (minor)., R isomer 176.4 
min (major)); [α]D
28
 +35.6 (c 0.5, CHCl3) 41% ee (R) (lit.
10h
 [α]D
25 
-73.2 (c 0.24, CHCl3) 
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91% ee (S)); δH (300 MHz, CDCl3) 6.98-6.94 (2 H, m, (7)-CH + (5)-CH), 6.60 (1 H, td, 
J 7.2, 1.2, (6)-CH), 6.47 (1 H, dd, J 8.4, 1.3, (8)-CH), 3.77 (1 H, br s, (2)-NH), 3.19-
3.13 (1 H, m, (2)-CH), 2.85-2.69 (2 H, m, (4)-CH2), 2.00-1.94 (1 H, m, (3)-CH), 1.63-
1.48 (3 H, m, (3)-CH + (2)-CHCH2CH3) and 0.98 (3 H, t, J 7.5, (2)-CHCH2CH3); δC (75 
MHz, CDCl3) 144.77 (C), 129.27 (CH), 126.73 (CH), 121.43 (C), 116.89 (CH), 114.02 
(CH), 52.06 (CH), 29.44 (CH2), 27.61 (CH2), 26.45 (CH2) and 10.12 (CH3). The data 
matched that previously reported for this compound. 
Reduction of 120b using catalyst 175; 91% ee and 67% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 90:10, flow rate 0.2 ml/min, 254 nm, 17.0°C): tR = 26.8 min 
(major), tS = 30.5 (minor). 
(R)-2-Propyl-1,2,3,4-tetrahydroquinoline (124a’).  
 
This is a known compound and has been fully characterised.
12b
 
Reduction of 124a using catalyst 163b; 42% ee and 94% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD, 
hexane:isopropanol = 90:10, flow rate 0.2 ml/min, 254 nm, 18.0°C): tR = 23.6 min 
(major), tS = 26.8 (minor); [α]D
24
 +54.1 (c 0.5, CHCl3) 42% ee (R) (lit.
12b
 [α]D
21 
-70.8 (c 
1.1, CHCl3) 80% ee (S)); δH (400 MHz, CDCl3) 6.97-6.94 (2 H, m, (7)-CH + (5)-CH), 
6.59 (1 H, t, J 7.3, (6)-CH), 6.47 (1 H, d, J 8.0, (8)-CH), 3.76 (1 H, br s, (1)-NH), 3.28-
3.21 (1 H, m, (2)-CH), 2.85-2.69 (2 H, m, (4)-CH2), 1.98-1.92 (1 H, m, (3)-CH), 1.64-
1.54 (1 H, m, (3)-CH), 1.51-1.39 (4 H, m, (2)-CHCH2CH2CH3) and 0.96 (3 H, t, J 6.6, 
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(2)-CHCH2CH2CH3); δC (101 MHz, CDCl3) 144.77 (C), 129.29 (CH), 126.73 (CH), 
121.42 (C), 116.91 (CH), 114.06 (CH), 51.33 (CH), 38.93 (CH2), 28.15 (CH2), 26.47 
(CH2), 19.00 (CH2) and 14.30 (CH3). The data matched that previously reported for this 
compound. 
Reduction of 124a using catalyst 175; 90% ee and 65% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 90:10, flow rate 0.2 ml/min, 254 nm, 14.5°C): tR = 24.5 min 
(major), tS = 28.1 (minor). 
 (R)-2-Butyl-1,2,3,4-tetrahydroquinoline (115l’).  
 
This is a known compound and has been fully characterised.
10h
 
Reduction of 115l using catalyst 163b; 41% ee and 93% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD, 
hexane:isopropanol = 90:10, flow rate 0.2 ml/min, 254 nm, 18.5°C): tR = 21.8 min 
(major), tS = 24.4 (minor); [α]D
26
 +46.6 (c 0.5, CHCl3) 41% ee (R) (lit.
10h
 [α]D
25 
-78.2 (c 
0.53, CHCl3) 89% ee (S)); δH (400 MHz, CDCl3) 6.96-6.93 (2 H, m, (7)-CH + (5)-CH), 
6.59 (1 H, t, J 7.4, (6)-CH), 6.46 (1 H, d, J 8.3, (8)-CH), 3.72 (1 H, br s, (1)-NH), 3.24-
3.18 (1 H, m, (2)-CH), 2.84-2.68 (2 H, m, (4)-CH2), 1.98-1.91 (1 H, m, (3)-CH), 1.63-
1.53 (1 H, m, (3)-CH), 1.51-1.45 (2 H, m, (2)-CHCH2CH2CH2CH3), 1.41-1.32 (4 H, m, 
(2)-CHCH2CH2CH2CH3), 0.94-0.91 (3 H, t, J 7.0, (2)-CHCH2CH2CH2CH3); δC (101 
MHz, CDCl3) 144.77 (C), 129.28 (CH), 126.72 (CH), 121.43 (C), 116.90 (CH), 114.05 
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(CH), 51.61 (CH), 36.46 (CH2), 28.15 (CH2), 27.96 (CH2), 26.47 (CH2), 22.88 (CH2) 
and 14.10 (CH3). The data matched that previously reported for this compound. 
 
Reduction of 115l using catalyst 175; 92% ee and 64% conversion: Enantiomeric excess 
by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 90:10, flow rate 0.2 ml/min, 254 nm, 14.0°C): tR = 22.8 min 
(major), tS = 25.6 (minor). 
(S)-2-Phenyl-1,2,3,4-tetrahydroquinoline (115a’).  
 
This is a known compound and has been fully characterised.
10h
 
Reduction of 115 using catalyst 163b; 73% ee and 68% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD, 
hexane:isopropanol = 90:10, flow rate 0.5 ml/min, 254 nm, 21.0°C): tS = 17.0 min 
(major), tR = 21.1 (minor); [α]D
27
 -31.3 (c 0.5, CHCl3) 73% ee (S) (lit.
10h
 [α]D
25 
+71.2 (c 
1.0, CHCl3) 72% ee (R)); δH (400 MHz, CDCl3) 7.40-7.26 (5 H, m, (2)-CHC6H5), 7.00 
(2 H, m, (7)-CH + (5)-CH), 6.65 (1 H, t, J 6.7, (6)-CH), 6.55 (1 H, d, J 7.7, (8)-CH), 
4.43 (1 H, dd, J 9.6, 3.3, (2)-CH), 4.04 (1 H, br s, (2)-NH), 2.97-2.88 (1 H, m, (4)-CH), 
2.73 (1 H, dt, J 4.7, 16.4, (4)-CH), 2.15-2.09 (1 H, m, (3)-CH) and 2.04-1.94 (1 H, m, 
(3)-CH); δC (101 MHz, CDCl3) 144.83 (C), 144.75 (C), 129.33 (CH), 128.60 (2 x CH), 
127.47 (CH), 126.93 (CH), 126.58 (2 x CH), 120.90 (C), 117.18 (CH), 114.00 (CH), 
56.28 (CH), 31.01 (CH2) and 26.42 (CH2). The data matched that previously reported 
for this compound. 
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Reduction of 115a using catalyst 175; 86% ee and 30% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 90:10, flow rate 0.5 ml/min, 254 nm, 19.0°C): tS = 17.1 min 
(major), tR = 21.5 (minor). 
 (R)-2-Phenethyl-1,2,3,4-tetrahydroquinoline (117a’).  
 
This is a known compound and has been fully characterised.
10h
 
Reduction of 117a using catalyst 163b; 50% ee and 90% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD, 
hexane:isopropanol = 90:10, flow rate 0.5 ml/min, 254 nm, 20.0°C): tR = 17.8 min 
(major), tS = 19.5 (minor); [α]D
25
 +45.5 (c 0.5, CHCl3) 50% ee (R) (lit.
10h
 [α]D
25 
-73.1 (c 
0.55, CHCl3) 92% ee (S)); δH (300 MHz, CDCl3) 7.30-7.16 (5 H, m, (2)-
CHCH2CH2C6H5), 6.97-6.92 (2 H, m, (7)-CH + (5)-CH), 6.59 (1 H, td, J 7.5, 1.1, (6)-
CH), 6.42 (1 H, dd, J 8.4, 1.3, (8)-CH), 3.80 (1 H, br s, (1)-NH), 3.31-3.22 (1 H, m, (2)-
CH), 2.85-2.66 (4 H, m, (4)-CH2 + (2)-CHCH2CH2C6H5), 2.01-1.92 (1 H, m, (3)-CH), 
1.84-1.77 (2 H, m, (2)-CHCH2CH2C6H5) and 1.71-1.59 (1 H, m, (3)-CH); δC (75 MHz, 
CDCl3) 143.90 (C), 141.30 (C), 128.66 (CH), 127.89 (2 x CH), 127.76 (2 x CH), 126.14 
(CH), 125.37 (CH), 120.70 (C), 116.43 (CH), 113.53 (CH), 50.51 (CH), 37.70 (CH2), 
31.60 (CH2), 27.40 (CH2) and 25.60 (CH2). The data matched that previously reported 
for this compound. 
Reduction of 117a using catalyst 175; 93% ee and 57% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
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hexane:isopropanol = 90:10, flow rate 0.5 ml/min, 254 nm, 15.0°C): tR = 19.7 min 
(major), tS = 21.7 (minor). 
2-tert-Butyl-1,2,3,4-tetrahydroquinoline
 (178’).  
 
This is a known compound and has been fully characterised.
32j
 
Reduction of 178 using catalyst 163b; 0% ee and 57% conversion: Enantiomeric excess 
by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 90:10, flow rate 0.5 ml/min, 254 nm, 15.0°C): tR = 20.5 min, tS = 
27.5; δH (300 MHz, CDCl3) 6.98-6.94 (2 H, m, (7)-CH + (5)-CH), 6.52 (1 H, td, J 7.5, 
1.2, (6)-CH), 6.45 (1 H, d, J 7.7, (8)-CH), 3.78 (1 H, br s, (1)-NH), 3.00-2.96 (1 H, m, 
(2)-CH), 2.83-2.70 (2 H, m, (4)-CH2), 2.00-1.95 (1 H, m, (3)-CH), 1.60-1.55 (1 H, m, 
(3)-CH), 0.98 (9 H, s, (2)-CHC(CH3)3); δC (75 MHz, CDCl3) 144.84 (C), 128.40 (CH), 
126.10 (CH), 120.86 (C), 116.10 (CH), 113.40 (CH), 60.30 (CH), 32.79 (C), 26.84 
(CH2), 25.40 (3 x CH3), 22.49 (CH2). The data matched that previously reported for this 
compound. 
Reduction of 178 using catalyst 175; 0% ee and 16% conversion; HPLC (Chiralcel OD-
H, hexane:isopropanol = 90:10, flow rate 0.2 ml/min, 254 nm, 14.0°C): tR = 20.6 min, tS 
= 27.9. 
(+)-2-(3,5-Dimethoxyphenethyl)-1,2,3,4-tetrahydroquinoline (195’).  
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This compound is novel. 
Reduction of 195 using catalyst 163b; 67% ee and 93% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 80:20, flow rate 0.6 ml/min, 254 nm, 18.0°C): tR = 28.1 min 
(major), tS = 36.8 (minor); *[α]D
24
 +39.5 (c 0.5, CHCl3) 67% ee (R); υmax 3675, 3396, 
2935, 2838, 1594, 1460, 1428, 1351, 1309, 1276, 1254, 1203, 1148, 1114, 1056, 924, 
830, 746, 718, 696 and 667 cm
-1; δH (300 MHz, CDCl3) 6.98-6.90 (2 H, m, (7)-CH + 
(5)-CH), 6.60 (1 H, td, J 7.5, 1.2, (6)-CH), 6.45 (1 H, dd, J 8.4, 1.4, (8)-CH), 6.38-6.35 
(2 H, d, J 2.3, (2)-CH2CH2Ar(o-CH‟s), 6.32-6.28 (1 H, t, J 2.3, (2)-CH2CH2Ar(p-CH), 
3.77 (6 H, s, (2)-CH2CH2Ar(m-OCH3‟s), 3.34-3.25 (1 H, m, (2)-CH), 2.81-2.72 (2 H, m, 
(4)-CH2), 2.69-2.63 (2 H, m, (2)-CH2CH2Ar), 2.2-1.94 (1 H, m, (3)-CH), 1.85-1.75 (2 
H, m, (2)-CH2CH2Ar) and 1.72-1.60 (1 H, m, (3)-CH); 
 δC (75 MHz, CDCl3) 160.88 (2 
x C), 144.51 (C) 144.28 (C), 129.26 (CH), 126.75 (CH), 121.29 (C), 117.04 (CH), 
114.15 (CH), 106.44 (2 x CH), 97.84 (CH), 55.29 (CH), 51.11 (2 x CH3), 37.99 (CH2), 
32.49 (CH2), 27.94 (CH2) and 26.17 (CH2); m/z (ESI-MS) 298.1 [M+H]
+
. Found (ESI-
HR-MS): 298.1798 [M+H]
+ 
, C19H24NO2 requires 298.1802 (1.3 ppm error). 
Reduction of 195 using catalyst 175; 94% ee and 58% conversion: Enantiomeric excess 
by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 80:20, flow rate 0.6 ml/min, 254 nm, 19.0°C): tR = 27.4 min 
(major), tS = 35.9 (minor). 
*The absolute configuration has not been determined, but is assigned by analogy with the reduction product of substrate 117a. 
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(+)-2-(2-(6-Bromobenzo[d][1,3]dioxol-5-yl)ethyl)-1,2,3,4-tetrahydroquinoline 
(194’).  
 
This compound is novel. 
Reduction of 194 using catalyst 163b; 47% ee and 86% conversion: Enantiomeric 
excess by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 80:20, flow rate 0.6 ml/min, 254 nm, 19.0°C): tS = 21.2 min 
(major), tR = 29.2 (minor); *[α]D
25
 +25.6 (c 0.5, CHCl3) 47% ee (R); υmax 3664, 3410, 
2912, 1606, 1585, 1500, 1473, 1434, 1408, 1353, 1309, 1275, 1227, 1111, 1066, 1035, 
964, 931, 858, 832, 746, 718 and 657 cm
-1; δH (300 MHz, CDCl3) 6.98 (1 H, s, (2)-
CH2CH2Ar(m-CH)), 6.96-6.92 (2 H, m, (5)-CH + (7)-CH), 6.70 (1 H, s, (2)-
CH2CH2Ar(o-CH)), 6.59 (1 H, td, J 7.3, 1.2, (6)-CH), 6.45 (1 H, dd, J 8.7, 1.3, (8)-CH), 
5.90 (2 H, s, (2)-CH2CH2Ar(O2CH2)), 3.84 (1 H, br s, (1)-NH), 3.38-3.30 (1 H, m, (2)-
CH), 2.88-2.72 (4 H, m, (2)-CH2CH2Ar + (4)-CH2), 2.10-2.00 (1 H, m, (3)-CH) and 
1.88-1.60 (3 H, m, (2)-CH2CH2Ar + (3)-CH); δC (75 MHz, CDCl3) 146.83 (C), 146.09 
(C), 143.89 (C), 133.53 (2 x C), 128.64 (CH), 126.14 (CH), 120.66 (C), 116.46 (CH), 
113.55 (CH), 112.12 (CH), 109.11 (CH), 100.99 (CH2), 50.29 (CH), 36.37 (CH2), 31.54 
(CH2), 27.22 (CH2) and 25.60 (CH2); m/z (ESI-MS) 360.1 [M+H]
+
. Found (ESI-HR-
MS): 360.0596 [M+H]
+ 
, C18H19BrNO2 requires 360.0594 (-0.7 ppm error). 
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Reduction of 194 using catalyst 175; 81% ee and 30% conversion: Enantiomeric excess 
by HPLC analysis and conversion by NMR analysis (Chiralcel OD-H, 
hexane:isopropanol = 80:20, flow rate 0.6 ml/min, 254 nm, 19.0°C): tS = 21.1 min 
(major), tR = 29.1 (minor). 
*The absolute configuration has not been determined, but is assigned by analogy with the reduction product of substrate 117a. 
(+)-6,7-Dimethoxy-2-methyl-1,2,3,4-tetrahydroquinoline (193’).  
 
This compound is novel. 
Reduction of 193 using catalyst 163b; 48 % ee and 53 % conversion. Enantiomeric 
excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-19 50m, T = 
150 °C, P = 15 psi, H2, imine 111.1 min., S isomer 113.6 min (minor)., R isomer 116.0 
min (major)); [α]D
30
 +64.0 (c 0.5, CHCl3) 48 % ee (R);
 υmax 3369, 2930, 2843, 1618, 
1516, 1449, 1398, 1375, 1335, 1317, 1255, 1229, 1200, 1133, 1069, 1021, 1001, 962, 
937, 909, 844 and 762 cm
-1
;
 δH (400 MHz, CDCl3) 6.53 (1 H, s, (5)-CH), 6.11 (1 H, s, 
(8)-CH), 3.79 (3 H, s, OCH3), 3.78 (3 H, s, OCH3), 3.55-3.05 (1 H, br s, NH), 3.37-3.27 
(1 H, m, (2)-CH), 2.84-2.73 (1 H, m, (4)-CH), 2.69-2.59 (1 H, m, (4)-CH), 1.96-1.86 (1 
H, m, (3)-CH), 1.63-1.49 (1 H, m, (3)-CH) and 1.20 (3 H, d, J 6.3, CH3); δC (101 MHz, 
CDCl3) 148.17 (C), 141.37 (C), 138.68 (C), 113.68 (CH), 112.54 (C), 99.57 (CH), 
56.71 (CH), 55.84 (CH3), 47.40 (CH3), 30.53 (CH2), 26.16 (CH2) and 22.52 (CH3); m/z 
(ESI-MS) 208.1 [M+H]
+
. Found (ESI-HR-MS): 208.1330 [M+H]
+ 
, C12H18NO2 requires 
208.1332 (1.1 ppm error).  
*The absolute configuration has not been determined, but is assigned by analogy with the reduction product of substrate 120a. 
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4.2     Procedures from Section 2.2. 
Synthesis of 4-methylcyclohexa-1,4-dienecarboxylic acid (199).  
 
This compound has been reported but not fully characterised.
27a
  
To a solution of propiolic acid (25.0 g, 22.0 cm
3
, 357 mmol) in toluene was added, 
isoprene (25.28 g, 37.13 cm
3
, 371.2 mmol) and hydroquinone (0.55 g, 5.01 mmol). The 
reaction was fitted with a condenser and heated to 130 °C overnight. The reaction 
mixture was cooled to room temperature, and a solid precipitate was filtered off and 
washed with cold toluene to give carboxylic acid 199 (26.5 g, 191.81 mmol, 54 %) as a 
white crystalline solid; Mp 181-184 °C; νmax 3675, 2963, 2882, 2631, 2532, 1701, 1666, 
1645, 1425, 1282, 1161, 1097, 1035, 1027, 957, 922, 800, 780, 736 and 716 cm
-1; δH 
(400 MHz, CDCl3) 7.10 (1 H, br s, CH=CCO2H), 5.48 (1 H, br s, CH=CCH3), 2.98-2.88 
(2 H, m, CH2C=CH), 2.82-2.72 (2 H, m, C=CCH2) and 1.70 (3 H, s, CH3); δC (101 
MHz, CDCl3) 172.44 (COOH), 139.17 (CH), 129.23 (C), 127.07 (C), 118.55 (CH), 
31.99 (CH2), 25.48 (CH2), 22.76 (CH3); m/z (ESI-MS) 137.0 [M-H]
+
. Found (ESI-HR-
MS): 137.0620 [M-H]
+ 
, C8H9O2 requires 137.0608 (-8.6 ppm error). The data matched 
that previously reported for this compound. 
Synthesis of (4-methylcyclohexa-1,4-dien-1-yl)methanol (200).  
 
This compound is novel. 
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4-Methylcyclohexa-1,4-dienecarboxylic acid (5.64 g, 40.8 mmol) in THF (50 cm
3
) was 
added drop wise to a solution of LiAlH4 (4.64 g, 123 mmol) in THF (250 cm
3
) stirring 
at 0 °C. After addition, the solution was allowed to stir at rt over the weekend. The 
solution was then cooled to 0 °C and quenched with a 50 : 50 mixture of water and THF 
(50 cm
3
: 50 cm
3
), followed by water (50 cm
3
). Rochelle salt (40 g, 142.12 mmol) was 
then added followed by DCM (75 cm
3
) and was further allowed to stir for 3 hrs. As the 
Rochelle salt absorbs all the water, the remaining solution was then filtered off through 
celite, dried (MgSO4), filtered and concentrated to give the alcohol as a white solid 200 
(4.1 g, 33 mmol, 81 %); Mp 39-43 °C; νmax 3361, 2963, 2908, 2818, 1429, 1338, 1185, 
1140, 1065, 1001, 949, 904, 835 and 783 cm
-1
; δH (400 MHz, CDCl3) 5.70 (1 H, s, 
CH=CCH2OH), 5.45 (1 H, s, CH=CCH3), 4.03 (2 H, s, CH2OH), 2.72-2.65 (2 H, m, 
CH2C=CH), 2.64-2.58 (2 H, m, C=CCH2) and 1.68 (3 H, s, CH3); δC (101 MHz, CDCl3) 
134.85 (C), 131.11 (C), 120.30 (CH), 118.25 (CH), 67.08 (CH2), 31.26 (CH2), 27.43 
(CH2) and 23.02 (CH3); m/z (ESI-MS) 271.2 [2M+Na]
+
. Found (ESI-HR-MS): 
271.1673 [2M+Na]
+
, C16H24NaO2 requires 271.1669 (-1.6 ppm error).  
Synthesis of 2-((4-methylcyclohexa-1,4-dien-1-yl)methoxy)acetic acid (202). 
 
This compound is novel. 
To a flame-dried flask containing (4-methylcyclohexa-1,4-dienyl)methanol 200 (3.73 g, 
30.0 mmol), tert-butyl bromoacetate (6.92 g, 5.20 cm
3
, 35.5 mmol) and TBAB (1.94 g, 
6.01 mmol) was added NaOH solution (9.27 g in 9.27 cm
3
 H2O, 232 mmol) at 0 °C. The 
reaction mixture was then stirred at 70 °C for 3 days. Saturated NaCl solution (60 cm
3
) 
was then added to the reaction mixture and then it was extracted using Et2O (3 x 90 
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cm
3
) to remove starting materials and other impurities. Conc. HCl was then added to the 
aqueous layer to obtain pH 1, and it was then extracted again using Et2O (3 x 90 cm
3
), 
dried (MgSO4), filtered and concentrated to give the product 202 as an orange oil  (4.1 
g, 22.50 mmol, 75 %); νmax 2963, 2855, 2819, 1724, 1426, 1244, 1196, 1106, 1055, 952, 
903, 834, 786, 764, 734 and 668 cm
-1; δH (400 MHz, CDCl3) 10.99 (1 H, br s, COOH), 
5.74 (1 H, s, CH=CCH2O), 5.44 (1 H, s, CH=CCH3), 4.08 (2 H, s, OCH2COOH), 4.02 
(2 H, s, CH=CCH2O), 2.71-2.59 (4 H, m, CH2C(CH3)=CCH2) and 1.67 (3 H, s, CH3); 
δC (101 MHz, CDCl3) 175.51 (COOH), 130.95 (C), 130.74 (C), 124.22 (CH), 118.25 
(CH), 75.53 (CH2), 65.93 (CH2), 31.33 (CH2), 27.64 (CH2) and 22.97 (CH3); m/z (ESI-
MS) 181.0 [M-H]
+
. Found (ESI-HR-MS): 205.0840 [M+Na]
+
, C10H14NaO3 requires 
205.0835 (-2.5 ppm error).  
Synthesis of 2-((4-methylcyclohexa-1,4-dien-1-yl)methoxy)ethanol (203). 
 
This compound is novel. 
2-((-4-Methylcyclohexa-1,4-dienyl)methoxy)acetic acid 202 (4.10 g, 22.5 mmol) in 
THF (28 cm
3
) was added dropwise to a solution of LiAlH4 (2.56 g, 67.5 mmol) in THF 
(138 cm
3
) with stirring at 0 °C. After addition, the solution was allowed to stir at rt for 
72h. The solution was then cooled to 0 °C and quenched with a 50 : 50 mixture of water 
and THF (28 cm
3
: 28 cm
3
), followed by water (28 cm
3
). Rochelle salt (40 g, 142.12 
mmol) was then added followed by DCM (41 cm
3
) and was further allowed to stir for 3 
hrs. The remaining solution was then filtered off through celite, dried (MgSO4), filtered 
and concentrated to give a light orange oil 203 (3.92 g, quantitative conversion, includes 
traces of solvent) which was characterised in crude form due to reoxidation during 
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chromatography; νmax 3393, 2855, 2819, 1446, 1428, 1351, 1259, 1142, 1105, 1051, 
951, 908, 889, 842, 783, 764 and 712 cm
-1; δH (400 MHz, CDCl3) 5.71 (1 H, s, 
CH=CCH2O), 5.44 (1 H, s, CH=CCH3), 3.93 (2 H, s, CH=CCH2O), 3.73 (2 H, t, J 4.8, 
OCH2CH2OH), 3.50 (2 H, J 4.8, OCH2CH2OH), 2.70-2.58 (4 H, m, 
CH2C(CH3)=CCH2), 2.17 (1 H, br s, OH) and 1.68 (3 H, s, CH3); δC (101 MHz, CDCl3) 
132.04 (C), 130.90 (C), 122.55 (CH), 118.34 (CH), 75.26 (CH2), 70.75 (CH2), 61.92 
(CH2), 31.31 (CH2), 27.74 (CH2) and 23.01 (CH3); m/z (ESI-MS) 191.0 [M+Na]
+
. 
Found (ESI-HR-MS): 191.1045 [M+Na]
+
, C10H16NaO2 requires 191.1043 (-1.1 ppm 
error). 
Synthesis of 2-((4-methylcyclohexa-1,4-dien-1-yl)methoxy)acetaldehyde (204). 
 
This compound is novel. 
The solution of oxalylchloride (2M in DCM, 15.14 cm
3
, 30.28 mmol) in anhydrous 
DCM (30 cm
3
) was cooled to -78 °C, and was slowly added a solution of 
dimethylsulfoxide (4.73 g, 4.30 cm
3
, 60.56 mmol) in DCM (15 cm
3
) by syringe. The 
solution was stirred for 30 minutes at -78 °C before a solution of 2-((4-
methylcyclohexa-1, 4-dien-1-yl) methoxy) ethanol 203 (3.92 g, 23.3 mmol) in DCM (50 
cm
3
) was slowly added at the same temperature. After stirring for 40 min at -78 °C, 
Et3N (14.22 g, 19.59 cm
3
, 139.58 mmol) was added and the reaction mixture was 
allowed to warm up to rt. After 30 mins, water (100 cm
3
) was added, and extracted with 
DCM, dried (MgSO4), filtered and then concentrated under vacuum to give the product 
as a orangey brown oil 204 (4.78 g, quantitative conversion, includes traces of solvent) 
which was characterised in crude form due to reoxidation and decomposition during 
Experimental 
 
190 
 
attempts to purify; νmax 2855, 2820, 1736, 1428, 1380, 1217, 1142, 1099, 952, 908, 752, 
733 and 667 cm
-1; δH (400 MHz, CDCl3) 9.72 (1 H, s, CHO), 5.73 (1 H, s, 
CH=CCH2O), 5.44 (1 H, s, CH=CCH3), 4.03 (2 H, s, OCH2CHO), 3.99 (2 H, s, 
CH=CCH2O), 2.72-2.57 (4 H, m, CH2C(CH3)=CCH2) and 1.68 (3 H, s, CH3); δC (101 
MHz, CDCl3) 200.98 (CHO), 131.16 (C), 130.84 (C), 124.03 (CH), 118.21 (CH), 75.82 
(CH2), 74.82 (CH2), 31.33 (CH2), 27.69 (CH2) and 22.99 (CH3); m/z (ESI-MS) 189.2 
[M+Na]
+
. Found (ESI-HR-MS): 189.0901 [M+Na]
+
, C10H14NaO2 requires 189.0886 (-
7.6 ppm error). 
Synthesis of N-((1R, 2R)-2-Amino-1, 2-diphenylethyl)-4-methylbenzenesulfonamide 
(81). 
 
This is a known compound and has been fully characterised.
27c 
 
A solution of p-TsCl (4.5 g, 24.0 mmol) in THF (50 cm
3
) was added to a mixture of 
(1R,2R)-(-)-1, 2-diphenylethylenediamine (5.0 g, 24.0 mmol) in THF (200 cm
3
) and 
triethylamine (10 cm
3
) over a period of 30 mins at 0 °C. After stirring for 12 hrs the 
solvent was removed under reduced pressure. The remaining solid was treated with 
aqueous sat. NaHCO3 solution (400 cm
3
) and DCM (400 cm
3
). The organic phase was 
washed with brine, dried (Na2SO4), and then concentrated in vacuo. The crude product 
was purified by flash chromatography (100 % ethyl acetate) giving yellow white 
crystals 81 (7.1 g, 19.37 mmol, 81 %); δH (400 MHz, CDCl3) 7.31 (2 H, d, J 8.3, 
NHSO2Ar(o-2CH), 7.20-7.08 (10 H, m, 2C6H5), 6.98 (2 H, d, J 8.3, NHSO2Ar(m-2CH), 
6.00 (1 H, br s, NHTs), 4.37 (1 H, d, J 5.1, TsNHCH), 4.13 (1 H, d, J 5.1, NH2CH), 
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2.32 (3 H, s, NHSO2Ar(CH3); δC  (101 MHz, CDCl3) 142.39 (C), 141.27 (C), 139.40 
(C), 136.69 (C), 129.12 (CH), 128.43 (CH), 128.26 (CH), 127.39 (CH), 127.06 (CH), 
126.99 (CH), 126.85 (CH), 126.50 (CH), 63.11 (CH), 60.52 (CH) and 21.42 (CH3). 
Synthesis of 4-methyl-N-((1R, 2R)-2-((2-((4-methylcyclohexa-1, 4-dien-1-
yl)methoxy)ethyl)amino)-1, 2-diphenylethyl)benzenesulfonamide (205).  
 
This compound is novel. 
To a suspension of powdered molecular sieves (4 Å, 4.2 g) in dry methanol (250 cm
3
) 
was added 2-((4-methylcyclohexa-1,4-dienyl)methoxy)acetaldehyde 204 (2.90 g, 17.43 
mmol),  (R,R)-TsDPEN 81 (7.10 g, 19.37 mmol) and glacial acetic acid (51 drops). The 
reaction mixture was stirred at rt and monitored by TLC. After 2 hrs, the imine had 
formed, and sodium cyanoborohydride (1.30 g, 21.05 mmol) was added. The reaction 
was left overnight at rt. The molecular sieves were removed by filtration, and the 
solution was concentrated under reduced pressure. The residue was re-dissolved in 
DCM (300 cm
3
). The organic phase was washed with saturated NaHCO3 (300 cm
3
) and 
brine (300 cm
3
), dried (MgSO4), filtered and concentrated. The resulting residue was 
purified by flash chromatography (10→50 % v/v ethyl acetate/pet ether) to give 205 as 
a colourless oil (2.58 g, 5.00 mmol, 29 %); [α]D
26
 -5.6 (c 0.5, CHCl3); νmax 3270, 3029, 
2855, 1599, 1495, 1454, 1397, 1327, 1218, 1184, 1156, 1092, 1027, 931, 812, 752, 699 
and 667 cm
-1; δH  (400 MHz, CDCl3) 7.36 (2 H, d, J  8.2, NHSO2Ar(o-2CH)), 7.15-6.90 
(12 H, m, 2C6H5 + NHSO2Ar(m-2CH)), 6.30 (1 H, br s, NHTs), 5.62 (1 H, s 
CH=CCH2O), 5.45 (1 H, s, CH=CCH3), 4.24 (1 H, d, J 7.6, TsNHCH), 3.77 (2 H, s, 
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CH=CCH2O), 3.66 (1 H, d, J 7.6, NHCH), 3.45-3.32 (2 H, m, NHCH2CH2OCH2), 2.65-
2.54 (5 H, m, NHCH(1)H(2)CH2OCH2  +  CH2C(CH3)=CCH2), 2.48-2.41 (1 H, m, 
NHCH(1)H(2)CH2OCH2), 2.33 (3 H, s, NHSO2ArCH3), 1.73 (1 H, br s, NHCH) and 1.69 
(3 H, s, CH2C(CH3)=CCH2); δC (101 MHz, CDCl3) 142.62 (C), 139.21 (C), 138.42 (C), 
137.12 (C), 132.17 (C), 130.92 (C), 129.08 (CH), 128.30 (CH), 127.92 (CH), 127.77 
(CH), 127.55 (CH), 127.46 (CH), 127.26 (CH), 127.12 (CH), 122.00 (CH), 118.42 
(CH), 75.00 (CH2), 69.00 (CH2), 67.83 (CH3), 63.10 (CH3), 46.74 (CH2), 31.33 (CH2) 
and 27.74 (CH2); m/z (ESI-MS) 539.2 [M+Na]
+
. Found (ESI-HR-MS): 517.2519 
[M+H]
+
, C31H37N2O3S requires 517.2519 (0.1 ppm error). 
Synthesis of ether linked “tethered” dimer (206).  
 
This compound is novel. 
To a stirred solution of 4-methyl-N-((1R,2R)-2-(2-((4-methylcyclohexa-1,4-
dienyl)methoxy)ethylamino)-1,2-diphenylethyl)benzenesulfonamide 205 (1.38 g, 2.67 
mmol) in DCM (39 cm
3
) was added 1.25 M HCl in EtOH (6.4 cm
3
, 8.01 mmol). The 
reaction mixture was stirred for 2 hrs and concentrated under vacuum. To a suspension 
of the residue in IPA (28 cm
3
) was added trihydrated ruthenium trichloride (880 mg, 
4.22 mmol). The reaction mixture was stirred at reflux temperature for 2 days. It was 
then filtered off and washed with cold IPA to give a dark blue solid 206 (1.70 g, 1.18 
mmol,  88 %); νmax 3676, 2988, 2902, 1454, 1406, 1394, 1382, 1324, 1250, 1230, 1155, 
1066, 1057, 892, 812, 763, 699 and 669 cm
-1
; δH (400 MHz, DMSO-d6) 9.47 (2 H, br s, 
2 x NH(1)H(2)
+
Cl
-
), 8.90 (2 H, br s, 2 x NH(1)H(2)
+
Cl
-
), 8.55 (2 H, d, J 9.8, 2 x NHTs), 
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7.35-6.70 (28 H, m, 2 x (14 x Ar-H)), 6.05-5.75 (8 H, m, 2 x (4 x Ru-Ar-H)), 4.80 (2 H, 
t, J 9.8, 2 x CHNH2
+
Cl
-
), 4.63-4.50 (2 H, m, 2 x CHNHTs), 4.38 (3.2 H, s, 2 x 
ArCH2O), 4.31 (0.8 H, s, 2 x ArCH2O), 3.90-3.75 (4 H, m, 2 x NH2
+
Cl
-
CH2CH2O), 
3.10-2.97 (4 H, m, 2 x NH2
+
Cl
-
CH2CH2O),  2.21 (6 H, s, 2 x CH3Ts), 2.15 (4.8 H, s, 2 x 
CH3Ar) and 2.12 (1.2 H, s, 2 x CH3Ar); δC (101 MHz, DMSO-d6) 142.66 (2 x C), 
138.06 (2 x C), 135.90 (2 x C), 131.93 (2 x C), 129.52 (2 x (2 x CH)), 129.50 (2 x CH 
and 2 x (2 x CH)), 129.21 (2 x (2 x CH)), 128.55 (2 x CH), 128.28 (2 x (2 x CH)), 
128.15 (2 x (2 x CH)), 126.88 (2 x (2 x CH)), 122.62 (2 x CH), 118.73 (2 x CH),  
102.76 (2 x C), 94.90 (2 x C), 65.59 (2 x CH), 62.48 (2 x (2 x CH)), 60.85 (2 x CH), 
56.78 (2 x (2 x CH2)), 48.61 (2 x CH2), 26.00 (2 x CH3) and 21.53 (2 x CH3); m/z (ESI-
MS) 615.0 [Monomer+H]
+
. Found (ESI-HR-MS): 615.1266 [Monomer+H]
+
, 
C31H33N2O3
102
RuS (monomer formed in situ from dimer and loss of 3 x HCl) requires 
615.1257 (-2.0 ppm error). Optical rotation could not be obtained due to the product 
being highly coloured. 
Synthesis of ether linked “tethered” monomer (207).  
 
This compound is novel. 
To a suspension of dimer 206 (98 mg, 0.07 mmol) in IPA (9 cm
3
) was added Et3N (0.06 
cm
3
, 0.42 mmol). After stirring at 80 °C for 1.5 hrs, the hot IPA solution was filtered 
through a layer of cotton wool and filter paper to remove impurities. The solution was 
then concentrated, re-dissolved in DCM and washed with water. The organic layer was 
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then dried (Na2SO4), filtered and concentrated to give the monomer 207 as an orange 
solid (29 mg, 0.0446 mmol, 33 %). The crude product was isolated, and 
1
H NMR, 
LRMS and HRMS were carried out to confirm the presence of product. Several 
purification attempts on the crude product led to decomposition of the material; δH (300 
MHz, CDCl3) 7.30 (2 H, d, J 8.0, 2 x Ar-H), 7.15-7.10 (4 H, m, 4 x Ar-H), 6.85 (2 H, d, 
J 8.0, 2 x Ar-H), 6.80-6.70 (2 H, m, 2 x Ar-H), 6.70-6.55 (4 H, m, 4 x Ar-H), 6.15-6.05 
(1 H, m, Ru-Ar-H), 5.75 (1H, d, J 6.4, Ru-Ar-H), 5.65 (1H, d, J 6.4, RuArH), 5.50-5.40 
(1 H, m RuArH), 4.92 (1 H, brd, J 14.2, CHPh), 4.55-4.45 (2 H, m, CHPh + NH), 4.05-
3.88 (4 H, m, 2 x CH2), 3.65-3.55 (1 H, m, CHH), 3.20-3.05 (1 H, m, CHH), 2.60 (3 H, 
s, CH3), 2.24 (3 H, s, CH3); m/z (ESI-MS) 615.0 [Monomer+H]
+
. Found (ESI-HR-MS): 
615.1264 [Monomer+H]
+
, C31H33N2O3
102
RuS requires 615.1257 (-1.8 ppm error).  
The 
1
H NMR spectroscopic data of the monomeric complex obtained by Ikariya 
matched that of the crude material obtained from dimer 206 in this project.
27i
 
Synthesis of 2-phenoxy-1-phenylethanone (222). 
 
This is a known compound and has been fully characterised.
32k
 
Phenol (2.05 g, 1.91 cm
3
, 21.80 mmol) and potassium carbonate (2.70 g, 19.50 mmol) 
were dissolved in acetone (40 cm
3
) and the mixture was stirred for about 10 minutes. 
Phenacyl bromide (3.53 g, 17.70 mmol) was added to the mixture and the mixture was 
refluxed for 2 hrs. The reaction mixture was then quenched with water (100 cm
3
) and 
the phenacyl ether was extracted with diethyl ether (3 x 50 cm
3
). The organic extracts 
were washed with 2M NaOH (3 x 50 cm
3
), and water (3 x 50 cm
3
), dried (MgSO4) and 
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filtered. The solvent was concentrated under reduced pressure and a white solid was 
obtained. The crude was recrystallized with ethanol to give 222 as a white crystalline 
sold (1.73 g, 8.15 mmol, 46 %); δH (400 MHz, CDCl3) 8.01 (2 H, d, J 7.1, 2 x Ar-H o to 
C(C=O)CH2OPh), 7.62 (1 H, t, J 7.1, Ar-H p to C(C=O)CH2OPh), 7.50 (2 H, t, J 7.1, 2 
x Ar-H m to C(C=O)CH2OPh) 7.33-7.25 (2 H, m, 2 x Ar-H m to OCH2COPh), 7.02-
6.92 (3 H, m, 2 x Ar-H o and 1 x Ar-H p to OCH2COPh) and  5.27 (2 H, s, CH2); δC  
(101 MHz, CDCl3) 194.58 (C=O), 158.04 (C), 134.64 (C), 133.88 (CH), 129.60 (2 x 
CH), 128.85 (2 x CH), 128.18 (2 x CH), 121.68 (CH), 114.84 (2 x CH) and 70.84 
(CH2); m/z (ESI-MS) 235.1 [M+Na]
+
. The data matched that previously reported for this 
compound. 
Synthesis of tert-butyl benzyl(2-oxo-2-phenylethyl)carbamate (225).  
 
This is a known compound and has been fully characterised.
32l
 
Benzylamine (1.02 g, 9.5 mmol) and triethylamine (5.06 g, 50.0 mmol) were stirred in 
dichloromethane (20 cm
3
) for 30 minutes. 2-Bromoacetophenone (1.99 g, 10.00 mmol) 
in dichloromethane (10 cm
3
) was added dropwise and the reaction was stirred for 3 hrs. 
Di-tert-butyl dicarbonate (2.18 g, 10.0 mmol) in dichloromethane (10 cm
3
) was added 
and the reaction mixture was stirred overnight. Saturated ammonium chloride solution 
(30 cm
3
) was added,the phases were separated and the aqueous layer extracted with 
dichloromethane (3 x 20 cm
3
). The combined organic layers were dried (MgSO4), 
filtered and the solvent removed in vacuo, to give the crude as a yellow oil. Purification 
by flash chromatography (5→10% v/v ethyl acetate/pet ether) gave 225 as a light 
yellow solid (1.80 g, 5.53 mmol, 58 %); δH  (300 MHz, CDCl3) (1 : 1 mixture of NCO 
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rotamers) 7.93-7.21 (10 H, m, 10 x Aryl-H), 4.63 (1 H, s, C(=O)-CH(1)H(2)), 4.61 (1 H, 
s, C(=O)-CH(1)H(2)), 4.56 (1 H, s, CH(1)H(2)-Ph), 4.46 (1 H, s, CH(1)H(2)-Ph), 1.50 (4.5 H, 
s, CH3) and 1.41 (4.5 H, s, CH3); δC (75 MHz, CDCl3) 195.87 (C=O), 155.27 (C=O), 
137.24 (C), 134.65 (C), 132.85 (CH), 128.13 (CH), 127.98 (3 x CH), 127.53 (CH), 
127.29 (CH), 127.07 (CH), 126.92 (CH), 126.86 (CH), 80.01 ((CH3)3C), 51.51 
(N(Boc)CH2), 50.76 (C(=O)CH2) and 27.79 ((CH3)3C). The data matched that 
previously reported for this compound.  
Synthesis of N-(3,4-Dimethoxyphenethyl)acetamide (306).  
 
This is a known compound and has been fully characterised.
27h
 
2-(3,4-Dimethoxyphenyl)ethylamine (5.00 g, 4.70 cm
3
, 27.60 mmol) was dissolved in 
dichloromethane (50 cm
3
) and stirred. Acetic anhydride (2.80 g, 2.60 cm
3
, 27.60 mmol) 
was then added dropwise, and the solution was left to stir for 1 hr. After the stirring was 
completed, the solution was washed with saturated citric acid (10 cm
3
), saturated 
NaHCO3 (10 cm
3
), brine (10 cm
3
) and then dried (MgSO4). After filtration the solvent 
was removed under reduced pressure giving 306 as a white solid (5.50 g, 24.63 mmol, 
90 %); δH  (300 MHz, CDCl3) 6.84-6.79 (1 H, m, Ar-H), 6.77-6.70 (2 H, m, 2 x Ar-H), 
5.60 (1 H, br s, NH), 3.88 (3 H, s, OCH3),  3.87 (3 H, s, OCH3), 3.49 (2 H, d, J 7.0, 
NHCH2), 2.77 (2 H, J 7.0, Ar-CH2) and 1.95 (3 H, s, CH3); δC  (75 MHz, CDCl3)  
170.40 (C), 149.27 (C), 147.92  (C), 131.58 (C), 120.86 (CH), 112.08 (CH), 111.56 
(CH), 56.17 (CH3), 56.13 (CH3), 41.04 (CH2), 35.44 (CH2) and 23.61 (CH3). The data 
matched that previously reported for this compound. 
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Synthesis of 6,7-Dimethoxy-1-methyl-3,4-dihydroisoquinoline (109a).  
 
This is a known compound and has been fully characterised.
27h
 
N-(3-4-Dimethoxyphenethyl)acetamide 306 (5.50 g, 24.67 mmol) and POCl3 (3.78 g, 
2.26 cm
3
, 24.7 mmol) were refluxed in toluene (50 cm
3
) for 2 hrs. Once the reflux was 
completed, the solvent was removed in vacuo and the residue was re-dissolved in 
dichloromethane (50 cm
3
). The organic layer was washed with saturated K2CO3 (2 x 20 
cm
3
), brine (20 cm
3
) and was then dried (Na2SO4). After filtration the solvent was 
removed in vacuo giving 109a (4.44 g, 21.63 mmol, 88 %) as a yellow solid; δH  (300 
MHz, CDCl3) 7.00 (1 H, s, Ar-H), 6.70 (1 H, s, Ar-H), 3.91 (6 H, s, 2 x OCH3), 3.62 (2 
H, t, J 7.4, NCH2), 2.63 (2 H, t, J 7.4, Ar-CH2) and 2.37 (3 H, s, CH3); δC (75 MHz, 
CDCl3) 164.20 (C), 150.70 (C), 147.30 (C), 130.96 (C), 122.30 (C), 110.11 (CH), 
108.86 (CH), 56.07 (CH3), 55.82 (CH3), 46.83 (CH2), 25.61 (CH2) and 23.28 (CH3). 
The data matched that previously reported for this compound. 
Ketone and  Imine Reduction. 
General procedure for the preparation of secondary alcohols and amines. 
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Method A (Racemic) To a stirred solution of ketone/imine (1 mmol) in methanol (12 
cm
3
) was added NaBH4 (3.0 eq.) portion-wise and the reaction mixture was allowed to 
stir until completion while monitoring the conversion by TLC, after completion the 
solution was diluted with saturated NH4Cl(aq) (12 cm
3
) and extracted with 
dichloromethane (3 x 12 cm
3
). The combined extracts were dried (MgSO4), filtered and 
concentrated under reduced pressure to give the racemic secondary alcohol or amine. 
Method B (Asymmetric) using “tethered” Ru (II) dimer for ketones A solution of 
ruthenium dimer (0.0025 mmol) in formic acid/triethylamine (5:2) azeotrope (0.5 cm
3
) 
was stirred in a flame dried Schlenk tube (The Schlenk tube was degassed and purged 
with argon 3x before and after the addition of reagents) at 28 °C for 30 minutes. Ketone 
(1 mmol) was added and dichloromethane (0.5 cm
3
) was added if required to dissolve 
the substrate. The reaction mixture was stirred at 28 °C and monitored by TLC or GC, 
for which a drop of sample was filtered through a small plug of silica in a glass pipette 
using ethyl acetate and maybe a few drops of methanol depending on the polarity of the 
compound. After completion, the reaction mixture was diluted with dichloromethane 
(6.7 cm
3
) and washed with NaCO3 solution (3 x 5 cm
3
). The organic phase was dried 
(MgSO4), filtered and concentrated under reduced pressure to give the desired alcohol. 
Method C (Asymmetric) using “tethered” Ru (II) dimer for imines A solution of 
ruthenium dimer (0.0025 mmol) and imine (1 mmol) in methanol (1.6 cm
3
) was stirred 
in a flame dried Schlenk tube at 28 °C for 10 minutes. Formic acid/triethylamine (5:2) 
azeotrope (0.5 cm
3
) was then added (The Schlenk tube was degassed and purged with 
argon 3x before and after the addition of reagents). The reaction mixture was stirred at 
28 °C and monitored by TLC or GC, for which a drop of sample was filtered through a 
small plug of silica in a glass pipette using ethyl acetate and maybe a few drops of 
methanol depending on the polarity of the compound. After completion, NaHCO3 
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solution (5 cm
3
) was added, and was extracted with dichloromethane (3 x 6.7 cm
3
). The 
organic phase was dried (MgSO4), filtered and concentrated under reduced pressure to 
give the desired amine. 
Reduction product analysis. 
(R)-1-Phenylethanol (49a’).  
 
This is a known compound and has been fully characterised.
20a
  
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β- 236M-
19 50m, T = 115 °C, P = 15 psi, H2, R isomer 15.0 min., S isomer 16.7 min.); [α]D
28
 
+56.0 (c 1.0, CHCl3) >99% ee (R) (lit.
20a
 [α]D
22
 +49.0 (c 1.0, CHCl3) 98% ee (R)); δH 
(400 MHz, CDCl3) 7.39-7.24 (5 H, m, 5 x Ar-H), 4.88 (1 H, q, J 6.4, CHOH), 2.03 (1 
H, br s, OH) and 1.49 (3 H, d, J 6.4, CH3); δC  (101 MHz, CDCl3) 145.83 (C), 128.52 (2 
x CH), 127.49 (CH), 125.41 (2 x CH), 70.43 (CH) and 25.16 (CH3). The data matched 
that previously reported for this compound. 
 (S)-1-Cyclohexylethanol (141’).  
 
This is a known compound and has been fully characterised.
32m
 
Using catalyst 183; Enantiomeric excess and conversion by GC analysis (Chrompac 
cyclodextrin-β-236M-19 50m, (Product was converted to (S)-1-cyclohexylethyl acetate 
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for GC separation) T = 115 °C, P = 15 psi, He, S isomer 24.6 min., R isomer 27.6 min.); 
[α]D
28
 +5.6 (c 1.0, CHCl3) 74% ee (S) (lit.
32m
 [α]D
22
 +2.7 (c 0.5, CHCl3) 75% ee (S)); δH 
(400 MHz, CDCl3) 3.58-3.51 (1 H, m, CHOH), 1.90-1.62 (5 H, m, cyclohexyl), 1.50 (1 
H, br s, OH), 1.32-0.91 (6 H, m, cyclohexyl) and 1.16 (3 H, d, J 6.3, CH3); δC  (101 
MHz, CDCl3) 72.22 (CH), 45.13 (CH), 28.71 (CH2), 28.37 (CH2), 26.53 (CH2), 26.24 
(CH2), 26.15 (CH2) and 20.37 (CH3). The data matched that previously reported for this 
compound. 
 (R)-1-(3,5-Bis(trifluoromethyl)phenyl)ethanol (129’).  
 
This is a known compound and has been fully characterised.
32n
 
Enantiomeric excess and conversion by GC analysis (CP-Chirasil-Dex CB, 25 m, 0.25 
mm, 0.25 µm, T = 100 °C for 10 minutes then ramp at 10 °C/minute to 200 °C, P = 20 
psi, He,  S isomer 11.0 min., R isomer 12.0 min.); [α]54628 +11.2 (c 1.0, CHCl3) 60% ee 
(R) (lit.
32n
 [α]54622 +16.0 (c 1.2, CHCl3) >99% ee (R)); δH (400 MHz, CDCl3) 7.85 (2 H, 
s, 2 x Ar-H o to CHOH), 7.79 (1 H, s, Ar-H p to CHOH), 5.05 (1 H, q, J 6.5, CHOH), 
2.02 (1 H, br s, OH) and 1.55 (3 H, d, J 6.5, CH3); δC  (101 MHz, CDCl3) 148.22 (C), 
131.92 (C), 131.59 (C), 125.66 (2 x CH), 124.71 (C), 121.94 (C), 121.31 (CH), 69.28 
(CH) and 25.60 (CH3). The data matched that previously reported for this compound. 
1-(2-(Trifluoromethyl)phenyl)ethanol (224’).  
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This is a known compound and has been fully characterised.
17l
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 110 
o
C, P = 15 psi, H2,  R isomer 18.3 min., S isomer 20.0 min.); (lit.
17l
 
[α]D
29
 -30.4 (c 1.41, CHCl3) 96% ee (R)); δH (300 MHz, CDCl3) 7.82 (1 H, d, J 7.8 , Ar-
H o to CF3), 7.63-7.55 (2 H, m, Ar-H o to CHOHCH3 and Ar-H p to CHOHCH3), 7.40-
7.32 (1 H, m, Ar-H m to CHOHCH3 and p to CF3), 5.37-5.27 (1 H, m, CHOH), 2.10 (1 
H, d, J 3.0, OH) and 1.48 (3 H, d, J 6.3, CH3); δC  (75 MHz, CDCl3) 144.41 (C), 131.77 
(CH), 126.72 (CH), 126.47 (CH), 125.57 (C), 124.71 (CH), 121.94 (C), 65.06 (CH) and 
24.79 (CH3). The data matched that previously reported for this compound. 
 (S)-2-Chloro-1-phenylethanol (219’).  
 
This is a known compound and has been fully characterised.
20a
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β- 236M-
19 50m, T = 140 °C, P = 10 psi, H2, S isomer 29.9 min., R isomer 31.7 min.); [α]D
28
 
+43.4 (c 1.0, cyclohexane) >98% ee (S) (lit.
20a
 [α]D
25
 +51.5 (c 1.1, cyclohexane) 95% ee 
(S)); δH (300 MHz, CDCl3) 7.33-7.15 (5 H, m, 5 x Ar-H), 4.76 (1 H, dd, J  8.7, 3.4, 
CHOH),  3.61 (1 H, dd, J  3.4, 11.2 CH(1)H(2)Cl), 3.51 (1 H, dd, J  8.7, 11.2, 
CH(1)H(2)Cl) and 2.60 (1 H, br s, OH); δC (75 MHz, CDCl3) 139.27 (C), 128.07 (2 x 
CH), 127.87 (CH), 125.44 (2 x CH), 73.46 (CH) and 50.31 (CH2). The data matched 
that previously reported for this compound.  
 (R)-1-(4-Chlorophenyl)ethanol (49c’).  
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This is a known compound and has been fully characterised.
32o
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β- 236M-
19 50m, T = 130 °C, P = 15 psi, H2, R isomer 27.9 min., S isomer 31.4 min.); [α]D
20
 
+50.4 (c 1.0, CHCl3) 96% ee (R) (lit.
32o
 [α]D
22
 +45.6 (c 1.0, CHCl3) 91% ee (R)); δH 
(400 MHz, CDCl3) 7.33-7.25 (4 H, m, 4 x Ar-H), 4.87 (1 H, q, J 6.5, CHOH), 2.73 (1 
H, br s, OH) and 1.47 (3 H, d, J 6.5, CH3); δC  (101 MHz, CDCl3)  144.17 (C), 133.12 
(C), 128.80 (2 x CH), 126.82 (2 x CH), 69.81 (CH) and 25.24 (CH3). The data matched 
that previously reported for this compound. 
 (R)-1-(3-Chlorophenyl)ethanol (49b’).  
 
This is a known compound and has been fully characterised.
33a
  
Enantiomeric excess and conversion by GC analysis (CP-Chirasil-Dex CB, 25 m, 0.25 
mm, 0.25 µm, T = 120 °C for 20 minutes then ramp at 15 °C/minute to 200 °C, P = 20 
psi, He, R isomer 19.2 min., S isomer 21.1 min.); [α]D
29
 +34.8 (c 1.0, CHCl3) 94% ee 
(R) (lit.
33a
 [α]D
22
 +43.3 (c 1.0, CHCl3) 90% ee (R)); δH (300 MHz, CDCl3) 7.37-7.32 (1 
H, m, Ar-H o to Cl and CHOHCH3), 7.30-7.19 (3 H, m, 1 x Ar-H m to Cl/CHOHCH3 
and 1 x Ar-H p to Cl and 1 x Ar-H p to CHOHCH3), 4.85 (1 H, q, J 6.5, CHOH), 2.50 
(1 H, br s, OH) and 1.46 (3 H, d, J 6.5, CH3); δC  (75 MHz, CDCl3) 147.18 (C), 133.74 
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(C), 129.18 (CH), 126.92 (CH), 125.02 (CH), 122.93 (CH), 69.29 (CH) and 24.59 
(CH3). The data matched that previously reported for this compound. 
(R)-1-(2-Chlorophenyl)ethanol (216’).  
 
This is a known compound and has been fully characterised.
32o
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β- 236M-
19 50m, T = 130 °C, P = 15 psi, H2, R isomer 22.9 min., S isomer 28.8 min.); [α]D
29
 
+49.2 (c 1.0, CHCl3) 87% ee (R) (lit.
32o
 [α]D
22
 +40.8 (c 1.0, CHCl3) 77% ee (R)); δH 
(300 MHz, CDCl3) 7.59 (1 H, dd, J 1.8, 1.8, Ar-H o to Cl), 7.34-7.25 (2 H, m, 1 x Ar-H 
o to CHOHCH3 and 1 x Ar-H p to CHOHCH3), 7.19 (1 H, ddd, J 1.8, 1.8, 1.8, Ar-H p 
to Cl), 5.29 (1 H, q, J 6.4, CHOH), 2.20 (1 H, br s, OH) and 1.49 (3 H, d, J 6.4, CH3); 
δC  (75 MHz, CDCl3) 142.41 (C), 131.02 (C), 128.79 (CH), 127.79 (CH), 126.60 (CH), 
125.79 (CH), 66.36 (CH) and 22.88 (CH3). The data matched that previously reported 
for this compound. 
(S)-2-Chloro-1-(4-chlorophenyl)ethanol (220’).  
 
This is a known compound and has been fully characterised.
20a
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β- 236M-
19 50m, T = 160 °C, P = 11 psi, H2, S isomer 38.2 min., R isomer 40.9 min.); [α]D
31
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+44.8 (c 1.0, CHCl3) 96% ee (S) (lit.
20a
 [α]D
25
 +47.0 (c 1.1, CHCl3) 93% ee (S)); δH (400 
MHz, CDCl3) 7.37-7.30 (4 H, m, 4 x Ar-H), 4.88 (1 H, dd, J 3.5, 8.6, CHOH), 3.71 (1 
H, dd, J  3.5, 11.3, CH(1)H(2)Cl), 3.61 (1 H, dd, J  8.6, 11.3, CH(1)H(2)Cl) and 2.95 (1 H, 
br s, OH); δC  (101 MHz, CDCl3) 138.37 (C), 134.26 (C), 128.86 (2 x CH), 127.47 (2 x 
CH), 73.39 (CH) and 50.67 (CH2). The data matched that previously reported for this 
compound. 
(S)-2-Chloro-1-(4-methoxyphenyl)ethanol (221’).  
 
This is a known compound and has been fully characterised.
20a
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β- 236M-
19 50m, T = 160 °C, P = 14 psi, H2, S isomer 33.2 min., R isomer 34.6 min.); [α]D
31
 
+50.0 (c 1.0, CHCl3) 97% ee (S) (lit.
20a
 [α]D
24
 +52.9 (c 1.1, CHCl3) 95% ee (S)); δH (400 
MHz, CDCl3) 7.34-7.27 (2 H, m, 2 x Ar-H o to CHOHCH2Cl), 6.93-6.87 (2 H, m, 2 x 
Ar-H o to MeO), 4.85 (1 H, dd, J 3.6, 8.7, CHOH), 3.81 (3 H, s, CH3O), 3.70 (1 H, dd, J 
3.6, 11.2, CH(1)H(2)Cl), 3.63 (1 H, dd, J 8.7, 11.2, CH(1)H(2)Cl) and 2.65 (1 H, br s, OH); 
δC  (101 MHz, CDCl3) 159.72 (C-OMe), 132.06 (C), 127.35 (2 x CH), 114.09 (2 x CH), 
73.75 (CH), 55.33 (CH3) and 50.92 (CH2). The data matched that previously reported 
for this compound. 
 (S)-2-Phenoxy-1-phenylethanol (222’).  
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This is a known compound and has been fully characterised.
33b
 
Enantiomeric excess by HPLC analysis and conversion by GC analysis (ChiralPak IA 
Column: 0.46 cm
3
 x 25 cm, hexane:isopropanol = 95:5, flow rate 0.5 ml/min, 254 nm, 
24 °C: tR = 28.9 min (minor), tS = 36.4 (major)); [α]D
30
 +58.8 (c 1.0, CHCl3) 95% ee (S) 
(lit.
33b
 [α]D
20
 +50.0 (c 1.7, CHCl3) 98% ee (S)); δH (400 MHz, CDCl3) 7.47-7.23 (7 H, 
m, 5 x Ar-H and 2 x Ar-H m to CH2O), 6.97 (1 H, t, J 7.4, Ar-H p to CH2O), 6.91 (2 H, 
d, J 7.8, 2 x Ar-H o to CH2O), 5.12 (1 H, dd, J 3.2, 8.8, CHOH), 4.10 (1 H, dd, J 3.2, 
9.6, CH(1)H(2)OPh), 4.01 (1 H, t, J 9.6, 8.8, CH(1)H(2)OPh) and 2.90 (1 H, br s, OH); δC  
(101 MHz, CDCl3) 158.41 (C), 139.66 (C), 129.60 (2 x CH), 128.61 (2 x CH), 128.23 
(CH), 126.32 (2 x CH), 121.35 (CH), 114.68 (2 x CH), 73.32 (CH2) and 72.63 (CH). 
The data matched that previously reported for this compound. 
(R)-1-phenylpropan-1-ol (49g’).  
 
This is a known compound and has been fully characterised.
32b
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 110 
o
C, P = 15 psi, H2, R isomer 31.1 min., S isomer 33.8 min.); []D
26
 
+53.6 (c 1.0, CHCl3) >99% ee (R) (lit.
32b
 []D
26
 -40.0 (c 0.85, CHCl3) 66% ee (S)); δH 
(400 MHz, CDCl3) 7.38-7.24 (5 H, m, 5 x Ar-H), 4.59 (1 H, t, J 6.5, CHOH), 2.40 (1 H, 
br s, OH), 1.90-1.68 (2 H, m, CH2) and 0.91 (3 H, t, J 7.4, CH3); δC (101 MHz, CDCl3) 
144.55 (C), 128.43 (2 x CH), 127.54 (CH), 125.99 (2 x CH), 76.09 (CH), 31.88 (CH2) 
and 10.15 (CH3). The data matched that previously reported for this compound. 
 2-Methyl-1-phenylpropan-1-ol (217’).  
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This is a known compound and has been fully characterised.
33c
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 110 °C, P = 15 psi, H2, R isomer 39.4 min., S isomer 40.8 min.); (lit.
33c
 
[α]D
20
 +34.6 (c 1.0, CHCl3) 68.5% ee (R)); δH (400 MHz, CDCl3) 7.36-7.22 (5 H, m, 5 x 
Ar-H), 4.33 (1 H, d, J 6.8, CHOH), 1.97 (1 H, br s, OH), 1.94 (1 H, oct, J 6.8, 
CH(CH3)2), 0.99 (3 H, d, J 6.8, CH3) and 0.78 (3 H, d, J 6.8, CH3); δC (101 MHz, 
CDCl3) 143.68 (C), 127.94 (2 x CH), 127.01 (CH), 126.60 (2 x CH), 80.05 (CH), 35.09 
(CH), 19.02 (CH3) and 18.28 (CH3). The data matched that previously reported for this 
compound. 
 2,2-Dimethyl-1-phenylpropan-1-ol (218’).  
 
This is a known compound and has been fully characterised.
33d
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 125 
o
C, P = 15 psi, H2, S isomer 29.5 min., R isomer 30.5 min.); (lit.
33d
 
[α]D
20
 +12.2 (c 1.0, CHCl3) 45% ee (R)); δH (400 MHz, CDCl3) 7.34-7.22 (5 H, m, 5 x 
Ar-H), 4.38 (1 H, s, CHOH), 1.92 (1 H, br s, OH) and 0.92 (9 H, s, 3 x CH3); δC (101 
MHz, CDCl3) 142.23 (C), 127.64 (2 x CH), 127.57 (2 x CH), 127.29 (CH), 82.41 (CH), 
35.64 (C) and 25.96 (3 x CH3). The data matched that previously reported for this 
compound. 
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 (R)-1,2,3,4-Tetrahydronaphthalen-1-ol (214’).  
 
This is a known compound and has been fully characterised.
33e
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 115 
o
C, P = 15 psi, H2, S isomer 74.1 min., R isomer 74.3 min.); []D
29
 -
19.2 (c 1.0, CHCl3) >99% ee (R) (lit.
33e
 []D
20
 +38.9 (c 1.45, CHCl3) 99% ee (S)); δH 
(300 MHz, CDCl3) 7.45-7.36 (1 H, m, 1 x Ar-H), 7.22-7.04 (3 H, m, 3 x Ar-H), 4.77 (1 
H, t, J 4.4, CHOH), 2.88-2.62 (2 H, m, CH2 p to CHOH), 2.50 (1 H, br s, OH) and 2.05-
1.69 (4 H, m, 2 x CH2 o and m to CHOH); δC (75 MHz, CDCl3) 138.10 (C), 136.52 (C), 
128.42 (CH), 128.06 (CH), 127.00 (CH), 125.58 (CH), 67.57 (CH), 31.62 (CH2), 28.63 
(CH2) and 18.16 (CH2). The data matched that previously reported for this compound. 
(R)-Chroman-4-ol (215’).  
 
This is a known compound and has been fully characterised.
33e
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 160 
o
C, P = 15 psi, H2, S isomer 13.4 min., R isomer 13.6 min.); []D
30
 
+77.6 (c 1.0, CHCl3) >99% ee (R) (lit.
33e
 []D
20
 -62.0 (c 1.8, CHCl3) 98% ee (S)); δH 
(400 MHz, CDCl3) 7.32 (1 H, dd, J 7.6, 1.6, Ar-H), 7.21 (1 H, dt, J 7.4, 1.6, Ar-H), 6.93 
(1 H, dt, J 7.4, 1.1, Ar-H), 6.85 (1 H, d, J 8.3, Ar-H), 4.80 (1 H, t, J 4.0, CHOH), 4.31-
4.24 (2 H, m, CH2 m to CHOH), 2.18-2.09 (1 H, m, CH(1)H(2) o to CHOH), 2.08-2.00 (1 
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H, m, CH(1)H(2) o to CHOH) and 1.80 (1 H, br s, OH); δC (101 MHz, CDCl3) 154.45 
(C), 129.76 (CH), 129.64 (CH), 124.42 (C), 120.62 (CH), 117.11 (CH), 63.29 (CH), 
61.93 (CH2) and 30.84 (CH2). The data matched that previously reported for this 
compound. 
(R)-1-(Pyridin-2-yl)ethanol (107a’). 
 
This is a known compound and has been fully characterised.
20a
 
Using catalyst 163b; Enantiomeric excess and conversion by GC analysis (Chrompac 
cyclodextrin-β-236M-19 50m, (Product was converted to (R)-1-(pyridin-2-yl)ethyl 
acetate for GC separation)  T = 115 
o
C, P = 15 psi, G = H2, S isomer 19.3 min., S isomer 
20.0 min.); []D
28
 +24.8 (c 1.0, CHCl3) 88% ee (R) (lit.
20a
 []D
24
 +18.9 (c 1.5, CHCl3) 
91% ee (R)); δH (400 MHz, CDCl3) 8.55 (1 H, d, J 4.9, Ar-H o to N), 7.76 (1 H, dt, J 
7.8, 1.7, Ar-H p to N), 7.38 (1 H, d, J 7.8, Ar-H o to CHOHCH3), 7.29-7.24 (1 H, m, 
Ar-H m to N and p to CHOHCH3), 4.95 (1 H, q, J 6.6, CHOH) and 1.53 (3 H, d, J 6.6, 
CH3); δC (101 MHz, CDCl3) 163.01 (C), 147.48 (CH), 137.77 (CH), 122.61 (CH), 
120.31 (CH), 68.97 (CH) and 23.95 (CH3). The data matched that previously reported 
for this compound. 
(S)-tert-Butyl benzyl(2-hydroxy-2-phenylethyl)carbamate (225’).  
 
This is a known compound and has been fully characterised.
32l
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Enantiomeric excess by HPLC analysis and conversion by NMR analysis (ChiralPak IA 
Column: 0.46 cm
3
 x 25 cm, hexane:isopropanol = 98:2, flow rate 0.5 ml/min, 254 nm, 
21 °C: tR = 49.6 min (minor), tS = 64.9 (major)); [α]D
29
 +2.4 (c 0.5, ethanol) >99% ee (S) 
(lit.
32l
 [α]D
20
 +3.3 (c 2.0, ethanol) 80% ee (S)); δH (400 MHz, CDCl3) 7.34-7.15 (10 H, 
m, 10 x Ar-H), 4.92-4.86 (1 H, m, CHOH), 4.51-4.41 (2 H, m, CH(1)H(2)-Ar and OH), 
4.19 (1 H, d, J 14.4, CH(1)H(2)-Ar), 3.64-3.49 (1 H, m, CH(OH)CH(1)H(2)), 3.33 (1 H, d, 
J 13.0, CH(OH)CH(1)H(2)) and 1.49 (9 H, s, CH3); δC (101 MHz, CDCl3)  155.91 (C=O) 
142.39 (C), 137.96 (C), 128.62 (4 x CH), 128.41 (CH), 127.51 (CH), 127.38 (CH), 
127.34 (CH), 125.80 (2 x CH), 81.51 ((CH3)3C), 74.23 (CH(OH)), 57.30 (CH2), 52.53 
(CH2) and 28.42 ((CH3)3C);  m/z (ESI-MS) 350.2 [M+Na]
+
. The data matched that 
previously reported for this compound.
 
 
(R)-1-(Cyclohex-1-en-1-yl)ethanol (226’).  
 
This is a known compound and has been fully characterised.
33f
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 115 
o
C, P = 15 psi, H2, S isomer 13.5 min., R isomer 13.9 min.); []D
30
 
+26.4 (c 0.5, CHCl3) 71% ee (R) (lit.
33f
 []589
20
 +19.7 (c 1.69, CHCl3) 83% ee (R)); δH 
(400 MHz, CDCl3) 5.66 (1 H, s, CH=C), 4.16 (1 H, q, J 6.4, CHOH), 2.10-1.90 (4 H, m, 
2 x CH2), 1.72-1.49 (5 H, m, 2 x CH2 + OH) and  1.25 (3 H, d, J 6.4, CH3); δC (101 
MHz, CDCl3) 141.27 (C), 121.49 (CH), 72.14 (CH), 24.89 (CH2), 23.67 (CH2), 22.66 
(CH2), 22.60 (CH2) and 21.50 (CH3). The data matched that previously reported for this 
compound. 
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 (S)-6,7-Dimethoxy-1-methyl-1,2,3,4-tetrahydroisoquinoline (109a’).  
 
This is a known compound and has been fully characterised.
26a
 
Enantiomeric excess and conversion by GC analysis (Chrompac cyclodextrin-β-236M-
19 50m, T = 170 
o
C, P = 15 psi, He, S isomer 35.5 min., R isomer 36.1 min.); []D
27
 -
40.0 (c 0.5, CHCl3) 87% ee (R) (lit.
26a
 []D
28
 -32.9 (c 0.3, CHCl3) 84% ee (S)); δH (400 
MHz, CDCl3) 6.63 (1 H, s, Ar-H), 6.57 (1 H, s, Ar-H), 4.05 (1 H, q, J 6.6, CHNH), 3.85 
(6 H, s, 2 x CH3O), 3.29-3.21 (1 H, m, CH(1)H(2)  p to CH(CH3)), 3.04-2.95 (1 H, m, 
CH(1)H(2) p to CH(CH3)), 2.85-2.73 (1 H, m, CH(1)H(2) m to CH(CH3)), 2.69-2.60 (1 H, 
m, CH(1)H(2) m to CH(CH3)), 1.73 (1 H, br s, NH) and 1.44 (3 H, d, J 6.6, CH3); δC (101 
MHz, CDCl3)  147.30 (C), 147.22 (C), 132.52 (C), 126.85 (C), 111.77 (CH), 109.04 
(CH), 56.00 (1 x CH3O), 55.86 (1 x CH3O), 51.25 (CH), 41.89 (CH2), 29.61 (CH2) and 
22.90 (CH3). The data matched that previously reported for this compound. 
4.3     Procedures from Section 2.3. 
Synthesis of 2-((tert-butyldiphenylsilyl)oxy)ethanol (230a).  
 
This is a known compound and has been fully characterised.
26c
 
 tert-Butyl-chlorodiphenylsilane (2.29 g, 2.17 cm
3
, 8.33 mmol) was added to a stirred 
solution of ethane-1,2-diol (3.10 g, 2.79 cm
3
, 50.00 mmol) and imidazole (0.63 g, 9.18 
mmol) in THF (43 cm
3
) under argon atmosphere. The resulting mixture was stirred for 
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24 hrs at rt and quenched with water (43 cm
3
) followed by the addition of Et2O (43 
cm
3
). After phase separation and extraction of the aqueous phase with Et2O (3 x 43 
cm
3
), the combined organic phases were dried (MgSO4), filtered, concentrated and 
purified by flash chromatography (10→20 % v/v ethyl acetate/pentane)  to afford the 
monosilyl alcohol 230a as a colourless oil (1.1 g, 3.66 mmol, 44 %); δH (400 MHz, 
CDCl3) 7.74-7.64 (4 H, m, 4 x Ar-H), 7.48-7.35 (6 H, m, 6 x Ar-H), 3.80-3.74 (2 H, m, 
SiOCH2), 3.72-3.65 (2 H, m, CH2OH), 2.16 (1 H, t, J 6.2, OH) and 1.07 (9 H, s, 3 x 
CH3); δC (101 MHz, CDCl3) 135.57 (4 x CH), 133.32 (2 x C), 129.84 (2 x CH), 127.81 
(4 x CH), 65.03 (CH2), 63.75 (CH2), 26.88 (3 x CH3) and 19.26 ((CH3)3C). The data 
matched that previously reported for this compound. 
Synthesis of 2-((tert-butyldiphenylsilyl)oxy)acetaldehyde (231a).  
 
This is a known compound and has been fully characterised.
26c
 
A solution of oxalylchloride (2M in DCM, 2.4 cm
3
, 4.75 mmol) in anhydrous DCM (5 
cm
3
) was cooled to -78 °C, and was slowly added to a solution of dimethylsulfoxide 
(0.74 g, 0.68 cm
3
, 9.52 mmol) in DCM (2.5 cm
3
) by syringe. The solution was stirred 
for 30 minutes at -78 °C before a solution of 2-((tert-butyldiphenylsilyl)oxy)ethanol 
230a (1.10 g, 3.66 mmol) in DCM (8 cm
3
) was slowly added at the same temperature. 
After stirring for 40 min at -78 °C, Et3N (2.24 g, 3.1 cm
3
, 21.94 mmol) was added and 
the reaction mixture was allowed to warm up to rt. After 30 mins, water (16 cm
3
) was 
added, and extracted with DCM, dried (MgSO4), filtered and then concentrated under 
vacuum to give the product as a orange oil 231a (1.09 g, 3.66 mmol, >99 % quantitative 
conversion, includes traces of solvent); δH (400 MHz, CDCl3) 9.72 (1 H, s, CHO), 7.68-
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7.64 (4 H, m, 4 x Ar-H), 7.48-7.37 (6 H, m, 6 x Ar-H), 4.22 (2 H, s, CH2) and 1.10 (9 H, 
s, 3 x CH3); δC (101 MHz, CDCl3) 201.73 (CH=O), 135.52 (4 x CH), 132.49 (2 x C), 
130.08 (2 x CH), 127.94 (4 x CH), 70.00 (CH2), 26.71 (3 x CH3) and 19.27 ((CH3)3C). 
The data matched that previously reported for this compound. 
Synthesis of (2S,4R,5R)-2-(((tert-butyldiphenylsilyl)oxy)methyl)-4,5-diphenyl-1-
tosylimidazolidine (232a).  
 
This is a known compound and has been fully characterised.
29a
 
To a stirred solution of (R, R)-TsDPEN 81 (1.11 g, 3.04 mmol) and molecular sieves (4 
Å, 2.1 g) in dry methanol (24 cm
3
) was added a solution of 2-((tert-
butyldiphenylsilyl)oxy)acetaldehyde 231a (1.09 g, 3.66 mmol) in methanol (10 cm
3
) 
followed by the addition of glacial acetic acid (0.21 cm
3
). The reaction was stirred for 4 
hrs during which time a white precipitate formed. The precipitate (molecular sieves and 
the product) was filtered off and washed with cold methanol. The remaining solid was 
washed thoroughly with DCM to separate the product from molecular sieves, and was 
then concentrated in vacuo. 232a was obtained as a white solid (690 mg, 1.07 mmol, 35 
%); δH (400 MHz, CDCl3) 7.72 (4 H, td, J 8.2, 1.3, 4 x Ar-H), 7.51 (2 H, d, J 8.2, 2 x 
Ar-H), 7.48-7.34 (6 H, m, 6 x Ar-H), 7.29-7.12 (10 H, m, 10 x Ar-H), 6.90 (2 H, d, J 
7.0, 2 x Ar-H), 4.91 (1 H, dd, J 6.1, 3.2, TsNCHNH), 4.48 (1 H, d, J 6.1,  CHNTs), 4.17 
(1 H, d, J 6.1, CH(1)H(2)OSi),  4.15 (1 H, d, J 6.1, CHNH), 4.07 (1 H, dd, J 10.7, 3.2, 
CH(1)H(2)OSi), 2.81 (1 H, br s, NH), 2.40 (3 H, s, CH3Ts) and 1.09 (9 H, s, 3 x CH3); δC 
(101 MHz, CDCl3) 143.63 (C), 139.81 (C), 138.76 (C), 135.74 (2 x CH), 135.70 (2 x 
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CH), 134.00 (C), 133.08 (C), 133.04 (C), 129.87 (2 x CH), 129.52 (2 x CH), 128.46 (2 x 
CH), 128.33 (2 x CH), 127.86 (4 x CH), 127.82 (2 x CH), 127.57 (CH), 127.48 (CH), 
126.89 (2 x CH), 126.75 (2 x CH), 77.30 (CH), 71.06 (CH), 69.07 (CH), 65.03 (CH2), 
26.97 (3 x CH3), 21.56 (CH3) and 19.29 (C). The data matched that previously reported 
for this compound. 
Synthesis of N-((1R,2R)-2-((2-hydroxyethyl)amino)-1,2-diphenylethyl)-4-
methylbenzenesulfonamide (233).  
 
This is a known compound and has been fully characterised.
 29a
  
(2S,4R,5R)-2-(((tert-Butyldiphenylsilyl)oxy)methyl)-4,5-diphenyl-1-tosylimidazolidine 
232a (3.24 g, 5 mmol) in THF (7 cm
3
) was added dropwise to a solution of LiAlH4 
(0.60 g, 15 mmol) in THF (31 cm
3
) stirring at 0 °C. After addition, the solution was 
allowed to stir at rt over the weekend. The solution was then cooled to 0 °C and 
quenched with a 50 : 50 mixture of water and THF (6 cm
3
: 6 cm
3
), followed by water (6 
cm
3
). Rochelle salt (4.91 g, 17.40 mmol) was then added followed by DCM (9 cm
3
) and 
was further allowed to stir for 3 hrs. The remaining solution was then filtered off 
through celite, dried (MgSO4), filtered and concentrated to give the alcohol as a white 
solid 233 (1.58 g, 3.85 mmol, 77 %); δH (400 MHz, CDCl3) 7.39 (2 H, d, J 8.2, 2 x Ar-
H), 7.16-7.10 (3 H, m, 3 x Ar-H), 7.06-6.92 (7 H, m, 7 x Ar-H), 6.88-6.84 (2 H, m, 2 x 
Ar-H), 4.36 (1 H, d, J 8.2, CHTs), 3.73 (1 H, d, J 8.2, CHNH), 3.71-3.63 (1 H, m, 
CH(1)H(2)OH), 3.63-3.55 (1 H, m, CH(1)H(2)OH), 2.62-2.47 (2 H, m, CH2NH) and 2.32 
(3 H, s, CH3); δC (101 MHz, CDCl3) 142.83 (C), 139.00 (C), 137.96 (C), 137.05 (C), 
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129.12 (2 x CH), 128.35 (2 x CH), 127.91 (2 x CH), 127.63 (2 x CH), 127.58 (CH), 
127.55 (2 x CH), 127.26 (CH), 127.10 (2 x CH), 67.80 (CH), 63.32 (CH), 61.74 (CH2), 
49.03 (CH2) and 21.45 (CH3). The data matched that previously reported for this 
compound. 
Synthesis of 2-(((1R,2R)-2-(4-methylphenylsulfonamido)-1,2-
diphenylethyl)amino)ethyl 4-methylcyclohexa-1,4-dienecarboxylate (240).  
 
This compound is novel. 
4-Methylcyclohexa-1,4-diene carboxylic acid (18 mg, 0.13 mmol) was added to a 
solution of N-((1R,2R)-2-((2-hydroxyethyl)amino)-1,2-diphenylethyl)-4-
methylbenzenesulfonamide 233 (53 mg, 0.13 mmol) in DCM (2 cm
3
) at rt, followed by 
addition of DCC (165 mg, 0.80 mmol) and DMAP (16 mg, 0.13 mmol). The resulting 
mixture was stirred overnight and the concentrated under reduced pressure. The crude 
white residue was then purified by flash chromatography (10→30 % v/v ethyl 
acetate/hexane) giving 240 as a colourless gum (58 mg, 0.11 mmol, 84 %); [α]D
22
 -10.4 
(c 0.5, CHCl3); νmax 3663, 3259, 2902, 1712, 1690, 1651, 1600, 1495, 1454, 1395, 1327, 
1304, 1252, 1185, 1157, 1092, 1048, 960, 920, 812, 756, 719, 699 and 668 cm
-1; δH 
(400 MHz, CDCl3) 7.38 (2 H, d, J 8.3, 2 x Ar-H), 7.16-7.10 (3 H, m, 3 x Ar-H), 7.09-
7.03 (3 H, m, 3 x Ar-H), 7.02-6.94 (6 H, m, 6 x Ar-H), 6.90-6.85 (1 H, m, CH=C(CO2)), 
6.04 (1 H, d, J 3.3, NHTs), 5.50-5.45 (1 H, m, CH=C(CH3)), 4.30 (1 H, dd, J 7.3, 3.3, 
CHNHTs), 4.25-4.17 (1 H, m, CH(1)H(2)OC=O), 4.09-4.02 (1 H, m, CH(1)H(2)OC=O), 
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3.74 (1 H, d, J 7.3, CHNH), 2.87-2.75 (4 H, m, CH2C=CCH2), 2.75-2.67 (1 H, m, 
CH(1)H(2)NH), 2.62-2.53 (1 H, m, CH(1)H(2)NH), 2.32 (3 H, s, CH3Ts) and 1.72 (3 H, s, 
CH3); δC (101 MHz, CDCl3) 166.85 (C=O), 142.67 (C), 138.78 (2 x C), 138.36 (2 x C), 
137.03 (CH), 129.39 (C), 129.10 (2 x CH), 128.42 (2 x CH), 128.04 (2 x CH), 127.64 
(CH), 127.44 (2 x CH), 127.35 (3 x CH), 127.03 (2 x CH), 118.55 (CH), 67.14 (CH), 
63.13 (CH2), 63.07 (CH), 45.66 (CH2), 31.89 (CH2), 26.07 (CH2), 22.83 (CH3) and 
21.42 (CH3); m/z (ESI-MS) 531.1 [M+H]
+
, 553.1 [M+Na]
+
. Found (ESI-HR-MS): 
531.2330 [M+H]
+
, C31H35N2O4S requires 531.2312 (-3.2 ppm error). 
Synthesis of 2-(((1R,2R)-2-(4-methylphenylsulfonamido)-1,2-
diphenylethyl)amino)ethyl 4-methylbenzoate (241).  
 
This compound is novel. 
p-Toluic acid (18 mg, 0.13 mmol) was added to a solution of N-((1R, 2R)-2-((2-
hydroxyethyl)amino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 233 (53 mg, 
0.13 mmol) in DCM (2 cm
3
) at rt, followed by addition of DCC (165 mg, 0.80 mmol) 
and DMAP (16 mg, 0.13 mmol). The resulting mixture was stirred overnight and then 
concentrated under reduced pressure. The crude white residue was then purified by flash 
chromatography (10→30 % v/v ethyl acetate/hexane) giving 241 as white crystals (58 
mg, 0.11 mmol, 84 %); Mp 61-64 °C; [α]D
23
 -17.6 (c 0.5, CHCl3); νmax 3266, 3031, 
1712, 1611, 1495, 1453, 1406, 1327, 1271, 1178, 1156, 1093, 1020, 917, 841, 812, 753, 
698 and 666 cm
-1; δH (400 MHz, CDCl3) 7.83 (2 H, d, J 8.1, 2 x Ar-H), 7.33 (2 H, d, J 
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8.1, 2 x Ar-H), 7.25 (2 H, d, J 7.7, 2 x Ar-H), 7.18-7.09 (3 H, m, 3 x Ar-H), 7.08-7.01 (3 
H, m, 3 x Ar-H), 6.98 (6 H, d, J 7.7, 6 x Ar-H), 6.07 (1 H, br s, NHTs), 4.40-4.28 (1 H, 
m, CH(1)H(2)OC=O), 4.31 (1 H, d, J 7.3, CHNHTs), 4.26-4.17 (1 H, m, 
CH(1)H(2)OC=O), 3.77 (1 H, d, J 7.3, CHNH), 2.84-2.75 (1 H, m, CH(1)H(2)NH), 2.71-
2.62 (1 H, m, CH(1)H(2)NH), 2.44 (3 H, s, CH3Ts), 2.30 (3 H, s, CH3) and 1.76 (1 H, br 
s, NH); δC (101 MHz, CDCl3)  166.53 (C=O), 143.79 (C), 142.68 (C), 138.80 (C), 
138.37 (C), 137.01 (C), 129.69 (2 x CH), 129.15 (2 x CH), 129.11 (2 x CH), 128.43 (2 x 
CH), 128.06 (2 x CH), 127.66 (CH), 127.46 (2 x CH), 127.35 (3 x CH), 127.20 (C), 
127.04 (2 x CH), 67.29 (CH), 63.72 (CH2), 63.11 (CH), 45.73 (CH2), 21.72 (CH3) and 
21.41 (CH3); m/z (ESI-MS) 529.1 [M+H]
+
, 551.2 [M+Na]
+
. Found (ESI-HR-MS): 
529.2159 [M+H]
+
, C31H33N2O4S requires 529.2156 (-0.6 ppm error).  
Synthesis of bis(2-(((1R,2R)-2-(4-methylphenylsulfonamido)-1,2-
diphenylethyl)amino)ethyl) terephthalate (242).  
 
This compound is novel. 
Terephthalic acid (11 mg, 0.065 mmol) was added to a solution of N-((1R, 2R)-2-((2-
hydroxyethyl)amino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 233 (53 mg, 
0.13 mmol) in DCM (2 cm
3
) at rt, followed by addition of EDC (150 mg, 0.80 mmol) 
and DMAP (16 mg, 0.13 mmol). The resulting mixture was stirred overnight and then 
water (2 cm
3
) was added. The organic phase was separated from the aqueous, and then 
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DCM (2 x 2 cm
3
) was further added to extract the remaining product from the aqueous 
layer. The organic layers were then combined, dried (MgSO4), filtered and concentrated 
under reduced pressure giving the crude product, which was then purified by flash 
chromatography (10→30 % v/v ethyl acetate/hexane)  giving 242 as white crystals 
(14.5 mg, 0.02 mmol, 24 %); Mp 80-83 °C; [α]D
22
 -54.4 (c 0.25, CHCl3); νmax 3272, 
1716, 1599, 1495, 1454, 1408, 1325, 1267, 1155, 1092, 1018, 918, 876, 812, 767, 731, 
698 and 667 cm
-1; δH (400 MHz, CDCl3) 8.10 (4 H, s, 4 x CO2Ar-H), 7.36 (4 H, d, J 8.2, 
4 x Ar-H), 7.21-7.06 (6 H, m, 6 x Ar-H), 7.05-6.91 (14 H, m, 14 x Ar-H), 6.91-6.84 (4 
H, m, 4 x Ar-H), 6.20 (2 H, br s, 2 x NHTs), 4.51-4.28 (2 H, m, 2 x CH(1)H(2)OC=O), 
4.35-4.21 (4 H, m, 2 x CH(1)H(2)OC=O + CHNHTs), 3.81 (2 H, d, J 7.9, 2 x CHNH), 
2.86-2.76 (2 H, m, 2 x CH(1)H(2)NH), 2.76-2.66 (2 H, m, 2 x CH(1)H(2)NH) and 2.29 (6 
H, s, 2 x CH3Ts); δC (101 MHz, CDCl3) 165.61 (2 x C), 142.83 (2 x C), 138.76 (2 x C), 
138.26 (2 x C), 136.96 (2 x C), 133.90 (2 x C), 129.77 (4 x CH), 129.14 (5 x CH), 
128.38 (4 x CH), 128.01 (4 x CH), 127.63 (5 x CH), 127.30 (6 x CH), 127.09 (4 x CH), 
67.44 (2 x CH), 64.24 (2 x CH2), 63.52 (2 x CH), 45.74 (2 x CH2) and 21.42 (2 x CH3);  
m/z (ESI-MS) 951.1 [M+H]
+
, 973.1 [M+Na]
+
. Found (ESI-HR-MS): 476.1755 
[M+2H]
2+
, C54H56N4O8S2 requires 476.1764 (2.6 ppm error).  
Synthesis of 3-((tert-butyldiphenylsilyl)oxy)propan-1-ol (230b).  
 
This is a known compound and has been fully characterised.
33g
 
To a solution of 1,3-propanediol (0.85 g, 0.80 cm
3
, 11.1 mmol) and imidazole (1.0 g, 
14.45 mmol) in dry DCM (35 cm
3
) was added tert-butyl-chlorodiphenylsilane (6.1 g, 
5.8 cm
3
, 22.2 mmol) dropwise under a nitrogen atmosphere at rt followed by stirring at 
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the same temperature for 4 hrs. The reaction mixture was then concentrated under 
reduced pressure and the residue was then purified by flash chromatography (1→9 % 
v/v ethyl acetate/pet ether) to give 230b as a colourless oil (1.54 g, 4.90 mmol, 44 %); 
νmax 3349, 3072, 2931, 2858, 1712, 1590, 1472, 1428, 1390, 1361, 1264, 1189, 1106, 
1083, 1008, 998, 965, 822, 735, 688 and 700  cm
-1; δH (400 MHz, CDCl3) 7.68 (4 H, dd, 
J 7.6, 1.3, 4 x Ar-H), 7.47-7.33 (6 H, m, 6 x Ar-H), 3.93-3.77 (4 H, m, CH2CH2CH2OH 
+ CH2CH2CH2OH), 2.70 (1 H, br s, OH), 1.81 (2 H, quin, J 5.3, CH2CH2CH2OH) and 
1.06 (9 H, s, 3 x CH3); δC (101 MHz, CDCl3) 135.59 (4 x CH), 133.29 (2 x C), 129.82 
(2 x CH), 127.79 (4 x CH), 63.28 (CH2), 61.94 (CH2), 34.31 (CH2), 26.86 (3 x CH3) and 
19.11 ((CH3)3C); m/z (ESI-MS) 337.1 [M+Na]
+
. Found (ESI-HR-MS): 337.1587 
[M+Na]
+
, C19H26NaO2Si requires 337.1594 (2.0 ppm error). The data matched that 
previously reported for this compound. 
Synthesis of 3-((tert-butyldiphenylsilyl)oxy)propanal (231b).  
 
This is a known compound and has been fully characterised.
33g
 
The solution of oxalylchloride (2M in DCM, 3.2 cm
3
, 6.37 mmol) in anhydrous DCM 
(6.8 cm
3
) was cooled to -78 °C, and was slowly added a solution of dimethylsulfoxide 
(1.0 g, 0.90 cm
3
, 12.74 mmol) in DCM (3.4 cm
3
) by syringe. The solution was stirred 
for 30 minutes at -78 °C before a solution of 3-((tert-butyldiphenylsilyl)oxy)propan-1-ol 
230b (1.54 g, 4.90 mmol) in DCM (10.6 cm
3
) was slowly added at the same 
temperature. After stirring for 40 min at -78 °C, Et3N (3.0 g, 4.13 cm
3
, 29.4 mmol) was 
added and the reaction mixture was allowed to warm up to rt. After 30 mins, water (21.2 
cm
3
) was added, and extracted with DCM, dried (MgSO4), filtered and then 
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concentrated under vacuum to give the product as a orange oil 231b (1.53 g, 4.90 mmol, 
>99 % quantitative conversion, includes traces of solvent); νmax 3072, 2932, 2858, 1726, 
1589, 1473, 1428, 1390, 1362, 1266, 1212, 1106, 1008, 998, 971, 875, 823, 737 and 
701 cm
-1; δH (400 MHz, CDCl3) 9.81 (1 H, t, J 2.1, CHO), 7.66 (4 H, dd, J 7.8, 1.5, 4 x 
Ar-H), 7.46-7.34 (6 H, m, 6 x Ar-H), 4.01 (2 H, t, J 6.0, SiOCH2), 2.60 (2 H, td, J 6.0, 
2.1, CH2CHO) and 1.04 (9 H, s, 3 x CH3); δC (101 MHz, CDCl3) 201.91 (CH=O), 
135.56 (4 x CH), 133.27 (2 x C), 129.84 (2 x CH), 127.80 (4 x CH), 58.31 (CH2), 46.40 
(CH2), 26.77 (3 x CH3) and ((CH3)3C); m/z (ESI-MS) 335.1 [M+Na]
+
. Found (ESI-HR-
MS): 367.1707 [M+MeOH+Na]
+
, C20H28NaO3Si requires 367.1700 (-2.0 ppm error). 
The data matched that previously reported for this compound.  
Synthesis of (2S,4R,5R)-2-(2-((tert-butyldiphenylsilyl)oxy)ethyl)-4,5-diphenyl-1-
tosylimidazolidine (232b).  
 
This compound is novel. 
To a suspension of powdered molecular sieves (4 Å, 1.2 g) in dry methanol (70 cm
3
) 
was added 3-((tert-butyldiphenylsilyl)oxy)propanal 231b (1.53 g, 4.90 mmol),  (1R, 
2R)-TsDPEN (2.0 g, 5.44 mmol) and glacial acetic acid (14 drops). The reaction 
mixture was stirred at rt and monitored by TLC. After 2 hrs, the imine had formed, and 
sodium cyanoborohydride (0.92 g, 14.70 mmol) was added. The reaction was left to stir 
overnight at rt. Molecular sieves were removed by filtration, and the solution was 
concentrated under reduced pressure. The residue was re-dissolved in DCM (90 cm
3
). 
The organic phase was washed with saturated NaHCO3 (90 cm
3
) and brine (90 cm
3
), 
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dried (MgSO4), filtered and concentrated under reduced pressure to give 232b as a 
white solid (1.12 g, 1.70 mmol, 35 %); Mp 64-67 °C; [α]D
22
 -64 (c 0.5, CHCl3); νmax 
3322, 3030, 2930, 2856, 1600, 1495, 1472, 1450, 1428, 1349, 1305, 1258, 1163, 1091, 
1028, 949, 821, 736, 698 and 664 cm
-1; δH (400 MHz, CDCl3) 7.72-7.66 (4 H, m, 4 x 
Ar-H), 7.60 (2 H, d, J 8.2, 2 x Ar-H), 7.46-7.33 (6 H, m, 6 x Ar-H), 7.31-7.12 (10 H, m, 
10 x Ar-H), 6.94 (2 H, d, J 6.6, 2 x Ar-H), 5.18 (1 H, d, J 7.2, NTsCHNH), 4.62 (1 H, d, 
J 6.3, CHNTs), 4.21 (1 H, br s, CHNH), 4.02-3.93 (1 H, m, CH(1)H(2)OSi), 3.92-3.84 (1 
H, m, CH(1)H(2)OSi), 2.54 (1 H, br s, NH), 2.49-2.37 (1 H, m, CHCH(1)H(2)), 2.40 (3 H, 
s, CH3Ts), 2.09-1.98 (1 H, m, CHCH(1)H(2)) and 1.06 (9 H, s, 3 x CH3); δC (101 MHz, 
CDCl3) 143.57 (C), 140.41 (C), 138.45 (C), 135.65 (2 x CH), 135.61 (2 x CH), 134.52 
(C), 133.63 (C), 133.58 (C), 129.71 (CH), 129.69 (CH), 129.59 (2 x CH), 128.59 (2 x 
CH), 128.45 (2 x CH), 127.79 (2 x CH), 127.72 (4 x CH), 127.64 (CH), 127.43 (CH), 
126.84 (2 x CH), 126.49 (2 x CH), 76.22 (CH), 71.05 (CH), 69.90 (CH), 60.98 (CH2), 
38.63 (CH2), 26.88 (3 x CH3), 21.55 (CH3) and 19.21 ((CH3)3C); m/z (ESI-MS) 661.2 
[M+H]
+
, 683.2 [M+Na]
+
. Found (ESI-HR-MS): 661.2920 [M+H]
+
, C40H45N2O3SSi 
requires 661.2915 (0.1 ppm error). 
Synthesis of N-((1R,2R)-2-((3-hydroxypropyl)amino)-1,2-diphenylethyl)-4-
methylbenzenesulfonamide (234).  
 
This compound is novel.  
(2S,4R,5R)-2-(2-((tert-Butyldiphenylsilyl)oxy)ethyl)-4,5-diphenyl-1-tosylimidazolidine 
232b (143 mg, 0.22 mmol) in THF (0.32 cm
3
) was added dropwise to a solution of 
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LiAlH4 (25 mg, 122.52 mmol) in THF (1.4 cm
3
) with stirring at 0 °C. After addition, the 
solution was allowed to stir at rt over the weekend. The solution was then cooled to 0 
°C and quenched with a 50 : 50 mixture of water and THF (0.32 cm
3
: 0.32 cm
3
), 
followed by water (0.32 cm
3
). Rochelle salt (216 g, 0.77 mmol) was then added 
followed by DCM (0.40 cm
3
) and was further allowed to stir for 3 hrs. The remaining 
solution was then filtered off through celite, dried (MgSO4), filtered and concentrated to 
give the crude product, which was then purified by flash chromatography (10→30 % 
v/v ethyl acetate/pet ether) to give 234 as a white solid (22 mg, 0.05 mmol, 24 %); Mp 
110-113 °C; [α]D
27
 -12.8 (c 0.25, CHCl3); νmax 3274, 3029, 2922, 1599, 1495, 1454, 
1321, 1184, 1153, 1091, 1052, 922, 845, 812, 758, 698 and 667 cm
-1; δH (400 MHz, 
CDCl3) 7.40 (2 H, d, J 8.3, 2 x Ar-H), 7.16-7.11 (3 H, m, 3 x Ar-H), 7.05-6.92 (7 H, m, 
7 x Ar-H), 6.84 (2 H, dd, J 8.0, 1.2, 2 x Ar-H), 4.35 (1 H, d, J 8.0, CHNHTs), 3.74 (1 H, 
d, J 8.0, CHNH), 3.73-3.64 (2 H, m, CH2OH), 2.58-2.52 (2 H, m, CH2NH), 2.31 (3 H, s, 
CH3Ts) and 1.76-1.56 (2 H, m, CH2CH2OH); δC (101 MHz, CDCl3) 142.80 (C), 138.56 
(C), 137.91 (C), 137.11 (C), 129.14 (2 x CH), 128.37 (2 x CH), 127.94 (2 x CH), 127.75 
(2 x CH), 127.65 (CH), 127.49 (2 x CH), 127.30 (CH), 127.09 (2 x CH), 67.94 (CH), 
63.05 (CH), 62.34 (CH2), 45.70 (CH2), 31.72 (CH2) and 21.42 (CH3); m/z (ESI-MS) 
425.1 [M+H]
+
. Found (ESI-HR-MS): 425.1895 [M+H]
+
, C24H29N2O3S requires 
425.1893 (-0.3 ppm error). 
Synthesis of 4-((tert-butyldiphenylsilyl)oxy)butan-1-ol (230c).  
 
This is a known compound and has been fully characterised.
28j
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To a solution of 1,4-butanediol (1.0 g, 1.0 cm
3
, 11.1 mmol) and imidazole (1.0 g, 14.45 
mmol) in dry DCM (35 cm
3
) was added tert-butyl-chlorodiphenylsilane (6.1 g, 5.8 cm
3
, 
22.2 mmol) dropwise under a nitrogen atmosphere at rt followed by stirring at the same 
temperature for 4 hrs. The reaction mixture was then concentrated under reduced 
pressure and the residue was then purified by flash chromatography (1→9 % v/v ethyl 
acetate/pet ether) to give 230c as a colourless oil (1.1 g, 3.35 mmol, 30 %); νmax 3349, 
3072, 2932, 2858, 1712, 1590, 1472, 1428, 1389, 1361, 1265, 1188, 1107, 998, 940, 
861, 822, 793, 739, 700 and 688 cm
-1; δH (400 MHz, CDCl3) 7.67 (4 H, dd, J 7.7, 1.4, 4 
x Ar-H), 7.46-7.33 (6 H, m, 6 x Ar-H), 3.70 (2 H, t, J 5.9, SiOCH2), 3.66 (2 H, t, J 5.9, 
CH2OH), 2.4 (1 H, br s, OH), 1.75-1.60 (4 H, m, CH2CH2CH2OH) and 1.05 (9 H, s, 3 x 
CH3); δC (101 MHz, CDCl3) 135.60 (4 x CH), 133.67 (2 x C), 129.68 (2 x CH), 127.70 
(4 x CH), 64.05 (CH2), 62.85 (CH2), 29.86 (CH2), 29.30 (CH2), 26.86 (3 x CH3) and 
19.20 ((CH3)3C); m/z (ESI-MS) 351.2 [M+Na]
+
. Found (ESI-HR-MS): 351.1745 
[M+Na]
+
, C20H28NaO2Si requires 351.1751 (1.4 ppm error). The data matched that 
previously reported for this compound. 
Synthesis of 4-((tert-butyldiphenylsilyl)oxy)butanal (231c).  
 
This is a known compound and has been fully characterised.
28j
 
A solution of oxalylchloride (2M in DCM, 2.18 cm
3
, 4.36 mmol) in anhydrous DCM 
(4.6 cm
3
) was cooled to -78 °C, and was slowly added a solution of dimethylsulfoxide 
(0.68 g, 0.62 cm
3
, 8.71 mmol) in DCM (2.3 cm
3
) by syringe. The solution was stirred 
for 30 minutes at -78 °C before a solution of 4-((tert-butyldiphenylsilyl)oxy)butan-1-ol 
230c (1.1 g, 3.35 mmol) in DCM (7.3 cm
3
) was slowly added at the same temperature. 
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After stirring for 40 min at -78 °C, Et3N (2.1 g, 2.82 cm
3
, 20.1 mmol) was added and 
the reaction mixture was allowed to warm up to rt. After 30 mins, water (14.5 cm
3
) was 
added, and the mixture was extracted with DCM, dried (MgSO4), filtered and then 
concentrated under vacuum to give the product as a orange oil 231c (1.1 g, 3.37 mmol, 
>99 % quantitative conversion, includes traces of solvent); νmax 3072, 2932, 2858, 1724, 
1472, 1428, 1390, 1110, 1008, 822, 737 and 701 cm
-1; δH (400 MHz, CDCl3) 9.79 (1 H, 
t, J 1.5, CHO), 7.64 (4 H, dd, J 7.8, 1.5, 4 x Ar-H), 7.46-7.35 (6 H, m, 6 x Ar-H), 3.69 
(2 H, t, J 6.0, SiOCH2), 2.55 (2 H, td, J 7.2, 1.6, CH2CHO), 1.89 (2 H, quin, J 6.0, 
CH2CH2CHO) and 1.04 (9 H, s, 3 x CH3); δC (101 MHz, CDCl3) 202.57 (CHO), 135.56 
(4 x CH), 133.61 (2 x C), 129.70 (2 x CH), 127.71 (4 x CH), 62.93 (CH2), 40.78 (CH2), 
26.84 (3 x CH3), 25.27 (CH2) and 19.20 ((CH3)3C); m/z (ESI-MS) 349.1 [M+Na]
+
. 
Found (ESI-HR-MS): 327.1781 [M+H]
+
, C20H27O2Si requires 327.1775 (-1.7 ppm 
error). The data matched that previously reported for this compound. 
(2S,4R,5R)-2-(3-((tert-butyldiphenylsilyl)oxy)propyl)-4,5-diphenyl-1-
tosylimidazolidine (232c).  
 
This compound is novel. 
To a stirred solution of (R,R)-TsDPEN 81 (117 mg, 0.32 mmol) and molecular sieves (4 
Å, 221 g) in dry methanol (2.5 cm
3
) was added a solution of 4-((tert-
butyldiphenylsilyl)oxy)butanal 231c (125 mg, 0.38 mmol) in methanol (1.0 cm
3
) 
followed by the addition of glacial acetic acid (0.022 cm
3
). The reaction was stirred for 
4 hrs during which time a white precipitate formed. The precipitate (molecular sieves 
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and the product) was filtered off and washed with cold methanol. The remaining solid 
was washed thoroughly with DCM to separate the product from molecular sieves, and 
was then concentrated in vacuo. Aminal 232c was obtained as a white solid (78 mg, 
0.12 mmol, 36 %); Mp 45-47 °C; [α]D
25
 -45.6 (c 0.5, CHCl3); νmax 3069, 2930, 2857, 
1600, 1495, 1472, 1449, 1428, 1349, 1304, 1163, 1091, 1029, 867, 821, 758, 741, 698 
and 664 cm
-1; δH (400 MHz, CDCl3) 7.71-7.65 (4 H, m, 4 x Ar-H), 7.60 (2 H, d, J 8.2, 2 
x Ar-H), 7.46-7.32 (6 H, m, 6 x Ar-H), 7.27-7.14 (10 H, m, 10 x Ar-H), 6.88 (2 H, d, J 
6.7, 2 x Ar-H), 5.01 (1 H, dd, J 8.5, 5.2, NTsCHNH), 4.59 (1 H, d, J 6.8, CHNTs), 4.22 
(1 H, d, J 6.8, CHNH), 3.77 (2 H, t, J 6.1, CH2OSi), 2.40 (3 H, s, CH3Ts), 2.31-2.13 (2 
H, m, CH(1)H(2)CH2OSi + NH), 2.02-1.88 (1 H, m, CH(1)H(2)CH2OSi), 1.87-1.76 (2 H, 
m, CHCH2) and 1.06 (9 H, s, 3 x CH3); δC (101 MHz, CDCl3) 143.62 (C), 140.10 (C), 
138.15 (C), 135.63 (3 x CH), 135.03 (C), 133.99 (C), 133.93 (C), 129.64 (2 x CH), 
129.59 (CH), 128.71 (2 x CH), 128.43 (2 x CH), 127.88 (CH), 127.76 (2 x CH), 127.68 
(3 x CH), 127.67 (3 x CH), 127.40 (CH), 126.90 (2 x CH), 126.45 (2 x CH), 78.75 
(CH), 70.81 (CH), 70.48 (CH), 63.48 (CH2), 33.20 (CH2), 29.22 (CH2), 26.92 (3 x 
CH3), 21.55 (CH3) and 19.27 ((CH3)3C); m/z (ESI-MS) 675.2 [M+H]
+
, 697.2 [M+Na]
+
. 
Found (ESI-HR-MS): 675.3082 [M+H]
+
, C41H47N2O3SSi requires 675.3071 (-1.5 ppm 
error). 
Synthesis of N-((1R,2R)-2-((4-((tert-butyldiphenylsilyl)oxy)butyl)amino)-1,2-
diphenylethyl)-4-methylbenzenesulfonamide (235).  
 
Experimental 
 
225 
 
This compound is novel. 
To a suspension of powdered molecular sieves (4 Å, 0.8 g) in dry methanol (48 cm
3
) 
was added 4-((tert-butyldiphenylsilyl)oxy)butanal 231c (1.1 g, 3.35 mmol),  (1R,2R)-
TsDPEN 81 (1.36 g, 3.72 mmol) and glacial acetic acid (10 drops). The reaction 
mixture was stirred at rt and monitored by TLC. After 2 hrs, the imine had formed, and 
sodium cyanoborohydride (0.63 g, 10.05 mmol) was added. The reaction was left to stir 
overnight at rt. Molecular sieves were removed by filtration, and the solution was 
concentrated under reduced pressure. The residue was re-dissolved in DCM (64 cm
3
). 
The organic phase was washed with saturated NaHCO3 (64 cm
3
) and brine (64 cm
3
), 
dried (MgSO4), filtered and concentrated under reduced pressure to give the crude 
product, which after purification by flash chromatography (10→30 % v/v ethyl 
acetate/pet ether) gave 235 as a colourless gum (0.9 g, 1.33 mmol, 40 %); [α]D
23
 -8.8 (c 
0.5, CHCl3); νmax 3262, 3030, 2930, 2857, 1737, 1600, 1495, 1472, 1455, 1428, 1390, 
1328, 1185, 1154, 1108, 1091, 1027, 998, 927, 812, 771, 740, 698 and 667 cm
-1
; δH 
(400 MHz, CDCl3) 7.63 (4 H, d, J 7.5, 4 x Ar-H), 7.47-7.33 (8 H, m, 8 x Ar-H), 7.18-
6.98 (8 H, m, 8 x Ar-H), 6.94 (2 H, d, J 7.5, 2 x Ar-H), 6.91-6.85 (2 H, m, 2 x Ar-H), 
6.30 (1 H, br s, NHTs), 4.23 (1 H, d, J 7.9, CHNHTs), 3.64-3.54 (3 H, m, CHNH + 
CH2OSi), 2.42-2.34 (1 H, m, CH(1)H(2)NH), 2.32 (3 H, s, CH3Ts), 2.30-2.22 (1 H, m, 
CH(1)H(2)NH), 1.54-1.38 (4 H, m, CH2CH2CH2OSi) and 1.03 (9 H, s, 3 x CH3); δC (101 
MHz, CDCl3) 142.67 (C), 139.35 (C), 138.40 (C), 137.10 (C), 135.57 (4 x CH), 133.99 
(2 x C), 129.58 (2 x CH), 129.08 (2 x CH), 128.32 (2 x CH), 127.91 (2 x CH), 127.64 (4 
x CH), 127.59 (2 x CH), 127.45 (CH), 127.38 (2 x CH), 127.26 (CH), 127.15 (2 x CH), 
67.79 (CH), 63.61 (CH2), 63.06 (CH), 47.00 (CH2), 30.11 (CH2), 26.90 (3 x CH3), 26.45 
(CH2), 21.45 (CH3) and 19.23 ((CH3)3C); m/z (ESI-MS) 677.2 [M+H]
+
, 699.2 [M+Na]
+
. 
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Found (ESI-HR-MS): 677.3231 [M+H]
+
, C41H49N2O3SSi requires 677.3228 (-0.3 ppm 
error). 
Synthesis of N-((1R,2R)-2-((4-hydroxybutyl)amino)-1,2-diphenylethyl)-4-
methylbenzenesulfonamide (236).  
 
This compound is novel. 
To a solution of N-((1R,2R)-2-((4-((tert-butyldiphenylsilyl)oxy)butyl)amino)-1,2-
diphenylethyl)-4-methylbenzenesulfonamide 235 (730 mg, 1.08 mmol) in dry THF (7 
cm
3
) was added TBAF (1 M solution in THF, 1.62 cm
3
, 1.62 mmol) at 0 °C. The 
resulting mixture was stirred at rt for 24 hrs. The reaction mixture was then 
concentrated under reduced pressure to give a residue. The residue was purified by flash 
chromatography (10→100 % v/v ethyl acetate/pet ether) to give 236 as a white solid 
(360 mg, 0.82 mmol, 76 %); Mp 135-138 °C; [α]D
22
 -12.8 (c 0.25, CHCl3); νmax 3278, 
3091, 2836, 1598, 1495, 1450, 1429, 1350, 1333, 1259, 1215, 1189, 1181, 1156, 1090, 
1060, 1046, 1030, 1011, 996, 962, 922, 903, 843, 832, 820, 773, 757, 727, 698 and 668 
cm
-1; δH (400 MHz, CDCl3) 7.39 (2 H, d, J 8.2, 2 x Ar-H), 7.15-7.10 (3 H, m, 3 x Ar-H), 
7.08-6.97 (5 H, m, 5 x Ar-H), 6.96-6.91 (2 H, m, 2 x Ar-H), 6.88 (2 H, d, J 6.9, 2 x Ar-
H), 4.30 (1 H, d, J 8.0, CHNHTs), 3.67 (1 H, d, J 8.0, CHNH), 3.64-3.55 (2 H, m, 
CH2OSi), 2.50-2.34 (2 H, m, CH2NH), 2.32 (3 H, s, CH3Ts) and 1.60-1.40 (4 H, m, 
CH2CH2CH2OSi); δC (101 MHz, CDCl3) 142.80 (C), 138.98 (C), 138.13 (C), 137.04 
(C), 129.13 (2 x CH), 128.31 (2 x CH), 127.93 (2 x CH), 127.59 (2 x CH), 127.52 (3 x 
CH), 127.29 (CH), 127.14 (2 x CH), 67.82 (CH), 63.04 (CH), 62.62 (CH2), 47.01 
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(CH2), 30.72 (CH2), 26.79 (CH2) and 21.44 (CH3); m/z (ESI-MS) 439.1 [M+H]
+
, 461.1 
[M+Na]
+
. Found (ESI-HR-MS): 439.2050 [M+H]
+
, C25H31N2O3S requires 439.2050 (-
0.5 ppm error). 
Synthesis of bis(4-(((1R,2R)-2-(4-methylphenylsulfonamido)-1,2-
diphenylethyl)amino)butyl) terephthalate (243).  
 
This compound is novel. 
Terephthalic acid (11 mg, 0.065 mmol) was added to a solution of N-((1R,2R)-2-((4-
hydroxybutyl)amino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 236 (57 mg, 
0.13 mmol) in DCM (2 cm
3
) at rt, followed by addition of EDC (153 mg, 0.80 mmol) 
and DMAP (16 mg, 0.13 mmol). The resulting mixture was stirred overnight and then 
water (2 cm
3
) was added. The organic phase was separated from the aqueous, and then 
DCM (2 x 2 cm
3
) was further added to extract the remaining product from the aqueous. 
The organic layers were then combined, dried (MgSO4), filtered and concentrated under 
reduced pressure giving the crude product, which was then purified by flash 
chromatography (10→30 % v/v ethyl acetate/pet ether)  giving 243 as white crystals (20 
mg, 0.02 mmol, 31 %); Mp 199-202 °C; [α]D
27
 -12.8 (c 0.25, CHCl3); νmax 3267, 2931, 
1716, 1600, 1495, 1454, 1408, 1325, 1269, 1184, 1154, 1117, 1093, 1018, 928, 875, 
843, 812, 762, 731, 698 and 666 cm
-1; δH (400 MHz, CDCl3) 8.04 (4 H, s, 4 x CO2Ar-
H), 7.37 (4 H, d, J 8.0, 2 x Ar-H), 7.16-7.08 (6 H, m, 6 x Ar-H), 7.07-6.97 (10 H, m, 10 
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x Ar-H), 6.96-6.88 (8 H, m, 8 x Ar-H), 4.34-4.24 (6 H, m, 2 x CHNHTs + 2 x 
CH2OC=O), 3.65 (2 H, d, J 8.0, 2 x CHNH), 2.52-2.42 (2 H, m, 2 x CH(1)H(2)NH), 2.41-
2.33 (2 H, m, 2 x CH(1)H(2)NH), 2.31 (6 H, s, 2 x CH3Ts), 1.80-1.65 (4 H, m, 2 x 
CH2CH2CH2OC=O) and 1.63-1.45 (4 H, m, 2 x CH2CH2CH2OC=O); δC (101 MHz, 
CDCl3) 165.82 (2 x C=O), 142.74 (2 x C), 139.16 (2 x C), 138.24 (2 x C), 137.06 (2 x 
C), 134.10 (2 x C), 129.57 (4 x CH), 129.10 (4 x CH), 128.36 (4 x CH). 127.93 (4 x 
CH), 127.55 (6 x CH), 127.42 (4 x CH), 127.29 (2 x CH), 127.12 (4 x CH), 67.87 (2 x 
CH), 65.17 (2 x CH2), 63.11 (2 x CH), 46.76 (2 x CH2), 26.58 (2 x CH2), 26.37 (2 x 
CH2) and 21.43 (2 x CH3); m/z (ESI-MS) 1007.2 [M+H]
+
, 1029.1 [M+Na]
+
. Found 
(ESI-HR-MS): 504.2095 [M+2H]
2+
, C58H64N4O8S2 requires 504.2077 (-2.1 ppm error). 
Synthesis of catalyst (244).  
 
This compound is novel. 
A mixture of benzeneruthenium (II) chloride dimer (40 mg, 0.08 mmol), N-((1R,2R)-2-
((2-hydroxyethyl)amino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 233 (46 mg, 
0.11 mmol) and triethylamine (0.06 cm
3
, 0.43 mmol) in IPA (2.4 cm
3
) was heated at 80 
°C for 1 hr. The solution was then cooled to rt, and concentrated under reduced 
pressure. The residue was dissolved in CHCl3 (4.8 cm
3
) and then washed with water 
(2.4 cm
3
) over vigorous stirring for 3 minutes. The organic phase was separated, dried 
(Na2SO4), filtered and then concentrated under reduced pressure giving 244 as a brown 
solid (58 mg, 0.09 mmol, 85 %); Mp 250-253 °C (dec); [α]D
27
 +120 (c 0.02, CHCl3); 
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νmax 3435, 3063, 3030, 2917, 1730, 1599, 1494, 1453, 1435, 1398, 1266, 1128, 1084, 
1059, 1003, 932, 834, 808, 749, 697 and 663 cm
-1; δH (400 MHz, CDCl3) 7.55-6.65 (14 
H, m, 14 x Ar-H), 6.01 (6 H, s, 6 x Ar-H), 4.86 (1 H, d, J 10.3, CHNTs), 4.51 (1 H, d, J 
10.3, CHNH), 3.80-3.40 (1 H, br m, CH(1)H(2)OH), 3.35-3.10 (1 H, br m, CH(1)H(2)OH), 
2.50-2.25 (2 H, br m, CH2NH) and 2.20 (3 H, s, CH3Ts); δC (101 MHz, CDCl3) 140.12 
(C), 130.67 (CH), 128.84 (CH), 128.36 (5 x CH), 128.21 (CH), 127.63 (2 x CH), 126.86 
(4 x CH), 83.67 (6 x CH), 82.89 (2 x CH), 74.28 (2 x CH2) and 21.22 (CH3); m/z (ESI-
MS) 589.0 [M-Cl]
+
. Found (ESI-HR-MS): 589.1106 [M-Cl]
+
, C29H31N2O3
102
RuS 
requires 589.1100 (-0.3 ppm error). 
Synthesis of catalyst (245).  
 
This compound is novel. 
A mixture of benzeneruthenium(II) chloride dimer (13 mg, 0.025 mmol), N-((1R,2R)-2-
((3-hydroxypropyl)amino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 234 (14 
mg, 0.033 mmol) and triethylamine (0.018 cm
3
, 0.13 mmol) in IPA (0.75 cm
3
) was 
heated at 80 °C for 1 hr. The solution was then cooled to rt, and concentrated under 
reduced pressure. The residue was dissolved in CHCl3 (1.5 cm
3
) and then washed with 
water (0.75 cm
3
) over vigorous stirring for 3 minutes. The organic phase was separated, 
dried (Na2SO4), filtered and then concentrated under reduced pressure giving 245 as a 
brown solid (13.4 mg, 0.02 mmol, 64 %); Mp 210-213 °C (dec); [α]D
27
 -360 (c 0.02, 
CHCl3); νmax 3436, 3204, 3064, 3029, 2922, 2853, 1730, 1600, 1494, 1454, 1437, 1381, 
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1267, 1185, 1128, 1083, 1054, 1004, 912, 812, 759, 698, 682 and 658 cm
-1; δH (400 
MHz, CDCl3) 7.30-6.50 (14 H, m, 14 x Ar-H), 5.90 (6 H, s, 6 x Ru-Ar-H), 4.18-4.05 (1 
H, br m, CHNTs), 3.99-3.86 (1 H, br m, CHNH), 3.68-3.58 (1 H, br m, CH(1)H(2)OH), 
3.57-3.46 (1 H, br m, CH(1)H(2)OH), 3.16-3.04 (1 H, br m, CH(1)H(2)NH), 2.96-2.82 (1 
H, br m, CH(1)H(2)NH), 2.22 (3 H, s, CH3Ts), 2.12-2.01 (2 H, br m, CH2CH2OH) and 
1.41-1.33 (1 H, br m, NH); δC (101 MHz, CDCl3) 141.50 (C), 139.64 (C), 139.54 (C), 
136.91 (C), 128.60 (2 x CH), 128.50 (2 x CH), 128.17 (CH), 128.07 (4 x CH), 127.54 (2 
x CH), 127.06 (2 x CH), 126.37 (CH), 84.72 (6 x CH), 81.43 (CH), 69.84 (CH), 61.27 
(CH2), 53.62 (CH2), 29.70 (CH2) and 21.23 (CH3); m/z (ESI-MS) 603.0 [M-Cl]
+
. Found 
(ESI-HR-MS): 603.1259 [M-Cl]
+
, C30H33N2O3
102
RuS requires 603.1257 (0.1 ppm 
error). 
Synthesis of catalyst (246).  
 
This compound is novel. 
A mixture of benzeneruthenium(II) chloride dimer (28 mg, 0.056 mmol), N-((1R,2R)-2-
((4-hydroxybutyl)amino)-1,2-diphenylethyl)-4-methylbenzenesulfonamide 236 (32 mg, 
0.074 mmol) and triethylamine (0.04 cm
3
, 0.29 mmol) in IPA (2.2 cm
3
) was heated at 
80 °C for 1 hr. The solution was then cooled to rt, and concentrated under reduced 
pressure. The residue was dissolved in CHCl3 (4.4 cm
3
) and then washed with water 
(2.2 cm
3
) over vigorous stirring for 3 minutes. The organic phase was separated, dried 
(Na2SO4), filtered and then concentrated under reduced pressure giving 246 as orange 
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brown crystals (43 mg, 0.07 mmol, 89 %); Mp 220-223 °C (dec); [α]D
26
 -480 (c 0.02, 
CHCl3); νmax 3428, 3062, 2863, 1599, 1494, 1455, 1437, 1385, 1267, 1127, 1083, 1054, 
992, 915, 809, 750, 697, 681 and 656 cm
-1
; δH (400 MHz, CDCl3) 7.25 (2 H, d, J 7.8, 2 
x Ar-H), 7.15-7.00 (3 H, m, 3 x Ar-H), 6.80 (3 H, d, J 7.8, 3 x Ar-H), 6.75-6.64 (4 H, m, 
4 x Ar-H), 6.56 (2 H, d, J 6.8, 2 x Ar-H), 5.90 (6 H, s, 6 x Ar-Ru-H), 3.99 (1 H, t, J 
10.2, CHNTs), 3.92 (1 H, t, J 10.2, CHNH), 3.76 (1 H, br m, CHNH), 3.60 (2 H, br m, 
CH2OH), 3.44-3.30 (1 H, br m, CH(1)H(2)NH), 2.85-2.65 (1 H, br m, CH(1)H(2)NH), 2.22 
(3 H, s, CH3Ts), 2.16-1.98 (1 H, br m, CH(1)H(2)CH2NH), 1.80-1.66 (1 H, br m,  
CH(1)H(2)CH2NH),  1.64-1.48 (1 H, br m, CH(1)H(2)CH2OH) and 1.43-1.29 (1 H, br m, 
CH(1)H(2)CH2OH); δC (101 MHz, CDCl3) 141.80 (C), 139.57 (C), 139.45 (C), 137.10 
(C), 128.66 (2 x CH), 128.56 (2 x CH), 128.24 (CH), 128.06 (4 x CH), 127.43 (2 x CH), 
127.04 (2 x CH), 126.32 (CH), 86.64 (6 x CH), 80.89 (CH), 69.61 (CH), 61.62 (CH2), 
54.82 (CH2), 29.83 (CH2), 25.43 (CH2) and 21.23 (CH3); m/z (ESI-MS) 617.0 [M-Cl]
+
. 
Found (ESI-HR-MS): 617.1414 [M-Cl]
+
, C31H35N2O3
102
RuS requires 617.1406 (-2.03 
ppm error).    
Synthesis of catalyst (247).  
 
This compound is novel. 
A mixture of benzeneruthenium(II) chloride dimer (28 mg, 0.056 mmol), N-((1R,2R)-2-
((4-((tert-butyldiphenylsilyl)oxy)butyl)amino)-1,2-diphenylethyl)-4-
methylbenzenesulfonamide 235 (50 mg, 0.074 mmol) and triethylamine (0.04 cm
3
, 0.29 
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mmol) in IPA (2.2 cm
3
) was heated at 80 °C for 1 hr. The solution was then cooled to rt, 
and concentrated under reduced pressure. The residue was dissolved in CHCl3 (4.4 cm
3
) 
and then washed with water (2.2 cm
3
) over vigorous stirring for 3 minutes. The organic 
phase was separated, dried (Na2SO4), filtered and then concentrated under reduced 
pressure giving 247 as orange brown crystals (58 mg, 0.07 mmol, 88 %); Mp 205-208 
°C (dec); [α]D
26
 -240 (c 0.02, CHCl3); νmax 3067, 2930, 2856, 1600, 1494, 1455, 1428, 
1387, 1361, 1262, 1189, 1126, 1108, 1083, 992, 915, 822, 759, 728, 697 and 657 cm
-1
; 
δH (400 MHz, CDCl3) 7.60 (4 H, d, J 7.2, 4 x Ar-H), 7.45-7.25 (6 H, m, 6 x Ar-H), 7.13-
6.99 (4 H, m, 4 x Ar-H), 6.90-6.79 (4 H, m, 4 x Ar-H), 6.74 (2 H, t, J 7.2, 2 x Ar-H), 
6.65 (2 H, d, J 6.5, 2 x Ar-H), 6.59 (2 H, d, J 7.2, 2 x Ar-H), 5.79 (6 H, s, 6 x Ar-H), 
3.97 (1 H, d, J 10.3, CHNHTs), 3.84 (1 H, t, J 11.4, CHNH), 3.70 (1 H, t, J 11.4, 
CHNH), 3.61-3.50 (2 H, m, CH2OSi), 3.30-3.10 (1 H, br m, CH(1)H(2)NH), 2.85-2.70 (1 
H, br m, CH(1)H(2)NH), 2.22 (3 H, s, CH3Ts), 2.15-2.01 (1 H, br m, CH(1)H(2)CH2NH), 
1.72-1.60 (1 H, br m, CH(1)H(2)CH2NH), 1.58-1.46 (1 H, br m, CH(1)H(2)CH2OSi), 1.42-
1.27 (1 H, br m, CH(1)H(2)CH2OSi) and 1.03 (9 H, s, 3 x CH3); δC (101 MHz, CDCl3) 
141.54 (C), 139.83 (C), 139.46 (C), 137.01 (C), 133.55 (4 x CH), 133.76 (C), 133.62 
(C), 129.72 (2 x CH), 128.68 (2 x CH), 128.59 (2 x CH), 128.27 (CH), 128.01 (2 x CH), 
127.77 (5 x CH), 127.68 (2 x CH), 127.46 (CH), 127.04 (2 x CH), 126.37 (CH), 84.51 
(6 x CH), 81.05 (CH), 69.67 (CH),  63.16 (CH2), 54.88 (CH2), 30.12 (CH2), 27.00 (3 x 
CH3), 25.39 (CH2), 21.26 (CH3) and 19.25 ((CH3)3C); m/z (ESI-MS) 855.0 [M-Cl]
+
. 
Found (ESI-HR-MS): 855.2596 [M-Cl]
+
, C47H53N2O3
102
RuSSi requires 855.2584 (0.13 
ppm error). 
4.4     Procedures from Section 2.4. 
Synthesis of (E)-(3-Methylbuta-1,3-dien-1-yl)benzene (278).  
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This is a known compound and has been fully characterised. 
To a solution of methyltriphenylphosphonium bromide (3.93 g, 11.0 mmol) in 1,4-
dioxane (100 cm
3
), was added sodium hexamethyldisilazide (2.02 g, 11.0 mmol). The 
resulting yellow mixture was stirred for 1 hour at 60 °C. 4-Phenyl-3-buten-2-one (1.50 
g, 10.0 mmol) was then added and the solution was stirred at 60 °C until completion. 
The reaction was completed after 4 hrs as shown by TLC analysis, after which the 
solution was concentrated under reduced pressure, and purified by flash 
chromatography (pentane : diethyl ether/ 99 : 1)  giving 278 as a colourless oil (720 mg, 
5.00 mmol, 50 %); δH (400 MHz, CDCl3) 7.43 (2 H, d, J 7.8, 2 x Ar-H o to C=C), 7.31 
(2 H, d, J 7.8, 2 x Ar-H m to C=C), 7.25-7.19 (1 H, m, Ar-H p to C=C), 6.88 (1 H, d, J 
16.1, CH=CH cis to Ar ring), 6.53 (1 H, d, J 16.1, CH=CH cis to C(CH3)=CH2), 5.11 (1 
H, s, C(CH3)=CH(1)H(2)), 5.07 (1 H, s, C(CH3)=CH(1)H(2)) and 1.97 (3 H, s, CH3); δC 
(101 MHz, CDCl3) 142.07 (C), 137.41 (C), 131.71 (CH), 128.70 (CH), 128.62 (2 x 
CH), 127.44 (CH), 126.49 (2 x CH), 117.37 (CH2) and 18.62 (CH3). The data matched 
that previously reported for this compound. 
Synthesis of (E)-buta-1,3-diene-1,3-diyldibenzene (279).  
 
This is a known compound and has been fully characterised.
33i
 
To a solution of methyltriphenylphosphonium bromide (3.93 g, 11.0 mmol) in 1,4-
dioxane (100 cm
3
), was added sodium hexamethyldisilazide (2.02 g, 11.0 mmol). The 
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resulting yellow mixture was stirred for 1 hour at 60 °C. 1,3-Diphenyl-2-propenone 
(2.10 g, 10.0 mmol) was then added and the solution was stirred at 60 °C until 
completion. The reaction was completed after 4 hrs as shown by TLC analysis, after 
which the solution was concentrated under reduced pressure, and purified by flash 
chromatography (pentane : ethyl acetate/ 99 : 1)  giving 279 as a colourless oil (241 mg, 
1.17 mmol, 12 %); δH (400 MHz, CDCl3) 7.45-7.20 (10 H, m, 10 x Ar-H), 7.05 (1 H, d, 
J 16.1, CH=CH), 6.49 (1 H, d, J 16.1, CH=CH), 5.42 (1 H, s, CH(1)H(2)=C) and 5.24 (1 
H, d, J 1.6, CH(1)H(2)=C); δC (101 MHz, CDCl3)  148.18 (C), 140.23 (C), 137.21 (C), 
131.94 (CH), 130.38 (CH), 128.62 (2 x CH), 128.48 (2 x CH), 128.24 (2 x CH), 127.68 
(CH), 127.57 (CH), 126.58 (2 x CH) and 117.39 (CH2). The data matched that 
previously reported for this compound. 
Synthesis of 1-phenylprop-2-en-1-one (273).  
 
This is a known compound and has been fully characterised.
30a
 
A mixture of 3-chloro-1-phenyl-1-propanone (2.0 g, 11.8 mmol) and AcOK (1.28 g, 13 
mmol) in EtOH (100 cm
3
) was stirred under reflux for 4 hrs. After stirring overnight at 
rt, the solvent was evaporated off under reduced pressure. The residue was dissolved in 
AcOEt (100 cm
3
) and washed with H2O (3 x 100 cm
3
). Organic phase was dried 
(MgSO4), filtered, and concentrated under reduced pressure giving the crude product, 
which was then purified by flash chromatography (pentane: ethyl acetate/ 20 : 1) giving 
273 as a colourless oil (480 mg, 3.63 mmol, 31 %); δH (400 MHz, CDCl3) 7.98 (2 H, m, 
2 x Ar-H o to C=O), 7.58 (1 H, tt, J 7.4, 2.2, 1 x Ar-H p to C=O), 7.52-7.45 (2 H, m, 2 x 
Ar-H m to C=O), 7.17 (1 H, dd, J 17.1, 10.6, CH=CH2), 6.44 (1 H, dd, J 17.1, 1.7, 
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CH=CH(1)H(2)) and 5.94 (1 H, dd, J 10.6, 1.7, CH=CH(1)H(2)); δC (101 MHz, CDCl3) 
191.07 (C=O), 137.28 (C), 133.00 (CH), 132.39 (CH), 130.21 (CH2), 128.71 (2 x CH) 
and 128.63 (2 x CH). The data matched that previously reported for this compound. 
4.5     Procedures from Section 3.1 (Appendix). 
(E)-Methyl 2-(3,4-dihydronaphthalen-2(1H)-ylidene)hydrazinecarboxylate (296).  
 
This is a known compound and has been fully characterised.
31e
 
A solution of β-tetralone (1.46 g, 1.32 cm3, 10.00 mmol) and 
methylhydrazinocarboxylate (0.90 g, 10.00 mmol) in MeOH (20 cm
3
) was heated at 50 
°C for 8 hrs, after which the reaction was stirred at rt for 5 days. The solution was then 
filtered through a filter paper leaving behind impurities, and the filtrate was then 
concentrated under reduced pressure giving 296 as a yellow solid (1.44 g, 6.60 mmol,  
66 %); δH (400 MHz, CDCl3) (E/Z) 7.18-7.02 (4 H, m, 4 x Ar-H), 3.90-3.75 (3 H, br m, 
OCH3), 3.62 (0.8 H, br s C=CCH2C=N), 3.59 (1.2 H, s, C=CCH2C=N), 2.68 (2 H, q, J 
5.6, C=CCH2CH2), 2.63 (1 H, t, J 5.6, C=CCH2CH(1)H(2)) and 2.51-2.40 (1 H, br m, 
C=CCH2CH(1)H(2)); δC (101 MHz, CDCl3) (E/Z) 154.75 (C), 137.51 (C), 135.08 (C), 
128.68 (CH), 128.28 (CH), 127.52 (CH), 127.00 (CH), 126.89 (CH), 50.56 (CH3), 32.18 
(CH2), 30.41 (CH2), 29.03 (CH2), 27.56 (CH2) and 25.53 (CH2). The data matched that 
previously reported for this compound. 
(R)-N-(1-Phenylethyl)-3,4-dihydronaphthalen-2-amine (297).  
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This is a known compound and has been fully characterised.
31g
 
Synthesis of the imine from β-tetralone and (R)-(+)-α-methylbenzylamine; All solvents 
were dried and deoxygenated before use. Deoxygenation was carried out by passing a 
rapid stream of dry nitrogen through the dry solvent for ca. 15 min. Without this 
precaution highly coloured products were obtained. An oven-dried three-necked flask 
(100 cm
3
) was equipped with a dropping funnel, a Herschberg stirrer, and a reflux 
condenser. The flask was purged with nitrogen prior to introduction of the reagents, and 
a positive pressure of nitrogen was maintained in the apparatus throughout the whole 
operation. The flask was charged with (R)-(+)-α-methylbenzylamine (1.21 g, 1.27 cm3, 
10.00 mmol), triethylamine (6.07 g, 3.36 cm
3
, 60.00 mmol) and hexane (20 cm
3
). The 
mixture was cooled ca. 5 °C by means of an ice bath and a solution of titanium (IV) 
chloride (1.52 g, 0.88 cm
3
, 8.00 mmol) in hexane (10 cm
3
) was added dropwise over a 
period of ca. 10 min. The precipitated titanium (IV) chloride-amine complexes were 
homogenized and suspended by vigorous stirring for a few minutes prior to introduction 
of the ketone. The vigorous stirring of the suspended complexes was maintained and a 
solution of β-tetralone (1.46 g, 1.32 cm3, 10.00 mmol) in diethylether-hexane (1 : 1, 5 
cm
3
 : 5 cm
3
) was added in one batch. The ice bath was removed and the reaction was 
cooled to rt and diethylether (40 cm
3
) was added to precipitate the titanium complexes. 
Under a protective nitrogen atmosphere, the reaction mixture was filtered through a 
sintered glass filter. The solid material in the reaction flask and on the filter was rinsed 
with diethylether (4 x 10 cm
3
). The solvent was removed under reduced pressure and 
the residual crude product was obtained as a dark green oil, and after purification by 
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Kugelrohr distillation (200 °C) 297 was obtained as yellow oil (0.88 g, 3.53 mmol, 36 
%), which was stored under inert conditions; δH (300 MHz, CDCl3) 7.35-6.68 (9 H, m, 9 
x Ar-H), 5.03 (1 H, s, HC=CNH), 4.49 (1 H, q, J 6.4, CHCH3), 3.58 (1 H, br s, NH), 
2.80 (2 H, t, J 8.0, CH2CH2C(NH)=C), 2.30 (2 H, t, J 8.0, CH2CH2C(NH)=C) and 1.48 
(3 H, d, J 6.4, CH3); δC (75 MHz, CDCl3) 144.79 (C), 144.61 (C), 137.40 (C), 130.85 
(C), 128.60 (2 x CH), 126.92 (CH), 126.74 (CH), 126.48 (CH), 125.80 (2 x CH), 123.49 
(CH), 122.40 (CH), 94.52 (CH), 52.79 (CH), 29.30 (CH2), 28.49 (CH2) and 24.29 
(CH3). The data matched that previously reported for this compound. 
N-((R)-1-Phenylethyl)-1,2,3,4-tetrahydronaphthalen-2-amine (301).  
 
This compound is novel. 
A solution of (R)-N-(1-Phenylethyl)-3,4-dihydronaphthalen-2-amine 297 (0.42 g, 1.69 
mmol) with acetic acid (0.1 cm
3
) in MeOH (3 cm
3
) was stirred for an hour. Sodium 
cyanoborohydride (0.12 g, 1.69 mmol) was then added portionwise to the solution. The 
reaction mixture was stirred at rt until completion. After completion, the solution was 
concentrated under reduced pressure and water (5 cm
3
) was added, and the product was 
then extracted with DCM (3 x 5 cm
3
). The organic layers were combined, dried 
(MgSO4), filtered and concentrated under reduced pressure, giving 301 as a colourless 
oil after distillation (0.35 g, 1.39 mmol, 83 %); δH (400 MHz, CDCl3) 7.40-6.95 (9 H, 
m, 9 x Ar-H), 4.04 (1 H, q, J 6.6, CHCH3), 3.12-2.50 (5 H, m, CH2CH2CH(NH)CH2), 
1.66-1.49 (2 H, m, CH2CH2CH(NH)CH2) and 1.37 (3 H, d, J 6.6, CH3); δC (101 MHz, 
CDCl3)  145.94 (C), 136.36 (C), 136.31 (C), 128.54 (2 x CH), 128.52 (2 x CH), 126.93 
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(CH), 126.57 (4 x CH), 54.84 (CH), 50.53 (CH), 30.60 (CH2), 28.98 (CH2), 28.05 (CH2) 
and 24.95 (CH3); m/z (ESI-MS) 252.1 [M+H]
+
.  
(E)-2-(3,4-Dihydronaphthalen-2(1H)-ylidene)hydrazinecarboxamide (298).  
 
This is a known compound and has been fully characterised.
31g
 
A mixture of semicarbazide hydrochloride (1.12 g, 10.00 mmol), sodium acetate (0.82 
g, 10.00 mmol) and water (10 cm
3
) was added slowly to a stirred solution of β-tetralone 
(1.46 g, 1.32 cm
3
, 10.00 mmol) in ethanol (95 %, 30 cm
3
). The reaction mixture was 
stirred at rt for 24 hrs. The precipitate was collected, washed with ether and water and 
dried. Recrystallization from ethanol (95 %) gave 298 as white crystals (1.42 g, 7.00 
mmol, 70 %); νmax 3437, 3186, 1682, 1580, 1462, 1423, 1411, 1267, 1204, 1178, 1137, 
1108, 1137, 1108, 1074, 995, 948, 760, 751, 740 and 662 cm
-1; δH (400 MHz, DMSO-
d6) 8.90 (1 H, s, NH), 7.25-7.16 (4 H, m, 4 x Ar-H), 6.25 (2 H, s, NH2), 3.51 (2 H, s, 
CH2CH2C(=N)CH2), 2.85 (2 H, t, J 6.6, CH2CH2C(=N)CH2) and 2.46 (2 H, t, J 6.6, 
CH2CH2C(=N)CH2); δC (101 MHz, DMSO-d6) 157.32 (C=O), 150.15 (C=N), 138.19 
(C), 135.70 (C), 127.05 (CH), 126.97 (CH), 126.37 (CH), 126.27 (CH), 37.68 (CH2), 
27.05 (CH2) and 25.68 (CH2);  m/z (ESI-MS) 204.0 [M+H]
+
, 226.0 [M+Na]
+
. The data 
matched that previously reported for this compound. 
Compound (299).  
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This is a known compound and has been fully characterised.
31g
 
A solution of carbohydrazine (0.90 g, 10.00 mmol) in MeOH (20 cm
3
) was added to a 
solution of β-tetralone (2.92 g, 2.64 cm3, 20.00 mmol) in MeOH (25 cm3) and the 
resultant mixture was stirred at rt for 20 min. The solid was collected and 
recrystallization from ethanol (95 %) gave 299 as a white solid (1.59 g, 4.59 mmol, 46 
%); δH (400 MHz, CD3CN-d3) 7.30-7.20 (8 H, m, 8 x Ar-H), 3.73-3.58 (4 H, m, 2 x 
CH2CH2C(=N)CH2), 3.03-2.90 (4 H, m, 2 x CH2CH2C(=N)CH2) and 2.70-2.50 m, 2 x 
CH2CH2C(=N)CH2); m/z (ESI-MS) 347.1 [M+H]
+
, 369.1 [M+Na]
+
. The data matched 
that previously reported for this compound. 
N-(3,4-Dihydronaphthalen-2(1H)-ylidene)aniline (300).  
 
This compound is novel. 
Procedure from 297 was used for the formation of 300 as a brown oil (1.66 g, 7.50 
mmol, 75 %); δH (400 MHz, CDCl3) 7.32-6.86 (9 H, m, 9 x Ar-H), 6.03 (1 H, s, CH=C-
NH), 5.19 (1 H, br s, NH), 2.89 (2 H, t, J 8.4, CH2CH2C(NH)=CH) and 2.41 (2 H, t, J 
8.4, CH2CH2C(NH)=CH); δC (101 MHz, CDCl3) 141.74 (C), 141.37 (C), 136.41 (C), 
131.72 (C), 129.28 (2 x CH), 126.96 (CH), 126.66 (CH), 124.24 (CH), 123.79 (CH), 
121.95 (CH), 120.39 (2 x CH), 99.19 (CH), 29.20 (CH2) and 28.52 (CH2); m/z (ESI-
MS) 222.0 [M+H]
+
.  
2-(1,2,3,4-Tetrahydronaphthalen-2-yl)hydrazinecarboxamide (302).  
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This compound is novel. 
Procedure from 301 was used for the formation of 302 as a light yellow oil after flash 
chromatography (10→100 % v/v methanol/ethyl acetate) (0.04 g, 0.19 mmol, 19 %); 
νmax 3444, 3288, 3062, 2982, 2930, 2841, 2580, 2384, 2329, 1616, 1486, 1452, 1436, 
1345, 1312, 1254, 1238, 1164, 1135, 1071, 1062, 1038, 949, 925, 839, 814, 768, 741 
and 723 cm
-1; δH (400 MHz, MeOD-d4) 7.11-7.03 (4 H, m, 4 x Ar-H), 3.20-3.10 (1 H, 
m, CH(1)H(2)CH2CH(NH)CH2), 3.02-2.87 (2 H, m, CH2CH2CH(NH)CH2), 2.85-2.74 (1 
H, m, CH(1)H(2)CH2CH(NH)CH2), 2.65 (1 H, dd, J 16.1, 9.0, CH2CH2CH(NH)CH2), 
2.12-2.01 (1 H, m, CH2CH(1)H(2)CH(NH)CH2) and 1.70-1.57 (1 H, m, 
CH2CH(1)H(2)CH(NH)CH2); δC (400 MHz, MeOD-d4) 137.29 (C), 135.86 (C), 130.33 
(CH), 129.59 (CH), 126.89 (CH), 126.81 (CH), 57.27 (CH), 34.87 (CH2), 28.49 (CH2) 
and 28.47 (CH2); m/z (ESI-MS) 206.1 [M+H]
+
, 228.0 [M+Na]
+
. 
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